PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2462935-7	1989	In vitro studies of dual-fluorochrome-sorted, TPA-stimulated splenic B cells demonstrated significantly greater tritiated thymidine incorporation and Ig secretion by the CD20+ CD5- cells than by the CD20+ CD5+ subset.	Tetradecanoylphorbol Acetate	46-49	keratin 20	Homo sapiens	199-203
2531721-3	1989	TPA reduces the level of expression of CD20, CD21, mIg and CD45RA and increases CD45RO binding, thereby minimizing the phenotypic heterogeneity of the CLL clones and causing them to converge towards one end of the natural range.	Tetradecanoylphorbol Acetate	0-3	keratin 20	Homo sapiens	39-43
2472394-2	1989	We have previously shown that CD20 phosphorylation is increased in activated cells and in phorbol ester-treated resting cells.	Phorbol Esters	90-103	keratin 20	Homo sapiens	30-34
2462935-7	1989	In vitro studies of dual-fluorochrome-sorted, TPA-stimulated splenic B cells demonstrated significantly greater tritiated thymidine incorporation and Ig secretion by the CD20+ CD5- cells than by the CD20+ CD5+ subset.	Tetradecanoylphorbol Acetate	46-49	keratin 20	Homo sapiens	170-174
2666588-8	1989	A fifth patient, whose tumor did not express the CD37 antigen, was treated with 131I-labeled anti-CD20 MoAb 1F5 and achieved a partial response.	Iodine-131	80-84	keratin 20	Homo sapiens	98-102
2784064-5	1989	In the presence of the phorbol ester TPA, leukemic blasts from two cases differentiated along the B precursor pathway to the [CD2-CD10+CD19+CD20+C mu+slg-] pre-B cell stage.	Tetradecanoylphorbol Acetate	37-40	keratin 20	Homo sapiens	140-144
2462935-7	1989	In vitro studies of dual-fluorochrome-sorted, TPA-stimulated splenic B cells demonstrated significantly greater tritiated thymidine incorporation and Ig secretion by the CD20+ CD5- cells than by the CD20+ CD5+ subset.	Thymidine	122-131	keratin 20	Homo sapiens	170-174
3500472-0	1987	Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate.	Tetradecanoylphorbol Acetate	67-98	keratin 20	Homo sapiens	47-51
2830017-3	1988	Nanomolar concentrations of 1,25-dihydroxyvitamin D3 reduce the proliferation of RPMI 8226 cells significantly and simultaneously induce the appearance of both new properties and phenotype expression, such as butyrate esterase, enhanced expression of CD20 (B1), CD15 (Leu-M1) antigens and lambda chains, and decreased expression of the PC1 antigen using microfluorometric analysis.	Calcitriol	28-52	keratin 20	Homo sapiens	251-255
3500472-1	1987	The monoclonal antibody 1F5 recognizes human B-cell surface protein CD20 and can activate resting B cells; with this antibody we found CD20 to be a 35/37-kDa non-disulfide-linked protein.	Disulfides	162-171	keratin 20	Homo sapiens	135-139
3500472-4	1987	Because phorbol 12-myristate 13-acetate (PMA) supports the activation signal initiated by monoclonal antibody 1F5, we studied the effect of PMA on CD20 expression.	Tetradecanoylphorbol Acetate	140-143	keratin 20	Homo sapiens	147-151
3500472-7	1987	Furthermore, PMA not only induced phosphorylation of CD20 protein on Raji cells but also increased the internalization of CD20 molecules; both phosphorylation and internalization of CD20 molecules were decreased with the protein kinase C inhibitor palmitoyl carnitine.	Tetradecanoylphorbol Acetate	13-16	keratin 20	Homo sapiens	53-57
3500472-7	1987	Furthermore, PMA not only induced phosphorylation of CD20 protein on Raji cells but also increased the internalization of CD20 molecules; both phosphorylation and internalization of CD20 molecules were decreased with the protein kinase C inhibitor palmitoyl carnitine.	Tetradecanoylphorbol Acetate	13-16	keratin 20	Homo sapiens	122-126
3500472-7	1987	Furthermore, PMA not only induced phosphorylation of CD20 protein on Raji cells but also increased the internalization of CD20 molecules; both phosphorylation and internalization of CD20 molecules were decreased with the protein kinase C inhibitor palmitoyl carnitine.	Tetradecanoylphorbol Acetate	13-16	keratin 20	Homo sapiens	122-126
3500472-7	1987	Furthermore, PMA not only induced phosphorylation of CD20 protein on Raji cells but also increased the internalization of CD20 molecules; both phosphorylation and internalization of CD20 molecules were decreased with the protein kinase C inhibitor palmitoyl carnitine.	Palmitoylcarnitine	248-267	keratin 20	Homo sapiens	53-57
3500472-7	1987	Furthermore, PMA not only induced phosphorylation of CD20 protein on Raji cells but also increased the internalization of CD20 molecules; both phosphorylation and internalization of CD20 molecules were decreased with the protein kinase C inhibitor palmitoyl carnitine.	Palmitoylcarnitine	248-267	keratin 20	Homo sapiens	122-126
3500472-7	1987	Furthermore, PMA not only induced phosphorylation of CD20 protein on Raji cells but also increased the internalization of CD20 molecules; both phosphorylation and internalization of CD20 molecules were decreased with the protein kinase C inhibitor palmitoyl carnitine.	Palmitoylcarnitine	248-267	keratin 20	Homo sapiens	122-126
33221921-10	2021	Lacrimal gland 11C-MET uptake positively correlated with tear flow in patients, and parotid gland 18F-FDG uptake positively correlated with salivary gland CD20+ B-cell infiltration.	Fluorodeoxyglucose F18	98-105	keratin 20	Homo sapiens	155-159
2824347-3	1987	The anti-CD20 antibody B1, on the other hand, has little effect on anti-mu activation but prevents the stimulation of thymidine incorporation and transformation by EBV.	Thymidine	118-127	keratin 20	Homo sapiens	9-13
7438137-4	1980	In this chemogroup, the structures of the capsular polysaccharides of the serotypes K20 (ref.	Polysaccharides	51-66	keratin 20	Homo sapiens	84-87
33943049-9	2021	Our results showed that the IHC signature of KRT5/6(+)/KRT20(-), as a combined marker of basal subtype, was the only covariate significantly associated with complete response to NAC (p=0.037).	nac	178-181	keratin 20	Homo sapiens	55-60
34030100-2	2021	Here we demonstrated that, in progressive MS patients, CD3+CD20+ T cells share the ability to express cytotoxic factors such as perforin and serine-protease granzyme-B (GzmB), classically associated with CD8+ T cells functionality.	Serine	141-147	keratin 20	Homo sapiens	59-63
33909826-7	2021	The luminal immunohistochemical subtype (CK5 negative and CK20 positive, or CK5 negative and GATA3 positive) was associated with micropapillary and plasmacytoid variants.	Phenobarbital	4-11	keratin 20	Homo sapiens	58-62
33244584-1	2021	OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL).	fludarabine	11-22	keratin 20	Homo sapiens	117-121
33751401-2	2021	IBI301 is a recombinant chimeric murine/human anti-CD20 monoclonal antibody and is a candidate biosimilar to rituximab.	ibi301	0-6	keratin 20	Homo sapiens	51-55
33751401-12	2021	IBI301 plus CHOP could be suggested as a candidate treatment regimen for untreated patients with CD20+ DLBCL.	ibi301	0-6	keratin 20	Homo sapiens	97-101
33244584-1	2021	OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL).	4-(Trifluoromethyl)phenol	56-59	keratin 20	Homo sapiens	117-121
33518484-3	2021	The monoclonal antibody anti CD20, Rituximab, is likely to have beneficial effects in cases of steroid-dependent nephrotic syndrome patients with no easy resolution, even when we cannot make a statement about the specific role in the impact.	Steroids	95-102	keratin 20	Homo sapiens	29-33
33634050-5	2020	Rituximab is a human/mouse chimeric monoclonal antibody against CD20, which is primarily used for treating lymphomas and, most recently, has been used to treat certain kidney diseases including C1q nephropathy.	C10Ph	194-197	keratin 20	Homo sapiens	64-68
33628202-3	2020	The anti-CD20 antibody rituximab has shown promising results for treatment of steroid-sensitive nephrotic syndrome.	Steroids	78-85	keratin 20	Homo sapiens	9-13
33552071-6	2020	In this study we examine whether the SIRPalpha axis regulates ADP responses to the anti-CD20 antibody, obinutuzumab, by NLCs.	Adenosine Diphosphate	62-65	keratin 20	Homo sapiens	88-92
33494389-6	2021	A stratified survival analysis showed that tumoral CD20+ TILs were significantly associated with prognosis in male and younger patients, with tobacco or alcohol consumption, high tumoral CD8+ TILs, low tumoral infiltration by CD68+ macrophages, positive PD-L1 expression, and negative NANOG/SOX2.	Alcohols	153-160	keratin 20	Homo sapiens	51-55
33422061-3	2021	METHODS: In this study, we developed a humanized bispecific antibody (BsAbs: CD20 Ab-mPEG scFv) which retains the clinical anti-CD20 whole antibody (Ofatumumab) and is fused with an anti-mPEG single chain antibody (scFv) that can target the systemic liquid tumor cells.	monomethoxypolyethylene glycol	85-89	keratin 20	Homo sapiens	77-81
33422061-3	2021	METHODS: In this study, we developed a humanized bispecific antibody (BsAbs: CD20 Ab-mPEG scFv) which retains the clinical anti-CD20 whole antibody (Ofatumumab) and is fused with an anti-mPEG single chain antibody (scFv) that can target the systemic liquid tumor cells.	monomethoxypolyethylene glycol	187-191	keratin 20	Homo sapiens	77-81
33406104-3	2021	T cell recruiting therapies, such as the CD20xCD3 T cell bi-specific antibody CD20-TCB (RG6026 or glofitamab), represent a novel approach to target all stages of DLBCL, especially those that fail to respond to multiple lines of treatment.	rg6026	88-94	keratin 20	Homo sapiens	41-49
33406104-3	2021	T cell recruiting therapies, such as the CD20xCD3 T cell bi-specific antibody CD20-TCB (RG6026 or glofitamab), represent a novel approach to target all stages of DLBCL, especially those that fail to respond to multiple lines of treatment.	rg6026	88-94	keratin 20	Homo sapiens	41-45
34025110-6	2021	The anti-CD20 B cell depleting therapies (rituximab, ocrelizumab, and ofatumumab) have also demonstrated superiority in randomized clinical trials compared to their comparator group (placebo, interferon, and teriflunomide, respectively) and rituximab has shown in observational studies to be more effective than older injectable therapies and some of the oral therapies.	teriflunomide	208-221	keratin 20	Homo sapiens	9-13
32949676-7	2020	In the present study, we applied circular dichroism (CD) spectroscopy, native electrospray ionization mass spectrometry (ESI-MS) and electrophoretic mobility shift assays (EMSA) to show that a perylene derivative (K20) selects this topology.	Perylene	193-201	keratin 20	Homo sapiens	214-217
33188849-6	2021	Subsequently, EBF1 was overexpressed by transfection with EBF1 overexpression plasmid and the STAT5 pathway was also blocked by treatment with SH-4-54 in isolated CD20+ B lymphocytes to investigate their roles in the regulation of cellular functions.	SH-4-54	143-150	keratin 20	Homo sapiens	163-167
33441230-3	2021	Prokaryotic expression vector CD20-IgG Fc/pCZN1 was constructed and transformed into E.coli Arctic Express, and the expression of the recombinant protein was induced by IPTG at low temperature and purified by Ni column.	Isopropyl Thiogalactoside	169-173	keratin 20	Homo sapiens	30-34
32245896-2	2020	The next generation beta-particle emitting radioimmunoconjugate 177Lu-lilotomab-satetraxetan (Betalutin ) was shown to up-regulate CD20 expression in different rituximab-sensitive NHL cell lines and to act synergistically with rituximab in a rituximab-sensitive NHL animal model.	177lu-lilotomab-satetraxetan	64-92	keratin 20	Homo sapiens	131-135
32967913-5	2020	Idelalisib also promoted NK cell cytotoxicity against anti-CD20-coated primary human CLL cells and cultured malignant B cells.	idelalisib	0-10	keratin 20	Homo sapiens	59-63
33008453-2	2020	Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib.	Cytarabine	178-188	keratin 20	Homo sapiens	72-76
33008453-2	2020	Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib.	Dasatinib	194-203	keratin 20	Homo sapiens	72-76
32245896-2	2020	The next generation beta-particle emitting radioimmunoconjugate 177Lu-lilotomab-satetraxetan (Betalutin ) was shown to up-regulate CD20 expression in different rituximab-sensitive NHL cell lines and to act synergistically with rituximab in a rituximab-sensitive NHL animal model.	Betalutin	94-103	keratin 20	Homo sapiens	131-135
32567844-4	2020	Anti-CD20 antibody was labeled by the so obtained In(III) modified polylysine using the biotin/neutravidin interaction.	Polylysine	67-77	keratin 20	Homo sapiens	5-9
32941572-2	2020	In this article, biotinylated CD20 and CD3 antibodies were conjugated onto the surface of streptavidin modified ultra-small Fe3O4 nanoparticles via specific binding between streptavidin and biotin to construct a bi-specific nanoplatform (BSNP).	ferryl iron	124-129	keratin 20	Homo sapiens	30-34
32941572-2	2020	In this article, biotinylated CD20 and CD3 antibodies were conjugated onto the surface of streptavidin modified ultra-small Fe3O4 nanoparticles via specific binding between streptavidin and biotin to construct a bi-specific nanoplatform (BSNP).	Biotin	17-23	keratin 20	Homo sapiens	30-34
33109629-13	2020	CONCLUSIONS: Our results provide the rationale for the development of a clinical trial of N-820 alone or in combination with endogenous or ex vivo expanded NK cells in patients with CD20+ B-NHL failing prior rituximab containing chemoimmunotherapy regimens.	n-820	90-95	keratin 20	Homo sapiens	182-186
32645640-2	2020	Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced treatment interval.	Cladribine	67-77	keratin 20	Homo sapiens	116-120
32646922-7	2020	However, metformin reprogrammed the TIME towards "infiltrated-inflamed" and increased the numbers of infiltrated CD8+ cytotoxic T-lymphocyte and CD20+ B-lymphocyte.	Metformin	9-18	keratin 20	Homo sapiens	145-149
32847969-0	2020	Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction.	Calcium	0-7	keratin 20	Homo sapiens	63-67
32847969-3	2020	EGR-1 induction results from an increased calcium influx induced by anti-CD20 antibodies.	Calcium	42-49	keratin 20	Homo sapiens	73-77
32847969-5	2020	Inhibition of the calcium flux with calcium channel blockers (CCBs) abolished EGR-1 induction and impaired the efficacy of anti-CD20 antibodies in preclinical in vitro and in vivo models.	Calcium	18-25	keratin 20	Homo sapiens	128-132
32847969-8	2020	In addition, our findings show that calcium influx is required for anti-CD20-mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20 based immunotherapy.	Calcium	36-43	keratin 20	Homo sapiens	72-76
32847969-8	2020	In addition, our findings show that calcium influx is required for anti-CD20-mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20 based immunotherapy.	Calcium	36-43	keratin 20	Homo sapiens	231-235
32847969-8	2020	In addition, our findings show that calcium influx is required for anti-CD20-mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20 based immunotherapy.	Calcium	151-158	keratin 20	Homo sapiens	72-76
32847969-8	2020	In addition, our findings show that calcium influx is required for anti-CD20-mediated tumor cell death and suggest that simultaneous administration of calcium channel blocking agents could be deleterious in patients receiving anti-CD20 based immunotherapy.	Calcium	151-158	keratin 20	Homo sapiens	231-235
32687322-3	2020	Magnetic graphene nanoribbons (MGNRs) were modified with boronic acid (BA) to create a supporting matrix that is utilized by immobilizing anti-CD20 antibodies with good orientation.	Boronic Acids	71-73	keratin 20	Homo sapiens	143-147
33093947-15	2020	Discussion: ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL.	acalabrutinib	53-66	keratin 20	Homo sapiens	203-207
32715101-6	2020	Using an LpMab-7-Sepharose column, RIEDL-wPDPN and CD20-169RIEDL170 were efficiently purified in one-step purification procedures, and were strongly detected by LpMab-7 using Western blot and flow cytometry.	Sepharose	17-26	keratin 20	Homo sapiens	51-55
32538493-8	2020	GM-Beffs were enriched within CD20+ CD30+ CD38-/low cells, a distinct population from plasmablasts, suggesting that GM-Beffs exert antibody-independent functions.	gm-beffs	0-8	keratin 20	Homo sapiens	30-34
32538493-8	2020	GM-Beffs were enriched within CD20+ CD30+ CD38-/low cells, a distinct population from plasmablasts, suggesting that GM-Beffs exert antibody-independent functions.	gm-beffs	116-124	keratin 20	Homo sapiens	30-34
32669656-1	2020	This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20+) B-cell lymphoma, who achieved a complete response/unconfirmed complete response after standard treatments.	ibi301	116-122	keratin 20	Homo sapiens	155-159
32155551-5	2020	The repair process stimulated by Zn-Asp was also accompanied by increased fluorescence signal intensity of KRT20 and Villin; increased numbers of MUC2+, CAG+, LYZ+, BrdU+ and Ki67+ cells in mouse jejunum; and protein expression of Ki67 and PCNA in the jejunum, crypt and enteroid.	zn-asp	33-39	keratin 20	Homo sapiens	107-112
32619893-4	2020	CASE PRESENTATION: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy.	Steroids	113-121	keratin 20	Homo sapiens	206-210
32619893-4	2020	CASE PRESENTATION: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy.	Cyclophosphamide	126-142	keratin 20	Homo sapiens	206-210
32685310-5	2020	This case report is about a patient with a history of advanced acquired immunodeficiency syndrome (AIDS) with a cluster of differentiation 4 (CD4) count <20 who had CD20 negative plasmablastic lymphoma and was successfully treated with the combination of bortezomib and dose-adjusted EPOCH (V-EPOCH) and intrathecal chemotherapy, achieving complete response with optimal tolerance.	Bortezomib	255-265	keratin 20	Homo sapiens	165-169
32669169-7	2020	CONCLUSIONS: In children with B-ALL who are treated with CCLG-ALL2008 regimen, those with CD20 positive expression in lower WBC count at diagnosis have a poor prognosis; however, those with CD20 positive expression in higher WBC count at diagnosis have a better long-time survival.	cclg	57-61	keratin 20	Homo sapiens	90-94
32669169-7	2020	CONCLUSIONS: In children with B-ALL who are treated with CCLG-ALL2008 regimen, those with CD20 positive expression in lower WBC count at diagnosis have a poor prognosis; however, those with CD20 positive expression in higher WBC count at diagnosis have a better long-time survival.	cclg	57-61	keratin 20	Homo sapiens	190-194
32606843-9	2020	The gene wcaG was significantly associated with K54 positive isolates (p = 0.001), while rmpA was associated with K20 positive isolates (p = 0.01).	rmpa	89-93	keratin 20	Homo sapiens	114-117
32606843-11	2020	Carbapenems and levofloxacin were the best therapeutic options for the treatment of infections with serotypes K20 and K54.	Carbapenems	0-11	keratin 20	Homo sapiens	110-113
32606843-11	2020	Carbapenems and levofloxacin were the best therapeutic options for the treatment of infections with serotypes K20 and K54.	Levofloxacin	16-28	keratin 20	Homo sapiens	110-113
32272179-9	2020	Investigation of mechanisms of action on cells revealed that Au (I) compounds managed to inhibit cell migration and led to a decrease in cytoskeletal proteins such as CK7 and CK20.	Gold	61-65	keratin 20	Homo sapiens	175-179
32669656-1	2020	This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20+) B-cell lymphoma, who achieved a complete response/unconfirmed complete response after standard treatments.	ibi301	116-122	keratin 20	Homo sapiens	170-174
32297127-6	2020	A short treatment course of a pharmacologic agent hypothesized to act as an IRT, such as Cladribine Tablets 3.5 mg/kg or alemtuzumab, can provide long-term suppression of MS disease activity, without need for continuous treatment (the anti-CD20 mechanism of ocrelizumab has the potential to act as an IRT, but is administered continuously, at 6-monthly intervals).	Cladribine	89-99	keratin 20	Homo sapiens	240-244
32056202-7	2020	Given the apparent interaction between STIM1 and CD20, we observed Triton-X solubilized obinutuzumab-bound CD20 accompanied by STIM1.	Octoxynol	67-75	keratin 20	Homo sapiens	49-53
32056202-7	2020	Given the apparent interaction between STIM1 and CD20, we observed Triton-X solubilized obinutuzumab-bound CD20 accompanied by STIM1.	Octoxynol	67-75	keratin 20	Homo sapiens	107-111
32489049-10	2020	The in vitro experiments showed that scutellarin inhibited the growth, transformation and differentiation of HT-29 CSC cells, significantly down-regulated the mRNA levels of Lgr5, c-Myc, CK20 and Nanog in HT-29 CSC cells as well as the protein expression levels of c-Myc, Gli1 and Lgr5 in HT-29 CSC cells.	scutellarin	37-48	keratin 20	Homo sapiens	187-191
32245446-10	2020	To confirm these findings, four stem/progenitor marker expression patterns were compared with CD4, CD8 and CD20 in a ccRCC TMA which showed a number of similar trends with respect to frequency of the different tumour-infiltrating leukocytes.	tma	123-126	keratin 20	Homo sapiens	107-111
32098874-3	2020	Rituximab (RTX) is a monoclonal antibody directed against CD20 antigen on B cells which has been successfully employed in anti-MuSK-Ab+MG, but the efficacy in anti-AChR-Ab+MG is still debated.	musk-ab	127-134	keratin 20	Homo sapiens	58-62
32270047-3	2020	Here, we developed a nanoparticle (NP)-based pretargeted system for the therapeutic delivery of BEZ235 to CD20- and HLA-DR-expressing lymphoma cells for targeted therapy.	dactolisib	96-102	keratin 20	Homo sapiens	106-110
32270047-4	2020	The pretargeted system is composed of dibenzocyclooctyne-functionalized anti-CD20 and anti-Lym1 antibodies as the tumor-targeting components and azide-functionalized BEZ235-encapsulated NPs as the effector drug carrier.	dibenzocyclooctyne	38-56	keratin 20	Homo sapiens	77-81
31724191-16	2020	In this study, we showed equivalent efficacy of BCD-020 and reference rituximab when used in patients with CD20-positive indolent lymphomas.	bcd-020	48-55	keratin 20	Homo sapiens	107-111
31076361-4	2020	A possible causative role of humoral immune response has paved the way to anti CD-20 monoclonal antibody (rituximab; RTX).	resiniferatoxin	117-120	keratin 20	Homo sapiens	79-84
32196556-1	2020	Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx.	ittp	95-99	keratin 20	Homo sapiens	52-56
31915195-1	2020	Acalabrutinib is a selective irreversible Bruton tyrosine kinase inhibitor that does not affect interleukin-2 associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies.	acalabrutinib	0-13	keratin 20	Homo sapiens	250-254
33463947-0	2020	Cross-Talk Cell Signaling between Anti-CD20 Antibodies and Nitric Oxide Donors.	Nitric Oxide	59-71	keratin 20	Homo sapiens	39-43
31793167-5	2020	We found that IGF2R and the store-operated Ca2+ channel CD20 share a common hydrophobic binding motif that stabilizes their association.	Calcium	43-47	keratin 20	Homo sapiens	56-60
31793167-7	2020	Remarkably, anti-IGF2R induced CD20 phosphorylation, leading to the activation of sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase (SERCA) and removal of intracellular Ca2+ .	Calcium	117-121	keratin 20	Homo sapiens	31-35
31793167-7	2020	Remarkably, anti-IGF2R induced CD20 phosphorylation, leading to the activation of sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase (SERCA) and removal of intracellular Ca2+ .	Calcium	167-171	keratin 20	Homo sapiens	31-35
30847823-7	2019	TLG emerged as the only significant prognostic factor for 2-year PFS in the multivariate analyses with forward selection, both in entire cohort (hazard ratio HR, 1.001; 95 % CI, 1.001-1.002; P &lt; 0.0001) and in the CD20-antibody group (HR, 1.001; 95 % CI, 1.001-1.002; P = 0.001).	(5r)-3-Acetyl-4-Hydroxy-5-Methyl-5-[(1z)-2-Methylbuta-1,3-Dien-1-Yl]thiophen-2(5h)-One	0-3	keratin 20	Homo sapiens	217-221
31881522-11	2019	However, the patient was treated with anti-CD20 immunotherapy due to steroid-dependence.	Steroids	69-76	keratin 20	Homo sapiens	43-47
30564879-2	2020	Although the chimeric anti-CD20 monoclonal antibody rituximab has shown efficacy for frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome, its efficacy for refractory SRNS remains uncertain due to limited data.	Steroids	129-136	keratin 20	Homo sapiens	27-31
31903182-1	2019	The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index >=2).	imbruverchop	4-16	keratin 20	Homo sapiens	159-163
30847823-9	2019	CONCLUSIONS: TLG may improve early risk stratification of MALT lymphoma patients treated with CD20-antibody-based immunotherapy.	(5r)-3-Acetyl-4-Hydroxy-5-Methyl-5-[(1z)-2-Methylbuta-1,3-Dien-1-Yl]thiophen-2(5h)-One	13-16	keratin 20	Homo sapiens	94-98
30721106-0	2019	Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma.	Lenalidomide	97-109	keratin 20	Homo sapiens	123-127
31737848-6	2019	Accordingly, RTX micelles containing PCL22 or PBCL22 showed a higher percentage of Cy3+/Cy5.5+ cell population in CD20+ KG-15 cells, than those with PCL15.	poly(epsilon-caprolactone)-b-poly(ethyleneglycol)-b-poly(epsilon-caprolactone)	37-42	keratin 20	Homo sapiens	114-118
31230381-8	2019	Treatment of CD20+ PTLD with the response-dependent sequential use of RIS, rituximab, and cytotoxic chemotherapy is recommended.	Risedronic Acid	70-73	keratin 20	Homo sapiens	13-17
31365055-7	2019	CASE SUMMARY : Here, we present a case series of six patients with subacute and chronic endomyocardial biopsy-proven CD20+ B-lymphocyte-associated DCMi, where symptomatic heart failure therapy, with or without combined immunosuppressive therapy with steroid-based treatment regime, was insufficient to improve cardiac function.	Steroids	250-257	keratin 20	Homo sapiens	117-121
31538749-6	2019	SIBCs displayed markers typical of memory B cells (CD3- CD20+ CD27+ ) with EBV infection.	sibcs	0-5	keratin 20	Homo sapiens	56-60
31548565-3	2019	To improve the protein yield, we applied a calixarene-based detergent approach to solubilize, stabilize and purify native CD20 from HEK293 cells.	Calixarenes	43-53	keratin 20	Homo sapiens	122-126
31113778-0	2019	A population of CD20+CD27+CD43+CD38lo/int B1 cells in PNH are missing GPI-anchored proteins and harbor PIGA mutations.	Glycosylphosphatidylinositols	70-73	keratin 20	Homo sapiens	16-20
31382738-4	2019	The results showed that extracellular Glu promoted ISC expansion, indicated by increased intestinal organoid forming efficiency and budding efficiency as well as cell proliferation marker Ki67 immunofluorescence and differentiation marker Keratin 20 (KRT20) expression.	Glutamic Acid	38-41	keratin 20	Homo sapiens	251-256
31324820-5	2019	Terminal differentiation, characterized by the increased expression of uroplakins, CK13, and CK20, was induced with the combination of Troglitazone + PD153035.	Troglitazone	135-147	keratin 20	Homo sapiens	93-97
31324820-5	2019	Terminal differentiation, characterized by the increased expression of uroplakins, CK13, and CK20, was induced with the combination of Troglitazone + PD153035.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	150-158	keratin 20	Homo sapiens	93-97
31406628-1	2019	Background: The Bruton"s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models.	ibrutinib	57-66	keratin 20	Homo sapiens	147-151
31406628-2	2019	We investigated how antibody-dependent cellular cytotoxicity (ADCC) induced by type I/II anti-CD20 antibodies was affected by treatment with ibrutinib in MCL.	ibrutinib	141-150	keratin 20	Homo sapiens	94-98
31406628-3	2019	Furthermore, we investigated if lenalidomide, a potential sensitizer to anti-CD20 treatment, could prevent an inhibitory effect of ibrutinib.	Lenalidomide	32-44	keratin 20	Homo sapiens	77-81
31406628-7	2019	Conclusion: Ibrutinib negatively affects anti-CD20 induced cell death in MCL, not reversed by lenalidomide.	ibrutinib	12-21	keratin 20	Homo sapiens	46-50
30573691-5	2019	As expected, basal-like tumors were associated with increased expression of the basal markers KRT5/6 and KRT14, and luminal-like tumors were associated with increased expression of the luminal markers KRT20.	Phenobarbital	116-123	keratin 20	Homo sapiens	201-206
31205644-2	2019	The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in the frontline setting (e.g. rituximab) and for patients with relapsed/refractory disease (e.g. inotuzumab ozogamicin and blinatumomab).	OZOGAMICIN	250-260	keratin 20	Homo sapiens	64-68
30573691-5	2019	As expected, basal-like tumors were associated with increased expression of the basal markers KRT5/6 and KRT14, and luminal-like tumors were associated with increased expression of the luminal markers KRT20.	Phenobarbital	185-192	keratin 20	Homo sapiens	201-206
30976061-2	2019	We hypothesized that routine injection of rituximab, an anti-CD20 antibody, at the time of implantation would reduce the incidence of LTs.	lts	134-137	keratin 20	Homo sapiens	61-65
30787607-8	2019	Results: Cell targeting experiments and magnetic resonance (MR) signal and T2 measurements showed that the Fe3O4@DMSA@Ab nanoprobes have specific binding affinity for CD20-positive cells.	ferryl iron	107-112	keratin 20	Homo sapiens	167-171
30747341-1	2019	BACKGROUND: CT-P10 is the first biosimilar of the anti-CD20 monoclonal antibody, rituximab.	CT-P10	12-18	keratin 20	Homo sapiens	55-59
30787607-12	2019	Conclusion: These results indicate that Fe3O4@DMSA@Ab nanoprobes have the potential to serve as MRI tracers and therapeutic agents for CD20-positive cells.	ferryl iron	40-45	keratin 20	Homo sapiens	135-139
30787607-12	2019	Conclusion: These results indicate that Fe3O4@DMSA@Ab nanoprobes have the potential to serve as MRI tracers and therapeutic agents for CD20-positive cells.	Succimer	46-50	keratin 20	Homo sapiens	135-139
30867701-7	2019	Also, after rituximab treatment, the expression levels of CD20 and PA IgG in lymphocytes were significantly lower than those in cyclophosphamide group (P&lt;0.05), and platelet count was higher than that in cyclophosphamide group (P&lt;0.05).	Cyclophosphamide	207-223	keratin 20	Homo sapiens	58-62
30456475-0	2019	18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.	Cysteine	28-31	keratin 20	Homo sapiens	23-27
30456475-0	2019	18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.	Cysteine	28-31	keratin 20	Homo sapiens	113-117
30456475-12	2019	[18F]FB-GAcDb immunoPET detects disseminated lymphoma disease in the context of normal tissue expression of hCD20, with comparable sensitivity as [18F]FDG PET but with added specificity for the therapeutic target.	gacdb	8-13	keratin 20	Homo sapiens	108-113
29938548-4	2019	RESULTS: Staining for CK20, TDAG51, INSM1, and stromal CD10 was significantly more common in TB cases than in BCC cases ( P &lt; .001).	Terbium	93-95	keratin 20	Homo sapiens	22-26
30787607-8	2019	Results: Cell targeting experiments and magnetic resonance (MR) signal and T2 measurements showed that the Fe3O4@DMSA@Ab nanoprobes have specific binding affinity for CD20-positive cells.	Succimer	113-117	keratin 20	Homo sapiens	167-171
30671571-3	2019	Herein, we developed a surface enhanced Raman scattering (SERS)-based sandwich-type immunoassay for the simultaneous detection of two surface markers (i.e., CD19 and CD20) in Raji cell lines as well as in clinical blood samples.	sers	58-62	keratin 20	Homo sapiens	166-170
30639670-2	2019	Apoptosis is initiated by the biorecognition of complementary oligonucleotide motifs at the cell surface resulting in crosslinking of CD20 receptors.	Oligonucleotides	62-77	keratin 20	Homo sapiens	134-138
30639670-3	2019	DMFT is composed from two nanoconjugates: 1) bispecific engager, Fab"-MORF1 (anti-CD20 Fab" fragment conjugated with morpholino oligonucleotide), and 2) a crosslinking (effector) component P-(MORF2)X (N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer grafted with multiple copies of complementary morpholino oligonucleotide).	dmft	0-4	keratin 20	Homo sapiens	82-86
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	gemcitabine	27-38	keratin 20	Homo sapiens	96-100
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	gemcitabine	40-43	keratin 20	Homo sapiens	96-100
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	polymer-gemcitabine	48-67	keratin 20	Homo sapiens	96-100
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	2p-gem	79-85	keratin 20	Homo sapiens	96-100
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	dfmt	156-160	keratin 20	Homo sapiens	96-100
30671571-4	2019	First, to compare with the results obtained by flow cytometry, we evaluated the sensitivity and reproducibility of the SERS immunoassay for real-time detection of CD19 and CD20 expressions in Raji cells and blood samples.	sers	119-123	keratin 20	Homo sapiens	172-176
30671571-6	2019	In addition to the improved sensitivity of the SERS method, good linear correlations between the SERS intensities and flow cytometry results were also observed for both CD19 and CD20, which indicated the accuracy of this SERS-based strategy.	sers	97-101	keratin 20	Homo sapiens	178-182
30671571-6	2019	In addition to the improved sensitivity of the SERS method, good linear correlations between the SERS intensities and flow cytometry results were also observed for both CD19 and CD20, which indicated the accuracy of this SERS-based strategy.	sers	97-101	keratin 20	Homo sapiens	178-182
30465822-4	2019	The extracellular actuation by surface CD20 crosslinking boosts robust activations of numerous intracellular responses, and promotes cancer cell susceptibility to various anticancer drugs, including docetaxel (microtubule stabilizer), gemcitabine (nucleoside analogue) and GDC-0980 (PI3K/mTOR inhibitor).	Docetaxel	199-208	keratin 20	Homo sapiens	39-43
30847383-10	2019	The CAMP-HA-AAV-overexpressing group showed significantly reduced human CK20 protein (by 60%) and TUBB3 mRNA expression (by 40%) in the lungs and liver of the HT-29-loaded nude mice, compared to the HA-AAV control group.	Cyclic AMP	4-8	keratin 20	Homo sapiens	72-76
30847383-11	2019	Intraperitoneal injection of KN62 reversed the CAMP-HA-AAV-mediated inhibition of human CK20 and TUBB3 expression in the lungs and liver of HT-29-loaded nude mice.	camp-ha-aav	47-58	keratin 20	Homo sapiens	88-92
30465822-4	2019	The extracellular actuation by surface CD20 crosslinking boosts robust activations of numerous intracellular responses, and promotes cancer cell susceptibility to various anticancer drugs, including docetaxel (microtubule stabilizer), gemcitabine (nucleoside analogue) and GDC-0980 (PI3K/mTOR inhibitor).	gemcitabine	235-246	keratin 20	Homo sapiens	39-43
30465822-4	2019	The extracellular actuation by surface CD20 crosslinking boosts robust activations of numerous intracellular responses, and promotes cancer cell susceptibility to various anticancer drugs, including docetaxel (microtubule stabilizer), gemcitabine (nucleoside analogue) and GDC-0980 (PI3K/mTOR inhibitor).	Nucleosides	248-258	keratin 20	Homo sapiens	39-43
30465822-4	2019	The extracellular actuation by surface CD20 crosslinking boosts robust activations of numerous intracellular responses, and promotes cancer cell susceptibility to various anticancer drugs, including docetaxel (microtubule stabilizer), gemcitabine (nucleoside analogue) and GDC-0980 (PI3K/mTOR inhibitor).	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	273-281	keratin 20	Homo sapiens	39-43
29996743-4	2018	After treatment with HDIVIG + r-ATG + CSA, the percentage of CD20+ B cells in peripheral blood was decreased obviously, and the percentage of Tregs was significantly increased.	Cyclosporine	38-41	keratin 20	Homo sapiens	61-65
31099693-4	2019	The most impactful advance responsible for the improvement of OS in FL was the introduction of the anti-CD20 monoclonal antibody (mAb) rituximab over 20 years ago.	Osmium	62-64	keratin 20	Homo sapiens	104-108
30198798-2	2019	It is a consecutive delivery of two nanoconjugates: (1) bispecific engager that pretargets surface CD20, and (2) multivalent effector polymer that hybridises with CD20-bound engagers.	Polymers	134-141	keratin 20	Homo sapiens	163-167
30198798-3	2019	Without the need of low molecular weight drug, the hybridisation of morpholino oligonucleotide containing DFMT at NHL cell surface triggers CD20 crosslinking and subsequent apoptosis.	Morpholinos	68-94	keratin 20	Homo sapiens	140-144
30198798-3	2019	Without the need of low molecular weight drug, the hybridisation of morpholino oligonucleotide containing DFMT at NHL cell surface triggers CD20 crosslinking and subsequent apoptosis.	dfmt	106-110	keratin 20	Homo sapiens	140-144
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	144-148	keratin 20	Homo sapiens	128-132
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	144-148	keratin 20	Homo sapiens	128-132
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	182-186	keratin 20	Homo sapiens	128-132
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	182-186	keratin 20	Homo sapiens	128-132
30391799-8	2019	The altered molecular signaling pathways demonstrated the great potential of DFMT to overcome rituximab resistance resulting from either down-regulation of CD20 or endocytosis and trogocytosis of rituximab/CD20 complexes.	dfmt	77-81	keratin 20	Homo sapiens	156-160
30391799-8	2019	The altered molecular signaling pathways demonstrated the great potential of DFMT to overcome rituximab resistance resulting from either down-regulation of CD20 or endocytosis and trogocytosis of rituximab/CD20 complexes.	dfmt	77-81	keratin 20	Homo sapiens	206-210
30259654-7	2018	Selective surface binding of DFMT to CD20+ cells is validated in experiments on a coculture of CD20+ (Raji) and CD20-(DG-75) cells.	dfmt	29-33	keratin 20	Homo sapiens	37-41
30538425-11	2018	Results and Conclusion: Here, we report physicochemical and biological characterizations of Sun Pharma"s proposed biosimilar (SB-02) to rituximab, a monoclonal anti-CD20 antibody approved for the treatment of non-Hodgkin"s lymphoma and chronic lymphocytic leukemia.	sb-02	126-131	keratin 20	Homo sapiens	165-169
30413184-7	2018	RIVA is a two-stage open-label randomised phase IIa design in up to 40 patients with low- or high-grade relapsed or refractory CD20+ B-cell lymphoma.	riva	0-4	keratin 20	Homo sapiens	127-131
29725760-0	2018	Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.	Azacitidine	94-105	keratin 20	Homo sapiens	23-27
29725760-0	2018	Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.	Azacitidine	94-105	keratin 20	Homo sapiens	109-113
30259654-1	2018	A therapeutic platform-drug-free macromolecular therapeutics (DFMT)-that induces apoptosis in B cells by cross-linking of CD20 receptors, without the need for low molecular weight cytotoxic drug, is developed.	dfmt	62-66	keratin 20	Homo sapiens	122-126
30259654-7	2018	Selective surface binding of DFMT to CD20+ cells is validated in experiments on a coculture of CD20+ (Raji) and CD20-(DG-75) cells.	dfmt	29-33	keratin 20	Homo sapiens	95-99
30259654-7	2018	Selective surface binding of DFMT to CD20+ cells is validated in experiments on a coculture of CD20+ (Raji) and CD20-(DG-75) cells.	dfmt	29-33	keratin 20	Homo sapiens	95-99
30089638-11	2018	CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib.	adcp	17-21	keratin 20	Homo sapiens	0-4
29574274-4	2018	We have evaluated the pharmacokinetics of seven constructs derived from a CD20-targeting monomeric sdAb (alphaCD20).	sdab	99-103	keratin 20	Homo sapiens	74-78
30089638-11	2018	CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib.	acalabrutinib	80-93	keratin 20	Homo sapiens	0-4
30089638-11	2018	CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib.	ibrutinib	101-110	keratin 20	Homo sapiens	0-4
30089638-11	2018	CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib.	umbralisib	115-125	keratin 20	Homo sapiens	0-4
30089638-11	2018	CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib.	idelalisib	133-143	keratin 20	Homo sapiens	0-4
29884742-2	2018	The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models.	tcb	35-38	keratin 20	Homo sapiens	30-34
29716920-2	2018	Here, we present a next-generation CD20-targeting TCB (CD20-TCB) with significantly higher potency and a novel approach enabling safer administration of such potent drug.Experimental Design: We developed CD20-TCB based on the 2:1 TCB molecular format and characterized its activity preclinically.	tcb	50-53	keratin 20	Homo sapiens	55-59
29716920-4	2018	CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20.	tcb	5-8	keratin 20	Homo sapiens	0-4
29716920-2	2018	Here, we present a next-generation CD20-targeting TCB (CD20-TCB) with significantly higher potency and a novel approach enabling safer administration of such potent drug.Experimental Design: We developed CD20-TCB based on the 2:1 TCB molecular format and characterized its activity preclinically.	tcb	50-53	keratin 20	Homo sapiens	35-39
29716920-2	2018	Here, we present a next-generation CD20-targeting TCB (CD20-TCB) with significantly higher potency and a novel approach enabling safer administration of such potent drug.Experimental Design: We developed CD20-TCB based on the 2:1 TCB molecular format and characterized its activity preclinically.	tcb	50-53	keratin 20	Homo sapiens	55-59
30288053-8	2018	The drug-loading capacity of ATRA-PNP-CD20 was 8.7%, and ATRA-PNP-CD20 displayed a sustained release of ATRA for 144 hours.	Tretinoin	29-33	keratin 20	Homo sapiens	38-42
29716920-4	2018	CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20.	tcb	5-8	keratin 20	Homo sapiens	57-61
29716920-4	2018	CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20.	tcb	5-8	keratin 20	Homo sapiens	57-61
29716920-4	2018	CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20.	tcb	62-65	keratin 20	Homo sapiens	0-4
29716920-4	2018	CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20.	tcb	62-65	keratin 20	Homo sapiens	57-61
29716920-4	2018	CD20-TCB displays considerably higher potency than other CD20-TCB antibodies in clinical development and is efficacious on tumor cells expressing low levels of CD20.	tcb	62-65	keratin 20	Homo sapiens	57-61
29716920-7	2018	Gpt enables profound B-cell depletion in peripheral blood and secondary lymphoid organs and reduces T-cell activation and cytokine release in the peripheral blood, thus increasing the safety of CD20-TCB administration.	tcb	199-202	keratin 20	Homo sapiens	194-198
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Tretinoin	96-100	keratin 20	Homo sapiens	195-199
30288053-0	2018	All-trans retinoic acid-encapsulated, CD20 antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles effectively target and eliminate melanoma-initiating cells in vitro.	Tretinoin	10-23	keratin 20	Homo sapiens	38-42
30288053-8	2018	The drug-loading capacity of ATRA-PNP-CD20 was 8.7%, and ATRA-PNP-CD20 displayed a sustained release of ATRA for 144 hours.	Tretinoin	29-33	keratin 20	Homo sapiens	66-70
30288053-0	2018	All-trans retinoic acid-encapsulated, CD20 antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles effectively target and eliminate melanoma-initiating cells in vitro.	Polylactic Acid-Polyglycolic Acid Copolymer	63-92	keratin 20	Homo sapiens	38-42
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	atra-pnp	24-32	keratin 20	Homo sapiens	33-37
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Tretinoin	96-100	keratin 20	Homo sapiens	195-199
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Tretinoin	96-100	keratin 20	Homo sapiens	219-223
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Tretinoin	96-100	keratin 20	Homo sapiens	219-223
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Polylactic Acid-Polyglycolic Acid Copolymer	114-143	keratin 20	Homo sapiens	195-199
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Tretinoin	96-100	keratin 20	Homo sapiens	219-223
30288053-5	2018	In this study, we examined the activity of ATRA against melanoma-initiating cells and developed ATRA-encapsulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which were conjugated with a CD20 antibody (ATRA-PNP-CD20) for targeted delivery of ATRA to CD20+ melanoma-initiating cells.	Tretinoin	96-100	keratin 20	Homo sapiens	219-223
30288053-6	2018	Materials and methods: The effects of ATRA and ATRA-PNP-CD20 against melanoma-initiating cells were investigated using a cytotoxicity assay, tumorsphere formation assay, and flow cytometry.	atra-pnp	47-55	keratin 20	Homo sapiens	56-60
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	atra-pnp	24-32	keratin 20	Homo sapiens	89-93
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	atra-pnp	24-32	keratin 20	Homo sapiens	89-93
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	Tretinoin	24-28	keratin 20	Homo sapiens	33-37
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	Tretinoin	24-28	keratin 20	Homo sapiens	89-93
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	Tretinoin	24-28	keratin 20	Homo sapiens	89-93
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	Tretinoin	81-85	keratin 20	Homo sapiens	33-37
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	Tretinoin	81-85	keratin 20	Homo sapiens	89-93
30288053-9	2018	The results showed that ATRA-PNP-CD20 could effectively and specifically deliver ATRA to CD20+ melanoma-initiating cells, achieving superior inhibitory effects against CD20+ melanoma-initiating cells compared with those of free ATRA and nontargeted nanoparticles.	Tretinoin	81-85	keratin 20	Homo sapiens	89-93
30288053-10	2018	To the best of our knowledge, we report for the first time a potent activity of ATRA against CD20+ melanoma-initiating cells, targeted drug delivery of ATRA via nanoparticles to melanoma-initiating cells, and the achievement of a superior inhibitory effect against melanoma-initiating cells by using a CD20 antibody.	Tretinoin	80-84	keratin 20	Homo sapiens	93-97
30288053-10	2018	To the best of our knowledge, we report for the first time a potent activity of ATRA against CD20+ melanoma-initiating cells, targeted drug delivery of ATRA via nanoparticles to melanoma-initiating cells, and the achievement of a superior inhibitory effect against melanoma-initiating cells by using a CD20 antibody.	Tretinoin	80-84	keratin 20	Homo sapiens	302-306
30288053-10	2018	To the best of our knowledge, we report for the first time a potent activity of ATRA against CD20+ melanoma-initiating cells, targeted drug delivery of ATRA via nanoparticles to melanoma-initiating cells, and the achievement of a superior inhibitory effect against melanoma-initiating cells by using a CD20 antibody.	Tretinoin	152-156	keratin 20	Homo sapiens	302-306
30225153-0	2018	Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review.	Azathioprine	85-97	keratin 20	Homo sapiens	5-9
30235659-10	2018	When the first-line therapy of cyclophosphamide combined with prednisone is not enough to eradicate the inhibitor, especially for a higher inhibitor titer, anti-CD20 monoclonal antibody could play an important role.	Cyclophosphamide	31-47	keratin 20	Homo sapiens	161-165
30235659-10	2018	When the first-line therapy of cyclophosphamide combined with prednisone is not enough to eradicate the inhibitor, especially for a higher inhibitor titer, anti-CD20 monoclonal antibody could play an important role.	Prednisone	62-72	keratin 20	Homo sapiens	161-165
30112230-1	2018	During treatment with fingolimod, B cells are redistributed from blood to secondary lymphoid organs, where they are protected from the effect of anti-CD20 and other cell-depleting therapies.	Fingolimod Hydrochloride	22-32	keratin 20	Homo sapiens	150-154
29411669-1	2018	We report a rare case of pulmonary enteric adenocarcinoma (PEA) exhibiting a immunohistochemical feature of CK7/CK20 double-negativity by evaluating the transformation zone between PEA and conventional pulmonary adenocarcinoma (CPA).	cpa	228-231	keratin 20	Homo sapiens	112-116
29411669-11	2018	This is the first reported case of CK7/CK20 double-negative PEA, with analysis of the transformation zone between PEA and CPA components.	cpa	122-125	keratin 20	Homo sapiens	39-43
30264877-12	2018	CONCLUSION: Costimulatory blockade-based and anti-CD20 antibody/tacrolimus-based immunosuppressive therapies seem to be comparably safe with steroid therapy in nonhuman primates receiving corneal xenotransplantation, as they did not reactivate Rhesus Cytomegalovirus and maintained manageable systemic status.	Tacrolimus	64-74	keratin 20	Homo sapiens	50-54
30042825-1	2018	Background &amp; Aim: In randomised clinical trials, the type II anti-CD20 antibody obinutuzumab has been shown to be more effective than rituximab for therapy of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).	Adenosine Monophosphate	12-15	keratin 20	Homo sapiens	70-74
29710102-13	2018	In a simple linear regression model, the total number of lymphocytes, as well as the number of CD3- and CD20-positive subsets, correlated with CAS (R = 0.63; 95% CI, 0.27-0.84; P = .003; R = 0.59; 95% CI, 0.20-0.82; P = .006; and R = 0.65; 95% CI, 0.30-0.85; P = .002, respectively).	cas	143-146	keratin 20	Homo sapiens	104-108
29464806-9	2018	Biopsy specimens from Ipi-AC had a lower density of CD20-positive lymphocytes than UC (275.8 +- 253.3 cells mm-2 for Ipi-AC vs. 1173.3 +- 1158.2 cells mm-2 for UC, P = 0.022) but had a similar density of CD4, CD8, CD138 and FOXP3-positive cells.	ipi-ac	22-28	keratin 20	Homo sapiens	52-56
29436729-12	2018	The relatively safe profile of anti-CD20 antibodies supports their use as steroid-sparing agents in children with INS.	Steroids	74-81	keratin 20	Homo sapiens	36-40
29544762-11	2018	CONCLUSION: CD20 expression in adult ALL-B is associated with decreased OS.	Osmium	72-74	keratin 20	Homo sapiens	12-16
29797118-3	2018	Intoxication in monkeys determined by the damaging effects of doxorubicin on organs and tissues is also characterized by significant changes in the blood: leukopenia, thrombocytopenia, neutropenia, monocytopenia, lymphocytosis, and a sharp drop of CD20+ B cell content.	Doxorubicin	62-73	keratin 20	Homo sapiens	248-252
30108980-4	2018	Structure-activity relationship studies have led to the production of K20, an antifungal kanamycin that can be mass-produced for uses in agriculture as well as in animals.	Kanamycin	89-98	keratin 20	Homo sapiens	70-73
29595951-2	2018	Here, we apply drug-free macromolecular therapeutics (DFMT) that amplifies CD20 cross-linking to enhance apoptosis in RTX-resistant cells.	dfmt	54-58	keratin 20	Homo sapiens	75-79
29595951-4	2018	Second-step delivery of multivalent polymeric effector (linear copolymer conjugated with multiple copies of complementary oligonucleotide 2) simultaneously hybridizes multiple CD20-bound engagers and strengthens CD20 ligation.	copolymer	63-72	keratin 20	Homo sapiens	176-180
29595951-4	2018	Second-step delivery of multivalent polymeric effector (linear copolymer conjugated with multiple copies of complementary oligonucleotide 2) simultaneously hybridizes multiple CD20-bound engagers and strengthens CD20 ligation.	copolymer	63-72	keratin 20	Homo sapiens	212-216
29595951-4	2018	Second-step delivery of multivalent polymeric effector (linear copolymer conjugated with multiple copies of complementary oligonucleotide 2) simultaneously hybridizes multiple CD20-bound engagers and strengthens CD20 ligation.	Oligonucleotides	122-137	keratin 20	Homo sapiens	176-180
29595951-4	2018	Second-step delivery of multivalent polymeric effector (linear copolymer conjugated with multiple copies of complementary oligonucleotide 2) simultaneously hybridizes multiple CD20-bound engagers and strengthens CD20 ligation.	Oligonucleotides	122-137	keratin 20	Homo sapiens	212-216
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	gemcitabine	89-100	keratin 20	Homo sapiens	29-33
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	gemcitabine	89-100	keratin 20	Homo sapiens	114-118
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	gemcitabine	89-100	keratin 20	Homo sapiens	114-118
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	dfmt	172-176	keratin 20	Homo sapiens	29-33
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	dfmt	172-176	keratin 20	Homo sapiens	114-118
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	dfmt	172-176	keratin 20	Homo sapiens	114-118
30108980-5	2018	This review delineates the path to the discovery of K20 and other related antifungal amphiphilic kanamycins, determination of its mode of action, and findings in greenhouse and field trials with K20 that could lead to crop disease protection strategies.	Kanamycin	97-107	keratin 20	Homo sapiens	52-55
29309213-4	2018	Here, we developed a panel of ADAs against anti-CD20 rituximab (Rituxan , MabThera ); the panel consisted of eight clones of recombinant human-rat chimeric mAbs that target rituximab.	dSMP	30-34	keratin 20	Homo sapiens	48-52
29779330-0	2018	[Tolerance and pharmacodynamics phase I clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin"s lymphoma].	ibi301	103-109	keratin 20	Homo sapiens	78-82
29779330-0	2018	[Tolerance and pharmacodynamics phase I clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin"s lymphoma].	ibi301	103-109	keratin 20	Homo sapiens	135-139
29779330-1	2018	Objective: To evaluate the tolerance and safety of a human-mouse chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients achieved objective response with CD20(+) B-cell non-Hodgkin"s lymphoma (NHL).	ibi301	104-110	keratin 20	Homo sapiens	79-83
29779330-1	2018	Objective: To evaluate the tolerance and safety of a human-mouse chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients achieved objective response with CD20(+) B-cell non-Hodgkin"s lymphoma (NHL).	ibi301	104-110	keratin 20	Homo sapiens	164-168
29779330-17	2018	The IBI301 caused an elimination of the peripheral CD20-expressing B cells in all patients.	ibi301	4-10	keratin 20	Homo sapiens	51-55
29178403-0	2018	N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.	n-glycan	0-8	keratin 20	Homo sapiens	46-50
29750146-3	2018	The cytotoxicity owing to alloreactivity was less susceptible to interference by KI than the ADCC of anti-CD20 mAbs, which was markedly diminished by ibrutinib, but not by idelalisib.	ibrutinib	150-159	keratin 20	Homo sapiens	106-110
29443503-6	2018	The lower affinity of the CD20-derived cyclic peptide employed in the anti-CD20 LUMABS sensor ( Kd = 10-5 M), translated in a LUMABS sensor with a strongly attenuated sensor response.	lumabs	80-86	keratin 20	Homo sapiens	26-30
29443503-6	2018	The lower affinity of the CD20-derived cyclic peptide employed in the anti-CD20 LUMABS sensor ( Kd = 10-5 M), translated in a LUMABS sensor with a strongly attenuated sensor response.	lumabs	80-86	keratin 20	Homo sapiens	75-79
29534755-7	2018	CD20+ B lymphocytes represented 14.9% in the dnIH group and 29.1% in the CR group.	dnih	45-49	keratin 20	Homo sapiens	0-4
29534755-7	2018	CD20+ B lymphocytes represented 14.9% in the dnIH group and 29.1% in the CR group.	Chromium	73-75	keratin 20	Homo sapiens	0-4
29561444-0	2018	T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.	gemcitabine	88-99	keratin 20	Homo sapiens	30-34
29561444-0	2018	T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.	oxiplatin	101-110	keratin 20	Homo sapiens	30-34
30198340-0	2018	Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells.	azd	31-34	keratin 20	Homo sapiens	16-20
29388568-0	2018	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	0-11	keratin 20	Homo sapiens	57-61
29388568-0	2018	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	0-11	keratin 20	Homo sapiens	98-102
29388568-0	2018	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	Polymers	25-32	keratin 20	Homo sapiens	57-61
29388568-0	2018	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	Polymers	25-32	keratin 20	Homo sapiens	98-102
29388568-6	2018	In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs).	salinomycin	52-63	keratin 20	Homo sapiens	19-23
29388568-6	2018	In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs).	salinomycin	52-63	keratin 20	Homo sapiens	109-113
29388568-6	2018	In order to target CD20+ melanoma CSCs, we designed salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers (CD20-SA-NPs).	salinomycin	52-63	keratin 20	Homo sapiens	109-113
29388568-7	2018	Using a single-step nanoprecipitation method, salinomycin-loaded lipid-polymer nanoparticles (SA-NPs) were prepared, then CD20-SA-NPs were obtained through conjugation of thiolated anti-CD20 aptamers to SA-NPs via a maleimide-thiol reaction.	Sulfhydryl Compounds	171-176	keratin 20	Homo sapiens	122-126
29388568-9	2018	The uptake of CD20-SA-NPs by CD20+ melanoma CSCs was significantly higher than that of SA-NPs and salinomycin, leading to greatly enhanced cytotoxic effects in vitro, thus the IC50 values of CD20-SA-NPs were reduced to 5.7 and 2.6 mug/mL in A375 CD+20 cells and WM266-4 CD+ cells, respectively.	salinomycin	98-109	keratin 20	Homo sapiens	14-18
29388568-13	2018	CD20-SA-NPs display effective delivery of salinomycin to CD20+ melanoma CSCs and represent a promising treatment for melanoma.	salinomycin	42-53	keratin 20	Homo sapiens	0-4
29388568-13	2018	CD20-SA-NPs display effective delivery of salinomycin to CD20+ melanoma CSCs and represent a promising treatment for melanoma.	salinomycin	42-53	keratin 20	Homo sapiens	57-61
29388570-0	2018	Erratum: Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	9-20	keratin 20	Homo sapiens	66-70
29388570-0	2018	Erratum: Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	salinomycin	9-20	keratin 20	Homo sapiens	107-111
29388570-0	2018	Erratum: Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	Polymers	34-41	keratin 20	Homo sapiens	66-70
29388570-0	2018	Erratum: Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.	Polymers	34-41	keratin 20	Homo sapiens	107-111
29049862-4	2018	Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.	pmlbl	180-185	keratin 20	Homo sapiens	88-92
30198340-3	2018	In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect.	azd	84-87	keratin 20	Homo sapiens	53-57
29128836-4	2018	In this study, we fabricated liposome consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with anti-CD20 (Rituximab; RTX).	resiniferatoxin	146-149	keratin 20	Homo sapiens	129-133
29048639-7	2017	Furthermore, dabrafenib-resistant cells exhibited stem cell-like features, with Oct4 translocation from the cytoplasm to peri-nuclear sites and nuclei, and increased CD20 expression.	dabrafenib	13-23	keratin 20	Homo sapiens	166-170
30526461-7	2018	Among these inhibitors, etoposide (RMSD value -96.6481) showed high binding capacity with the receptor CD20 which was further subjected to virtual screening.	Etoposide	24-33	keratin 20	Homo sapiens	103-107
28440948-2	2017	The RDMN was fabricated by self-assembling of amphiphilic RTX-DOX conjugates (RDCs), which were synthesized by conjugating the hydrophilic Fab fragments of RTX (an anti-CD20 monoclonal antibody) and hydrophobic DOXs by a reduction-responsive linker, 3-(2-Pyridyldithio) propionyl hydrazide (PDPH).	rtx-dox	58-65	keratin 20	Homo sapiens	169-173
28440948-2	2017	The RDMN was fabricated by self-assembling of amphiphilic RTX-DOX conjugates (RDCs), which were synthesized by conjugating the hydrophilic Fab fragments of RTX (an anti-CD20 monoclonal antibody) and hydrophobic DOXs by a reduction-responsive linker, 3-(2-Pyridyldithio) propionyl hydrazide (PDPH).	resiniferatoxin	58-61	keratin 20	Homo sapiens	169-173
29054987-3	2017	In this study, a set of hCD20-targeting sdAbs was generated, and their capacity to bind hCD20 was evaluated in vitro and in vivo A lead sdAb, sdAb 9079, was selected on the basis of its specific tumor targeting and significant lower kidney accumulation compared with other sdAbs.	sdabs	40-45	keratin 20	Homo sapiens	24-29
29054987-3	2017	In this study, a set of hCD20-targeting sdAbs was generated, and their capacity to bind hCD20 was evaluated in vitro and in vivo A lead sdAb, sdAb 9079, was selected on the basis of its specific tumor targeting and significant lower kidney accumulation compared with other sdAbs.	sdabs	40-45	keratin 20	Homo sapiens	88-93
29054987-3	2017	In this study, a set of hCD20-targeting sdAbs was generated, and their capacity to bind hCD20 was evaluated in vitro and in vivo A lead sdAb, sdAb 9079, was selected on the basis of its specific tumor targeting and significant lower kidney accumulation compared with other sdAbs.	sdab	40-44	keratin 20	Homo sapiens	24-29
29054987-3	2017	In this study, a set of hCD20-targeting sdAbs was generated, and their capacity to bind hCD20 was evaluated in vitro and in vivo A lead sdAb, sdAb 9079, was selected on the basis of its specific tumor targeting and significant lower kidney accumulation compared with other sdAbs.	sdab	40-44	keratin 20	Homo sapiens	88-93
29054987-3	2017	In this study, a set of hCD20-targeting sdAbs was generated, and their capacity to bind hCD20 was evaluated in vitro and in vivo A lead sdAb, sdAb 9079, was selected on the basis of its specific tumor targeting and significant lower kidney accumulation compared with other sdAbs.	sdabs	273-278	keratin 20	Homo sapiens	24-29
29088062-3	2017	In this study, we have developed a chemo-enzymatic strategy by equipping the C-terminus of anti-CD20 ofatumumab with a click handle using Sortase A, followed by ligation of the payload based on a strain-promoted azide-alkyne cycloaddition to produce homogeneous conjugates.	azide-alkyne	212-224	keratin 20	Homo sapiens	96-100
28642301-0	2017	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.	acalabrutinib	46-59	keratin 20	Homo sapiens	154-158
28614905-0	2017	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).	Oxaliplatin	58-69	keratin 20	Homo sapiens	140-144
28614905-0	2017	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).	Dexamethasone	93-106	keratin 20	Homo sapiens	140-144
28232617-3	2017	Bortezomib treatment given intravenously twice weekly for 1 month (1.3 mg/m2 per dose) clearly reduced the numbers of antibody-producing cells and CD38+CD19+CD20- plasma cells in the bone marrow (P&lt;0.05), but donor-specific alloantibody levels did not decrease.	Bortezomib	0-10	keratin 20	Homo sapiens	157-161
29021954-6	2017	A few case reports have described patients with SLE and DAH in whom a single series of Rituximab (RTX), a specific anti-CD20-antigen B-cell antibody, successfully has been used to treat DAH.	dah	56-59	keratin 20	Homo sapiens	120-124
28810856-3	2017	At the 2017 ASCO Meeting, results of the GENUINE phase III trial showed that, by adding ublituximab, a glycoengineered, anti-CD20 type 1 monoclonal antibody, to ibrutinib, the overall response rate (ORR), complete response rate (CRR), and minimal residual disease (MRD) negativity may be improved in high-risk CLL patients.	ibrutinib	161-170	keratin 20	Homo sapiens	125-129
28963832-4	2017	Rituximab, a monoclonal antibody directed against CD20 expressed by lymphocytes B, has been used in several trials and appears able to induce remission of nephrotic syndrome in 60% of patients (GEMRITUX trial) with similar risk profile.	gemritux	194-202	keratin 20	Homo sapiens	50-54
28753442-8	2017	These findings suggest a novel mechanism whereby the potency of IMGN529 can be enhanced by CD20 binding, which results in the increased internalization and degradation of IMGN529 leading to the generation of greater amounts of cytotoxic catabolite.	catabolite	237-247	keratin 20	Homo sapiens	91-95
28497220-1	2017	CT-P10 (Truxima ) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab.	CT-P10	0-6	keratin 20	Homo sapiens	75-79
28415773-5	2017	The presence of CD20+ B cells in renal biopsies during allograft rejection was associated with graft loss and steroid resistance.	Steroids	110-117	keratin 20	Homo sapiens	16-20
28415773-7	2017	In conclusion, CD 20+ B cell infiltration during allograft rejection was associated with an increased risk of graft loss and steroid resistance.	Steroids	125-132	keratin 20	Homo sapiens	15-20
28363519-4	2017	Fusion proteins targeting CD20 or tumor-associated glycoprotein 72 (TAG-72) mediated the specific in vitro uptake of 100nm biotin-functionalized nanoparticles by Raji and Jurkat lymphoma cells (CD20-positive and TAG-72-positive cells, respectively).	Biotin	123-129	keratin 20	Homo sapiens	26-30
28363519-4	2017	Fusion proteins targeting CD20 or tumor-associated glycoprotein 72 (TAG-72) mediated the specific in vitro uptake of 100nm biotin-functionalized nanoparticles by Raji and Jurkat lymphoma cells (CD20-positive and TAG-72-positive cells, respectively).	Biotin	123-129	keratin 20	Homo sapiens	194-198
28445158-0	2017	The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.	Valproic Acid	19-28	keratin 20	Homo sapiens	62-66
28445158-0	2017	The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.	Valproic Acid	19-28	keratin 20	Homo sapiens	137-141
28445158-5	2017	However, although valproate induced expression of CD20 mRNA and protein in the del13q/NOTCH1wt I83-E95 CLL cell line, no such effects were observed in the patients studied.	Valproic Acid	18-27	keratin 20	Homo sapiens	50-54
28445158-6	2017	In contrast to the cell line, in patients valproate treatment resulted in transient recruitment of the transcriptional repressor EZH2 to the CD20 promoter, correlating to an increase of the repressive histone mark H3K27me3.	Valproic Acid	42-51	keratin 20	Homo sapiens	141-145
28445158-7	2017	This suggests that valproate-mediated induction of CD20 may be hampered by EZH2 mediated H3K27me3 in vivo in CLL.	Valproic Acid	19-28	keratin 20	Homo sapiens	51-55
28366912-2	2017	Rituximab, a chimeric monoclonal anti-CD20 antibody, in low doses has shown efficacy as an adjuvant to reduce the dose of steroids.	Steroids	122-130	keratin 20	Homo sapiens	38-42
28556822-7	2017	Oxidative stress seems to be involved in the cell killing activity of anti-CD20 IT, as demonstrated by the protective role of the H2O2 scavenger catalase, but not in that of anti-CD22 IT.	Hydrogen Peroxide	130-134	keratin 20	Homo sapiens	75-79
28367758-4	2017	In the face of persistent proteinuria despite combined conservative rituximab therapy over several months and the total eradication of CD20-positive cells, bortezomib was introduced.	Bortezomib	156-166	keratin 20	Homo sapiens	135-139
28529511-1	2017	The chimeric antibodies anti-CD20 rituximab (Rtx) and anti-TNFalpha infliximab (Ifx) induce antidrug antibodies (ADAs) in many patients with inflammatory diseases.	dSMP	113-117	keratin 20	Homo sapiens	29-33
28340228-7	2017	In contrast, DS with CDX2 and CK20/villin showed slightly higher sensitivity but much lower specificity.	ds	13-15	keratin 20	Homo sapiens	30-34
28428282-2	2017	Two "first-generation," directly radiolabeled anti-CD20 antibodies, 131iodine-tositumomab and 90yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little utilized because of a variety of medical, financial, and logistic obstacles.	90yttrium-ibritumomab tiuxetan	94-124	keratin 20	Homo sapiens	51-55
28278514-7	2017	CIMP-P1 showed female predominance, proximal location, advanced TNM stage, mild decrease of CK20 and CDX2 expression, mild increase of CK7 expression, BRAF mutation, MSI and MLH1 methylation.	cimp-p1	0-7	keratin 20	Homo sapiens	92-96
28278514-8	2017	CIMP-P2 showed older age, female predominance, proximal location, advanced T category, markedly reduced CK20 and CDX2 expression, rare KRAS mutation, high frequency of CK7 expression, BRAF mutation, MSI and MLH1 methylation.	cimp-p2	0-7	keratin 20	Homo sapiens	104-108
28979315-4	2017	Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radionuclide coupled to anti-CD20 antibody.	Ritonavir	144-147	keratin 20	Homo sapiens	202-206
28420140-10	2017	Histologically, OLE-treated colonic samples showed an amelioration of inflammatory damage with reduced infiltration of CD3, CD4, and CD20 cells, while CD68 numbers increased.	oleuropein	16-19	keratin 20	Homo sapiens	133-137
28378801-0	2017	Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.	Paclitaxel	18-28	keratin 20	Homo sapiens	71-75
28086834-7	2017	Detection of DTC in the bone marrow with CK20 RT-PCR was not associated with a worse OS or DFS.	dtc	13-16	keratin 20	Homo sapiens	41-45
27454143-7	2017	In the present study, the role of oral cyclophosphamide (100 mg per day for 15 consecutive days, every 30 for a total of six cycles) associated with anti-CD20 monoclonal antibody has been evaluated in 30 newly diagnosed SMZL patients, not fit for splenectomy or more toxic chemotherapic regimens.	Cyclophosphamide	39-55	keratin 20	Homo sapiens	154-158
28314744-4	2017	The anti-CD20 antibody rituximab has shown promising steroid-sparing properties in clinical trials, but benefits are less convincing in complicated forms of SD-INS.	Steroids	53-60	keratin 20	Homo sapiens	9-13
28314744-4	2017	The anti-CD20 antibody rituximab has shown promising steroid-sparing properties in clinical trials, but benefits are less convincing in complicated forms of SD-INS.	sd-ins	157-163	keratin 20	Homo sapiens	9-13
28177583-3	2017	The study aims to evaluate the clinical response and adverse effects as well as patients" self-perception of intralesional injection of anti-CD20 antibody for treatment of indolent PCBL compared to other treatment modalities.	pcbl	181-185	keratin 20	Homo sapiens	141-145
27684575-3	2017	Given the high potency and selectivity of the BTK inhibitor, ONO/GS-4059, it was hypothesized that, the anti-tumor activity of ONO/GS-4059 could be further enhanced by combining it with the anti-CD20 Abs, rituximab (RTX) or obinutuzumab (GA101).	Nitrogen Dioxide	61-64	keratin 20	Homo sapiens	195-199
27684575-3	2017	Given the high potency and selectivity of the BTK inhibitor, ONO/GS-4059, it was hypothesized that, the anti-tumor activity of ONO/GS-4059 could be further enhanced by combining it with the anti-CD20 Abs, rituximab (RTX) or obinutuzumab (GA101).	Nitrogen Dioxide	127-130	keratin 20	Homo sapiens	195-199
28210263-5	2017	Specifically, clinical trials using anti-CD20 monoclonal antibodies to deplete B cells and reverse DSA had a deleterious effect on rates of acute cellular rejection; a peculiar finding that calls into question a central paradigm in transplantation.	dsa	99-102	keratin 20	Homo sapiens	41-45
28038705-6	2017	In 4 cases, at least 20% of LP cells were positive for CD20/cyclin D1.	leucylproline	28-30	keratin 20	Homo sapiens	55-59
28038705-9	2017	Two of 5 cases of THRLBCL showed rare positive staining for CD20/cyclin D1; 1 case showed polysomy with CCND1/CEP11.	thrlbcl	18-25	keratin 20	Homo sapiens	60-64
27873460-3	2017	Here, sortase A (srtA)-mediated transpeptidation is used to specifically conjugate triple glycine-modified monomethyl auristatin E (MMAE), a highly toxic antimitotic agent, to anti-CD20 ofatumumab (OFA) equipped with a short C-terminal LPETG (5 amino acids) tag at heavy chain (HL), which generates ADCs that show extremely strong potency in killing CD20 positive cancer cells.	Glycine	90-97	keratin 20	Homo sapiens	181-185
27873460-3	2017	Here, sortase A (srtA)-mediated transpeptidation is used to specifically conjugate triple glycine-modified monomethyl auristatin E (MMAE), a highly toxic antimitotic agent, to anti-CD20 ofatumumab (OFA) equipped with a short C-terminal LPETG (5 amino acids) tag at heavy chain (HL), which generates ADCs that show extremely strong potency in killing CD20 positive cancer cells.	Glycine	90-97	keratin 20	Homo sapiens	350-354
27873460-3	2017	Here, sortase A (srtA)-mediated transpeptidation is used to specifically conjugate triple glycine-modified monomethyl auristatin E (MMAE), a highly toxic antimitotic agent, to anti-CD20 ofatumumab (OFA) equipped with a short C-terminal LPETG (5 amino acids) tag at heavy chain (HL), which generates ADCs that show extremely strong potency in killing CD20 positive cancer cells.	monomethyl	107-117	keratin 20	Homo sapiens	181-185
27873460-3	2017	Here, sortase A (srtA)-mediated transpeptidation is used to specifically conjugate triple glycine-modified monomethyl auristatin E (MMAE), a highly toxic antimitotic agent, to anti-CD20 ofatumumab (OFA) equipped with a short C-terminal LPETG (5 amino acids) tag at heavy chain (HL), which generates ADCs that show extremely strong potency in killing CD20 positive cancer cells.	monomethyl	107-117	keratin 20	Homo sapiens	350-354
27873460-3	2017	Here, sortase A (srtA)-mediated transpeptidation is used to specifically conjugate triple glycine-modified monomethyl auristatin E (MMAE), a highly toxic antimitotic agent, to anti-CD20 ofatumumab (OFA) equipped with a short C-terminal LPETG (5 amino acids) tag at heavy chain (HL), which generates ADCs that show extremely strong potency in killing CD20 positive cancer cells.	lpetg	236-241	keratin 20	Homo sapiens	181-185
27873460-4	2017	One of the srtA-generated ADCs with a cleavable dipeptide linker (valine-citrulline, vc), OFA-HL-vcMMAE, shows IC50 values ranging from 5 pg mL-1 to 4.1 ng mL-1 against CD20+ lymphoma cells.	valine-citrulline	66-83	keratin 20	Homo sapiens	169-173
27902473-2	2017	Rituximab, a monoclonal CD20 antibody, was attached to the surfaces of doxorubicin-loaded microbubbles.	Doxorubicin	71-82	keratin 20	Homo sapiens	24-28
28357915-4	2017	With the positive expression of CD20 in recurrent lesions, he received another four cycles of rituximab-based immunochemotherapy (R-GDP).	r-gdp	130-135	keratin 20	Homo sapiens	32-36
27982425-0	2017	Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.	Thioguanine	13-15	keratin 20	Homo sapiens	52-56
28086834-11	2017	Detection of DTC in the bone marrow with CK20 RT-PCR or immunohistochemistry with anti-EpCAM antibody is not associated with a negative prognostic influence.	dtc	13-16	keratin 20	Homo sapiens	41-45
28060891-10	2017	Intense tumor uptake of 89Zr-rituximab on PET (SUVpeak = 12.8) corresponded with uniformly positive CD20 expression on IHC in one patient.	Zirconium-89	24-28	keratin 20	Homo sapiens	100-104
27733358-8	2017	When applied in combination with a screening-identified chemical, ATO evoked reexpression of the CD20 antigen, which could be further therapeutically exploited by enabling CD20 antibody-mediated apoptosis of cHL cells.	Arsenic Trioxide	66-69	keratin 20	Homo sapiens	97-101
27733358-8	2017	When applied in combination with a screening-identified chemical, ATO evoked reexpression of the CD20 antigen, which could be further therapeutically exploited by enabling CD20 antibody-mediated apoptosis of cHL cells.	Arsenic Trioxide	66-69	keratin 20	Homo sapiens	172-176
27843311-0	2016	CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.	Doxorubicin	69-80	keratin 20	Homo sapiens	0-4
29212973-0	2017	[Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].	gemcitabine	176-187	keratin 20	Homo sapiens	12-16
29212973-11	2017	In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.	Vorinostat	115-125	keratin 20	Homo sapiens	30-34
29212973-11	2017	In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.	Vorinostat	115-125	keratin 20	Homo sapiens	79-83
29212973-11	2017	In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.	gemcitabine	130-141	keratin 20	Homo sapiens	30-34
29212973-11	2017	In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.	gemcitabine	130-141	keratin 20	Homo sapiens	79-83
27362307-6	2017	In alphaCD20-treated animals, detection of antidonor Ab and relatively severe CAV were anticipated by appearance of CD20 cells (&gt;1% of lymphocytes) in peripheral blood and were associated with low alphaCD154 trough levels (below 100 mug/mL).	alphacd154	200-210	keratin 20	Homo sapiens	8-12
27590740-1	2016	Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translation of this approach.	sa)-biotin	14-24	keratin 20	Homo sapiens	76-80
27590740-1	2016	Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translation of this approach.	Biotin	18-24	keratin 20	Homo sapiens	76-80
27789116-3	2017	METHODS AND RESULTS: Here, we report the long-term outcome in two steroid-refractory adolescents with Hashimoto encephalopathy who were treated with rituximab, a monoclonal antibody directed against CD20.	Steroids	66-73	keratin 20	Homo sapiens	199-203
29212973-0	2017	[Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].	Vorinostat	161-171	keratin 20	Homo sapiens	12-16
27888882-3	2016	Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes.	Methotrexate	67-79	keratin 20	Homo sapiens	5-9
27843311-3	2016	Active carbon nanoparticles (ACNP) were conjugated to the chemotherapeutic agent, doxorubicin (DOX), and the nanoliposome carrier, DSPE-PEG2000 and DSPE-PEG2000-NH2 conjugated to the human anti-CD20 monoclonal antibody that targets B-lymphocytes.	Carbon	7-13	keratin 20	Homo sapiens	194-198
27843311-4	2016	This monoclonal antibody targeted nanoparticle delivery system for chemotherapy formed the active NDDS complex, ACNP-DOX-DSPE-PEG2000-anti-CD20.	ndds	98-102	keratin 20	Homo sapiens	139-143
27843311-6	2016	When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt"s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro.	ndds	114-118	keratin 20	Homo sapiens	147-151
27843311-6	2016	When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt"s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro.	ndds	114-118	keratin 20	Homo sapiens	147-151
27843311-6	2016	When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt"s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro.	acnp-dox	120-128	keratin 20	Homo sapiens	147-151
27843311-6	2016	When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt"s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro.	acnp-dox	120-128	keratin 20	Homo sapiens	147-151
27843311-6	2016	When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt"s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro.	Doxorubicin	125-128	keratin 20	Homo sapiens	147-151
27843311-6	2016	When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt"s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro.	Doxorubicin	125-128	keratin 20	Homo sapiens	147-151
27843311-7	2016	The intracellular targeting efficiency of the ACNP-DOX-DSPE-PEG2000-anti-CD20 complex was assessed by confocal laser microscopy and flow cytometry.	Doxorubicin	51-54	keratin 20	Homo sapiens	73-77
27497027-3	2016	Zevalin( ) (ibritumomab tiuxetan) is a radioactive drug product, which is the combination of a beta-emitting isotope, (90)Y, linked to the anti-CD20 monoclonal antibody (mAb), rituximab.	ibritumomab tiuxetan	12-32	keratin 20	Homo sapiens	144-148
27578150-5	2016	The application of these two complementary approaches helped us to reveal that matrix protein specifically recognizes the PI(4,5)P2 molecule by the residues K20, K25, K27, K74, and Y28, while the residues K92 and K93 stabilizes the matrix protein orientation on the membrane by the interaction with another PI(4,5)P2 molecule.	pi(4,5)p2	122-131	keratin 20	Homo sapiens	157-160
27084027-1	2016	Rituximab is a chimeric anti-CD20 monoclonal antibody that is used as an immunosuppressive agent in cyclophosphamide refractory lupus nephritis to induce remission.	Cyclophosphamide	100-116	keratin 20	Homo sapiens	29-33
27698808-4	2016	Bone marrow trephines of CML patients in remission under imatinib therapy exhibited significantly higher numbers of CD3 and CD20 infiltrates (partly ordered in aggregates) compared with patients with newly diagnosed CML and control individuals.	Imatinib Mesylate	57-65	keratin 20	Homo sapiens	124-128
27698808-6	2016	Furthermore, since BACH2 is involved in B cell development, its altered expression patterns by imatinib may be one explanation for high B cell numbers, as revealed by CD20/BACH2 (nuclear)-positive cells.	Imatinib Mesylate	95-103	keratin 20	Homo sapiens	167-171
27626448-5	2016	Dextran sulphate sodium (DSS)-colitis was used as a model for intestinal inflammatory stress, which elicited a strong upregulation and widened crypt distribution of K7 and K20.	dextran sulphate sodium	0-23	keratin 20	Homo sapiens	172-175
27626448-5	2016	Dextran sulphate sodium (DSS)-colitis was used as a model for intestinal inflammatory stress, which elicited a strong upregulation and widened crypt distribution of K7 and K20.	dss	25-28	keratin 20	Homo sapiens	172-175
27689933-1	2016	PURPOSE: Directly radioiodinated [131I]-rituximab has been developed as a radioimmunotherapeutic agent in patients with CD20-positive B cell non-Hodgkin"s lymphoma.	Iodine-131	34-38	keratin 20	Homo sapiens	120-124
27500457-7	2016	Importantly, when PBMC from healthy donors were cultured with bendamustine at the concentration of 30muM, under the stimulation with an anti-IgM antibody, an anti-CD40 antibody, recombinant human IL-21 (rhIL-21) and recombinant human soluble BAFF (rhsBAFF), IL-10 production by B cells (CD20+CD4-CD8-CD14-) among peripheral blood mononuclear cell (PBMC) was significantly enhanced by adding bendamustine.	Bendamustine Hydrochloride	62-74	keratin 20	Homo sapiens	287-291
26180934-8	2016	Combining consecutive staining of E-cadherin and CK20 could even enhance specificity toward diagnosis of TE or TB.	Tellurium	105-107	keratin 20	Homo sapiens	49-53
27412413-9	2016	CD20-expressing T cells respond variably to immunomodulatory treatments given to MS patients: they are reduced by fingolimod, alemtuzumab, and dimethyl fumarate, whereas natalizumab disproportionally increases them in the blood.	Dimethyl Fumarate	143-160	keratin 20	Homo sapiens	0-4
27216702-7	2016	Using blends of material made in Chinese hamster ovary (CHO) and Fut8KO-CHO cells, we show that ADCC activity of an IgG4 version of an anti-human CD20 antibody is directly proportional to the fucose content.	Fucose	192-198	keratin 20	Homo sapiens	146-150
27345636-3	2016	METHODS: In this open-label, randomised, phase 3 study (GADOLIN), patients aged 18 years or older with histologically documented, CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab were enrolled at 83 hospital and community sites in 14 countries in Europe, Asia, and North and Central America.	gadolin	56-63	keratin 20	Homo sapiens	130-134
26180934-8	2016	Combining consecutive staining of E-cadherin and CK20 could even enhance specificity toward diagnosis of TE or TB.	Terbium	111-113	keratin 20	Homo sapiens	49-53
27246977-1	2016	PURPOSE: We aimed to develop and translate a CD20-antigen-targeted radiopharmaceutical, Technetium-99 m-labeled (99mTc) rituximab, for sentinel lymph node (SLN) detection.	Technetium-99	88-101	keratin 20	Homo sapiens	45-49
27374464-4	2016	METHODS: We did a phase 1 and feasibility study (NCCTG 1085) of oral everolimus 10 mg/day plus R-CHOP-21 in patients aged at least 18 years with new, untreated, CD20-positive DLBCL (stages II-IV) in the NCCTG (Alliance) National Cancer Institute Cooperative Group (USA).	Everolimus	69-79	keratin 20	Homo sapiens	161-165
27325329-1	2016	OBJECTIVES: To evaluate the cost-effectiveness of treatment with anti-CD20 monoclonal antibody obinutuzumab plus chlorambucil (GClb) in untreated patients with chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy.	gclb	127-131	keratin 20	Homo sapiens	70-74
26920337-0	2016	Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.	gemcitabine	0-11	keratin 20	Homo sapiens	96-100
27097113-0	2016	Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.	Reactive Oxygen Species	0-23	keratin 20	Homo sapiens	47-51
27097113-3	2016	The monoclonal CD20 antibodies rituximab and ofatumumab were found to trigger substantial release of ROS from monocytes.	Reactive Oxygen Species	101-104	keratin 20	Homo sapiens	15-19
27097113-6	2016	We propose that limiting the antibody-induced induction of immunosuppressive ROS may improve the anti-leukemic efficacy of anti-CD20 therapy in CLL.	Reactive Oxygen Species	77-80	keratin 20	Homo sapiens	128-132
26859679-0	2016	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.	graphene oxide	30-44	keratin 20	Homo sapiens	77-81
26800315-9	2016	Following treatment with mesalazine, the numbers of circulating IgG(+) IgD(-) CD27(+) CD19(+) memory B cells were significantly increased, while the numbers of CD138(+) CD38(+) CD20(-) CD19(+) and IgG(+) CD38(+) CD20(-) CD19(+) plasmablasts were reduced in UC patients.	Mesalamine	25-35	keratin 20	Homo sapiens	177-181
26800315-9	2016	Following treatment with mesalazine, the numbers of circulating IgG(+) IgD(-) CD27(+) CD19(+) memory B cells were significantly increased, while the numbers of CD138(+) CD38(+) CD20(-) CD19(+) and IgG(+) CD38(+) CD20(-) CD19(+) plasmablasts were reduced in UC patients.	Mesalamine	25-35	keratin 20	Homo sapiens	212-216
26880268-6	2016	Anti-CD20 treatment further enhanced secretion of senescence-associated cytokines, and augmented the DNA damage response signaling cascade triggered by adriamycin.	Doxorubicin	152-162	keratin 20	Homo sapiens	5-9
32206095-4	2016	Upon anti-CD20 functionalization, the CSS-PCL fiber scaffolds capture Granta-22 cells 2.4 times more than the PCL control does, although the two fiber scaffolds immobilize a comparable amount of anti-CD20.	thiocysteine	38-41	keratin 20	Homo sapiens	10-14
32206095-4	2016	Upon anti-CD20 functionalization, the CSS-PCL fiber scaffolds capture Granta-22 cells 2.4 times more than the PCL control does, although the two fiber scaffolds immobilize a comparable amount of anti-CD20.	thiocysteine	38-41	keratin 20	Homo sapiens	200-204
27127726-11	2015	CD20- and CD30-directed antibody therapy, local radiation therapy, local surgical excision, systemic chemotherapy, and a combination of these therapies have all been successfully used to treat EBVMCU with high rates of durable clinical remission.	ebvmcu	193-199	keratin 20	Homo sapiens	0-4
27383875-8	2016	Statistically significant changes in the MFI-levels of four CDs expressed by the leukemic blasts were observed: downmodulation of CD10, CD19 and CD34 and upmodulation of CD20.	Cadmium	60-63	keratin 20	Homo sapiens	170-174
26859566-4	2016	Although the numbers of circulating CD4 and CD20 B cells were reduced in the post-menopausal group receiving ET, we also detected a better preservation of naive B cells, decreased CD4 T cell inflammatory cytokine production, and slightly lower circulating levels of the pro-inflammatory cytokine IL-6.	et	109-111	keratin 20	Homo sapiens	44-48
27467962-0	2016	Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization.	Ceramides	43-51	keratin 20	Homo sapiens	103-107
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	Ceramides	60-68	keratin 20	Homo sapiens	38-42
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	Ceramides	60-68	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	Ceramides	60-68	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	(2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid	106-109	keratin 20	Homo sapiens	38-42
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	(2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid	106-109	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	(2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid	106-109	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	Ceramides	233-241	keratin 20	Homo sapiens	38-42
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	Ceramides	233-241	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	Ceramides	233-241	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	(2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid	336-339	keratin 20	Homo sapiens	38-42
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	(2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid	336-339	keratin 20	Homo sapiens	163-167
27467962-4	2016	Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death.	(2~{s},3~{r},4~{s})-2-[(2~{s},3~{r})-1,3-Bis(Oxidanyl)-1-Oxidanylidene-Butan-2-Yl]-4-[(3~{s},5~{s})-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl-3-Methyl-3,4-Dihydro-2~{h}-Pyrrole-5-Carboxylic Acid	336-339	keratin 20	Homo sapiens	163-167
26838941-0	2016	5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report.	Azacitidine	0-13	keratin 20	Homo sapiens	33-37
26838941-0	2016	5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report.	Azacitidine	0-13	keratin 20	Homo sapiens	82-86
26838941-2	2016	Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia.	Azacitidine	31-44	keratin 20	Homo sapiens	90-94
26838941-2	2016	Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia.	Azacitidine	31-44	keratin 20	Homo sapiens	98-102
26838941-5	2016	After treatment of 5-azacytidine for her myelodysplastic syndrome, CD20 expression was upregulated in the follicular lymphoma cells in her peripheral blood.	Azacitidine	19-32	keratin 20	Homo sapiens	67-71
26838941-7	2016	CONCLUSIONS: Although partial, CD20 expression was upregulated after treatment with 5-azacitidine.	Azacitidine	84-97	keratin 20	Homo sapiens	31-35
26838941-8	2016	However, CD20 expression was not re-upregulated after a second administration of 5-azacitidine and we also observed the risk of lymphoma cell stimulation due to 5-azacitidine.	Azacitidine	161-174	keratin 20	Homo sapiens	9-13
26951237-4	2016	For the frailest patients, CD20 monoclonal antibodies with or without chlorambucil have proven to be efficacious.	Chlorambucil	70-82	keratin 20	Homo sapiens	27-31
26695368-3	2016	Binding studies revealed that GB4542 preferentially bound CD20(+) cells yet also recognized CD20(-)FcgammaR(+) PBMC.	gb4542	30-36	keratin 20	Homo sapiens	58-62
26695368-3	2016	Binding studies revealed that GB4542 preferentially bound CD20(+) cells yet also recognized CD20(-)FcgammaR(+) PBMC.	gb4542	30-36	keratin 20	Homo sapiens	92-96
26695368-7	2016	However, at higher concentrations, an Fc analog of GB4542 inhibited anti-CD20 mAb-mediated B cell clearance through direct blocking of both Fc-FcgammaR interactions and C1q deposition on target cells.	gb4542	51-57	keratin 20	Homo sapiens	73-77
26110881-0	2016	Methotrexate-associated EBV-positive CD20-negative diffuse large B-cell lymphoma localized to skin presenting as multiple chronic lower leg ulcers.	Methotrexate	0-12	keratin 20	Homo sapiens	37-41
26841018-5	2016	The combination of the Bruton tyrosine kinase inhibitor ibrutinib with an anti-CD20 antibody is an attractive option, because both drugs act synergistically: ibrutinib redistributes the CLL cells from their homing organs to the peripheral blood, and obinutuzumab eliminates the leukemic cells in the blood with particular efficiency.	ibrutinib	158-167	keratin 20	Homo sapiens	79-83
26690706-5	2016	Based on four-color confocal microscopy real-time movies and high resolution digital imaging, we find that after CD20 mAb binding and C1q uptake, C3b deposits on cells, followed by Ca(2+) influx, revealed by bright green signals generated on cells labeled with FLUO-4, a Ca(2+) indicator.	Fluo 4	261-267	keratin 20	Homo sapiens	113-117
26700095-0	2016	Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab" Synthesis.	doxorubicin-peg	123-138	keratin 20	Homo sapiens	144-148
26700095-3	2016	The model drug doxorubicin (DOX) was coupled to the Fab" fragment of anti-CD20 IgG at its permissive sites through a heterotelechelic PEG linker, generating an antibody fragment-drug conjugate (AFDC).	Doxorubicin	15-26	keratin 20	Homo sapiens	74-78
26700095-3	2016	The model drug doxorubicin (DOX) was coupled to the Fab" fragment of anti-CD20 IgG at its permissive sites through a heterotelechelic PEG linker, generating an antibody fragment-drug conjugate (AFDC).	Doxorubicin	28-31	keratin 20	Homo sapiens	74-78
26700095-3	2016	The model drug doxorubicin (DOX) was coupled to the Fab" fragment of anti-CD20 IgG at its permissive sites through a heterotelechelic PEG linker, generating an antibody fragment-drug conjugate (AFDC).	Polyethylene Glycols	134-137	keratin 20	Homo sapiens	74-78
26700095-4	2016	Anti-CD20 IgG was digested and reduced specifically with beta-mercaptoethylamine to generate the Fab" fragment with two free mercapto groups in its hinge region.	Cysteamine	57-80	keratin 20	Homo sapiens	5-9
27980307-4	2016	Furthermore, some targeting drugs, such as lenalidomide, bortezomib and ibrutinib, directly or indirectly affect CD20 protein expression.	Lenalidomide	43-55	keratin 20	Homo sapiens	113-117
27593256-0	2016	Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma.	Yttrium-90	28-38	keratin 20	Homo sapiens	73-78
27386436-7	2016	CK19, CK20 and GCC expression had been detected in 68%, 76% &amp; 52% of patient group, respectively, which was higher than healthy group, with 8%, 32% and 0% expression, respectively (p&lt;0.05).	Adenosine Monophosphate	61-64	keratin 20	Homo sapiens	6-10
26307241-4	2016	Next-generation anti-CD20 mAbs (ofatumumab, ublituximab, obinutuzumab, ocaratuzumab) were significantly more effective at inducing ADP compared to rituximab, but none were as effective as the anti-CD52 mAb alemtuzumab.	Adenosine Diphosphate	131-134	keratin 20	Homo sapiens	21-25
26307241-8	2016	We show that anti-CD20 mAb ADP efficacy is determined by the mAb characteristics, target : effector ratio and incubation time.	Adenosine Diphosphate	27-30	keratin 20	Homo sapiens	18-22
26307241-9	2016	We suggest that preclinical evaluation of anti-CD20 mAbs to understand the determinants of ADP could be useful in designing future combination therapies for CLL.	Adenosine Diphosphate	91-94	keratin 20	Homo sapiens	47-51
27055578-4	2016	Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile.	Chlorambucil	144-156	keratin 20	Homo sapiens	83-87
27055578-4	2016	Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile.	Chlorambucil	302-314	keratin 20	Homo sapiens	83-87
27055578-4	2016	Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile.	Chlorambucil	302-314	keratin 20	Homo sapiens	83-87
27980307-4	2016	Furthermore, some targeting drugs, such as lenalidomide, bortezomib and ibrutinib, directly or indirectly affect CD20 protein expression.	Bortezomib	57-67	keratin 20	Homo sapiens	113-117
27980307-4	2016	Furthermore, some targeting drugs, such as lenalidomide, bortezomib and ibrutinib, directly or indirectly affect CD20 protein expression.	ibrutinib	72-81	keratin 20	Homo sapiens	113-117
27974949-0	2016	Partial Oxygen Pressure Affects the Expression of Prognostic Biomarkers HIF-1 Alpha, Ki67, and CK20 in the Microenvironment of Colorectal Cancer Tissue.	Oxygen	8-14	keratin 20	Homo sapiens	95-99
28058267-10	2016	Significantly more CD20-negative patients (49/83, 59.0%) received steroid plus antibody therapy compared with the CD20-positive group (52/133, 39.1%) (P = 0.004).	Steroids	66-73	keratin 20	Homo sapiens	19-23
28058267-15	2016	CD20-positive B cell infiltration in renal allograft biopsies with ACR is associated with less steroid resistance and better graft survival.	Steroids	95-102	keratin 20	Homo sapiens	0-4
26165233-6	2016	Finally, treatment with the HDAC inhibitor valproic acid upregulated CD20 in both NICD-mut transfectants and primary CLL cells.	Valproic Acid	43-56	keratin 20	Homo sapiens	69-73
27974949-11	2016	The levels of pO2 were positively related with the gray values of Ki67 and negatively related with the values of HIF-1 alpha and CK20 (P &lt; 0.05).	PO-2	14-17	keratin 20	Homo sapiens	129-133
25912635-9	2015	Survival inhibition by copanlisib and idelalisib was enhanced by the monoclonal CD20 antibodies rituximab and obinutuzumab (GA101), while antibody-dependent cellular cytotoxicity mediated by alemtuzumab and peripheral blood mononuclear cells was not substantially impaired by both PI3K inhibitors for the CLL-derived JVM-3 cell line as target cells.	copanlisib	23-33	keratin 20	Homo sapiens	80-84
26739069-0	2015	[Ceramide participates in cell programmed death induced by Type II anti-CD20 mAb].	Ceramides	1-9	keratin 20	Homo sapiens	72-76
26739069-12	2015	:  CONCLUSION: Type II but not Type I anti-CD20 mAbs can induce caspase independent PCD in CD20+ NHL cells through the elevation of cellular ceramide levels.	Ceramides	141-149	keratin 20	Homo sapiens	91-95
26807165-2	2015	To date, studies have shown that lysine residues of K4, K9, K27, K36 and K79 in histone H3 and K20 in histone H4 can be modified by histone methyltransferases (HMTs).	Lysine	33-39	keratin 20	Homo sapiens	95-98
26016446-6	2015	The CK20+AR- immunophenotype was 100% sensitive and specific in diagnosing DTE.	Dithioerythritol	75-78	keratin 20	Homo sapiens	4-8
26637852-0	2015	Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen.	Tretinoin	81-94	keratin 20	Homo sapiens	169-173
26637852-0	2015	Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen.	Curcumin	98-106	keratin 20	Homo sapiens	169-173
26398317-9	2015	Treatment with anti-CD20-hIFNalpha sensitized the cells to apoptosis by CDDP, doxorubicin and Treanda.	cddp	72-76	keratin 20	Homo sapiens	20-24
26398317-9	2015	Treatment with anti-CD20-hIFNalpha sensitized the cells to apoptosis by CDDP, doxorubicin and Treanda.	Doxorubicin	78-89	keratin 20	Homo sapiens	20-24
26398317-12	2015	Treatment with SB203580 enhanced the sensitization of the resistant clone by anti-CD20-hIFNalpha to CDDP apoptosis.	SB 203580	15-23	keratin 20	Homo sapiens	82-86
26398317-12	2015	Treatment with SB203580 enhanced the sensitization of the resistant clone by anti-CD20-hIFNalpha to CDDP apoptosis.	cddp	100-104	keratin 20	Homo sapiens	82-86
25920992-1	2015	INTRODUCTION: Recent studies have proposed that FXYD3 and KRT20 mRNA quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in paraffin could be biomarkers to detect lymph nodes with micrometastases that avoid detection by conventional analysis with hematoxylin-eosin (HE).	Paraffin	157-165	keratin 20	Homo sapiens	58-63
25920992-1	2015	INTRODUCTION: Recent studies have proposed that FXYD3 and KRT20 mRNA quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in paraffin could be biomarkers to detect lymph nodes with micrometastases that avoid detection by conventional analysis with hematoxylin-eosin (HE).	Hematoxylin Eosin	280-297	keratin 20	Homo sapiens	58-63
25920992-1	2015	INTRODUCTION: Recent studies have proposed that FXYD3 and KRT20 mRNA quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in paraffin could be biomarkers to detect lymph nodes with micrometastases that avoid detection by conventional analysis with hematoxylin-eosin (HE).	Helium	299-301	keratin 20	Homo sapiens	58-63
25912635-9	2015	Survival inhibition by copanlisib and idelalisib was enhanced by the monoclonal CD20 antibodies rituximab and obinutuzumab (GA101), while antibody-dependent cellular cytotoxicity mediated by alemtuzumab and peripheral blood mononuclear cells was not substantially impaired by both PI3K inhibitors for the CLL-derived JVM-3 cell line as target cells.	idelalisib	38-48	keratin 20	Homo sapiens	80-84
26159859-4	2015	Promising results with the combination of high-dose methotrexate-based chemotherapy with the CD20 antibody rituximab and consolidating the primary chemotherapy by other non-cross-resistant conventional chemotherapy or high-dose chemotherapy followed by autologous stem cell transplantation have been reported in non-comparative studies.	Methotrexate	52-64	keratin 20	Homo sapiens	93-97
25739815-2	2015	In this study, we successfully fabricated a CD20-targeting immuno-liposome based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC-8,9PC), which can form intermolecular cross-linking through the diacetylenic group by ultraviolet irradiation.	1,2-bis(10,12-tricosadiynoyl)phosphatidylcholine	84-141	keratin 20	Homo sapiens	44-48
25739815-2	2015	In this study, we successfully fabricated a CD20-targeting immuno-liposome based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC-8,9PC), which can form intermolecular cross-linking through the diacetylenic group by ultraviolet irradiation.	1,2-bis(10,12-tricosadiynoyl)phosphatidylcholine	143-151	keratin 20	Homo sapiens	44-48
26229120-6	2015	Notably, pharmacologic inhibition of SHP-1 with sodium stibogluconate counteracted CD20 mAb-induced NK hyporesponsiveness, unveiling an unrecognized role for CD16 as a bifunctional receptor capable of engendering long-lasting NK cell inhibitory signals.	Antimony Sodium Gluconate	48-69	keratin 20	Homo sapiens	83-87
26257518-3	2015	Herein, a novel mAb nanocomb (polyethylenimine polymer-RTX-tositumomab [PPRT nanocomb]) was firstly constructed through mass arming two different anti-CD20 mAbs (RTX and tositumomab) to one polymer by nanotechnology.	Polymers	47-54	keratin 20	Homo sapiens	151-155
25942994-0	2015	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.	navitoclax	93-103	keratin 20	Homo sapiens	174-178
25994015-6	2015	Confocal fluorescence microscopy analysis of Granta cells following incubation with alpha-CD20 scFv apoA-I ND formulated with the intrinsically fluorescent hydrophobic polyphenol, curcumin, revealed alpha-CD20 scFv apoA-I localizes to the cell surface, while curcumin off-loads and gains entry to the cell.	Polyphenols	168-178	keratin 20	Homo sapiens	90-94
25994015-6	2015	Confocal fluorescence microscopy analysis of Granta cells following incubation with alpha-CD20 scFv apoA-I ND formulated with the intrinsically fluorescent hydrophobic polyphenol, curcumin, revealed alpha-CD20 scFv apoA-I localizes to the cell surface, while curcumin off-loads and gains entry to the cell.	Curcumin	180-188	keratin 20	Homo sapiens	90-94
25994015-6	2015	Confocal fluorescence microscopy analysis of Granta cells following incubation with alpha-CD20 scFv apoA-I ND formulated with the intrinsically fluorescent hydrophobic polyphenol, curcumin, revealed alpha-CD20 scFv apoA-I localizes to the cell surface, while curcumin off-loads and gains entry to the cell.	Curcumin	180-188	keratin 20	Homo sapiens	205-209
25994015-6	2015	Confocal fluorescence microscopy analysis of Granta cells following incubation with alpha-CD20 scFv apoA-I ND formulated with the intrinsically fluorescent hydrophobic polyphenol, curcumin, revealed alpha-CD20 scFv apoA-I localizes to the cell surface, while curcumin off-loads and gains entry to the cell.	Curcumin	259-267	keratin 20	Homo sapiens	90-94
25994015-7	2015	Compared to control incubations, viability of cultured NHL cells was decreased upon incubation with alpha-CD20 scFv apoA-I ND harboring curcumin.	Curcumin	136-144	keratin 20	Homo sapiens	106-110
25994015-8	2015	Thus, formulation of curcumin ND with alpha-CD20 scFv apoA-I as the scaffold component confers cell targeting and enhanced bioactive agent delivery, providing a strategy to minimize toxicity associated with chemotherapeutic agents.	Curcumin	21-29	keratin 20	Homo sapiens	44-48
26284588-4	2015	These distinct anti-CD20 mAbs are mass grafted to a short chain polymer (polyethylenimine).	Polymers	64-71	keratin 20	Homo sapiens	20-24
26284588-4	2015	These distinct anti-CD20 mAbs are mass grafted to a short chain polymer (polyethylenimine).	Polyethyleneimine	73-89	keratin 20	Homo sapiens	20-24
26439033-1	2015	OBJECTIVE: To analyze the therapeutic actions of tegafur gimeracil oteracil combined with oxaliplatin for treating patients with advanced colorectal cancer, and its effects on the K-ras gene mutation and the CK20 mRNA.	tegafur gimeracil	49-66	keratin 20	Homo sapiens	208-212
25957396-0	2015	Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	14-17	keratin 20	Homo sapiens	115-119
25098425-5	2015	We scored patients on the basis of the respective CD20BG and TAM count and found that the combination of low CD20BG and high TAMs was related to a significantly reduced PFS and OS at univariate and multivariate analysis.	tam	61-64	keratin 20	Homo sapiens	109-113
25633990-10	2015	The CK positivity in GM may be due to CK molecules other than CK34BE12, CK5, CK6, CK7, CK8, CK14, CK18, CK19 and CK20.	gm	21-23	keratin 20	Homo sapiens	113-117
24231640-0	2015	Anti-CD20 Monoclonal Antibody Therapy in Functional Bile Salt Export Pump Deficiency After Liver Transplantation.	Bile Acids and Salts	52-61	keratin 20	Homo sapiens	5-9
26002964-7	2015	Of particular clinical importance, lenalidomide also allowed NK cells to be activated by lower doses of rituximab, an anti-CD20 monoclonal antibody (mAb) widely used to treat B-cell malignancies.	Lenalidomide	35-47	keratin 20	Homo sapiens	123-127
25098425-5	2015	We scored patients on the basis of the respective CD20BG and TAM count and found that the combination of low CD20BG and high TAMs was related to a significantly reduced PFS and OS at univariate and multivariate analysis.	tams	125-129	keratin 20	Homo sapiens	50-54
25832864-11	2015	The results showed that CK-20 mRNA positive rate in HES 200/0.5 group after surgery was decreased significantly as compared to group HES 130/0.4 (chi (2) = 6.164, P = 0.013).	Hydroxyethyl Starch Derivatives	52-55	keratin 20	Homo sapiens	24-29
25393677-0	2015	Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies.	Ceramides	0-8	keratin 20	Homo sapiens	78-82
25393677-5	2015	The clarification of ceramide involvement in type II anti-CD20 mAb-induced PCD may provide new ideas on CD20-based immunotherapy against NHLs.	Ceramides	21-29	keratin 20	Homo sapiens	58-62
25393677-5	2015	The clarification of ceramide involvement in type II anti-CD20 mAb-induced PCD may provide new ideas on CD20-based immunotherapy against NHLs.	Ceramides	21-29	keratin 20	Homo sapiens	104-108
25612325-2	2015	CCE is attached to the Fab" fragment of anti-CD20 1F5 antibody (Fab"-CCE), and CCK is conjugated in multiple grafts to poly[N-(2-hydroxypropyl)methacrylamide] (P-(CCK)x ).	Carbamylcholine	0-3	keratin 20	Homo sapiens	45-49
25832864-11	2015	The results showed that CK-20 mRNA positive rate in HES 200/0.5 group after surgery was decreased significantly as compared to group HES 130/0.4 (chi (2) = 6.164, P = 0.013).	Hydroxyethyl Starch Derivatives	133-136	keratin 20	Homo sapiens	24-29
25222059-3	2015	Some studies have demonstrated that CD20 overexpression correlates with worse survival in pediatric patients with BCP-ALL, but some other studies suggest a better outcome.	bcp	114-117	keratin 20	Homo sapiens	36-40
25632047-1	2015	PURPOSE: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb.	Lenalidomide	9-21	keratin 20	Homo sapiens	165-169
25749472-8	2015	Similar correlations are also known for a multitude of transporters, such as glucose transporters, amino acid transporters or hNIS (human sodium iodide symporter), as well as cell specific proteins, such as the prostate specific membrane antigen, integrins, and CD20.	Sodium Iodide	138-151	keratin 20	Homo sapiens	262-266
24552605-4	2015	Because of severe thrombocytopenia resistant to immunoglobulins, high-dose steroids, and cyclosporine treatment, anti-cluster of differentiation (CD20) therapy was introduced, with consequent normalization of thrombocytes and weaning off of steroids.	Steroids	241-249	keratin 20	Homo sapiens	146-150
25344523-0	2015	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.	ibrutinib	0-9	keratin 20	Homo sapiens	81-85
25568316-1	2015	Type I anti-CD20 mAb such as rituximab and ofatumumab engage with the inhibitory FcgammaR, FcgammaRIIb on the surface of B cells, resulting in immunoreceptor tyrosine-based inhibitory motif (ITIM) phosphorylation.	Tyrosine	158-166	keratin 20	Homo sapiens	12-16
25603047-0	2015	Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway.	Ceramides	81-89	keratin 20	Homo sapiens	13-17
25603047-4	2015	Herein, we reveal that the induction of ceramide generation by anti-CD20 mAbs directly correlates with their ability to induce PCD.	Ceramides	40-48	keratin 20	Homo sapiens	68-72
25603047-7	2015	These findings provide further insights into a previously unrecognized role for ceramide generation in mediating PCD evoked by type II anti-CD20 mAbs in Burkitt"s lymphoma cells.	Ceramides	80-88	keratin 20	Homo sapiens	140-144
24880619-16	2015	The efficacy on the inflammatory component of the disease is comparable to that of steroids and seems to be related with the reduction of peripheral CD20+ lymphocytes.	Steroids	83-91	keratin 20	Homo sapiens	149-153
25541029-2	2015	However, activity of rituximab may be reduced by conformational change in CD20 by statin-induced cholesterol depletion.	Cholesterol	97-108	keratin 20	Homo sapiens	74-78
25973343-0	2015	Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.	Valproic Acid	36-45	keratin 20	Homo sapiens	57-61
25973343-4	2015	Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.	Valproic Acid	0-9	keratin 20	Homo sapiens	36-40
25973343-4	2015	Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.	Valproic Acid	103-112	keratin 20	Homo sapiens	36-40
25973343-5	2015	FINDINGS: Pretreatment with valproate at oral doses comparable to anti-convulsive therapy, resulted in upregulation of CD20 mRNA and CD20 protein on the cell surface as measured by qPCR and FACS analysis in lymphoma biopsies from three evaluated patients from the VALFRID study.	Valproic Acid	28-37	keratin 20	Homo sapiens	119-123
25973343-5	2015	FINDINGS: Pretreatment with valproate at oral doses comparable to anti-convulsive therapy, resulted in upregulation of CD20 mRNA and CD20 protein on the cell surface as measured by qPCR and FACS analysis in lymphoma biopsies from three evaluated patients from the VALFRID study.	Valproic Acid	28-37	keratin 20	Homo sapiens	133-137
25973343-7	2015	CONCLUSIONS: Valproate treatment at pharmacologically relevant doses resulted in upregulation of CD20 in vivo, and also in expected epigenetic modifications.	Valproic Acid	13-22	keratin 20	Homo sapiens	97-101
25973343-8	2015	This suggests that pre-treatment with valproate or other HDACis before anti-CD20 therapy could be advantageous in CD20-low B-cell lymphomas.	Valproic Acid	38-47	keratin 20	Homo sapiens	114-118
25741456-1	2015	In the past 10 years, many reports have suggested that rituximab, a chimeric anti-CD20 monoclonal antibody, is effective for children with complicated, frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS).	Steroids	176-183	keratin 20	Homo sapiens	82-86
25479582-3	2015	In a recent randomized Phase III study of patients with newly diagnosed CLL and coexisting conditions, obinutuzumab, a humanized anti-CD20 glycoengineered type 2 antibody, used in combination with chlorambucil, demonstrated significant improvement in progression-free survival and several other outcome parameters, in comparison to rituximab plus chlorambucil.	Chlorambucil	347-359	keratin 20	Homo sapiens	134-138
25677780-2	2015	(90)Y ibritumomab tiuxetan ((90)Y-IT), an anti-CD20 radionuclide-conjugated antibody, has demonstrated clinical efficacy in DLBCL with a favorable toxicity profile.	ibritumomab tiuxetan	6-26	keratin 20	Homo sapiens	47-51
26087994-4	2015	AREA COVERED: Rituximab, an mAb directed against a specific antigen expressed on B lymphocytes, CD20 antigen, inducing a premature cell apoptosis became very important in the treatment of membranous glomerulonephritis, steroid-resistant nephrotic syndromes and membranoproliferative glomerulonephritis (MPGN).	Steroids	219-226	keratin 20	Homo sapiens	96-100
25344523-1	2015	The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-delta inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combination with anti-CD20 antibodies.	ibrutinib	43-52	keratin 20	Homo sapiens	266-270
25344523-1	2015	The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-delta inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combination with anti-CD20 antibodies.	phosphatidyl-4-5-biphosphate	57-85	keratin 20	Homo sapiens	266-270
25344523-1	2015	The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-delta inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combination with anti-CD20 antibodies.	idelalisib	111-121	keratin 20	Homo sapiens	266-270
25344523-5	2015	In contrast, ibrutinib strongly inhibited all cell-mediated mechanisms induced by anti-CD20 antibodies rituximab, ofatumumab or obinutuzumab, either in purified systems or whole blood assays.	ibrutinib	13-22	keratin 20	Homo sapiens	87-91
25344523-7	2015	Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo.	ibrutinib	107-116	keratin 20	Homo sapiens	17-21
25066039-6	2014	Flow cytometry of peripheral blood cells included gating of the CD5(+)CD19(+) tumor population, within which mean fluorescence intensity of fluorescein isothiocyanate (FITC) conjugated with anti-CD20 or anti-CD52 antibody was measured.	Fluorescein-5-isothiocyanate	168-172	keratin 20	Homo sapiens	195-199
25547653-0	2015	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	35-39
26261057-8	2015	The mass spectra of the N-glycosylated peptide revealed that the observed biological properties were attributable to the characteristic N-glycan structures of the anti-CD20 mAbs produced in the transgenic silkworms, i.e., the lack of the core-fucose and galactose at the non-reducing terminal.	Nitrogen	24-25	keratin 20	Homo sapiens	168-172
26261057-8	2015	The mass spectra of the N-glycosylated peptide revealed that the observed biological properties were attributable to the characteristic N-glycan structures of the anti-CD20 mAbs produced in the transgenic silkworms, i.e., the lack of the core-fucose and galactose at the non-reducing terminal.	n-glycan	136-144	keratin 20	Homo sapiens	168-172
25594706-3	2015	After initiation of therapy with the monoclonal CD20 antibody Rituximab, steroids could be stopped completely and the patient remains in remission.	Steroids	73-81	keratin 20	Homo sapiens	48-52
25580376-2	2014	Exposure of B-cells to an anti-CD20 Fab"-morpholino oligonucleotide1 (MORF1) conjugate decorated the cell surface with MORF1; further exposure of the decorated cells to multivalent polymer-oligonucleotide2 conjugates (P-MORF2) resulted in CD20 clustering at the cell surface with induction of apoptosis.	fab"-morpholino oligonucleotide1	36-68	keratin 20	Homo sapiens	31-35
25580376-2	2014	Exposure of B-cells to an anti-CD20 Fab"-morpholino oligonucleotide1 (MORF1) conjugate decorated the cell surface with MORF1; further exposure of the decorated cells to multivalent polymer-oligonucleotide2 conjugates (P-MORF2) resulted in CD20 clustering at the cell surface with induction of apoptosis.	polymer-oligonucleotide2	181-205	keratin 20	Homo sapiens	31-35
25596049-7	2014	Ibritumomab tiuxetan (Zevalin) is an anti-CD20 mouse monoclonal antibody labeled with Yttrium-90 (Y-90).	ibritumomab tiuxetan	0-20	keratin 20	Homo sapiens	42-46
25596049-7	2014	Ibritumomab tiuxetan (Zevalin) is an anti-CD20 mouse monoclonal antibody labeled with Yttrium-90 (Y-90).	Yttrium-90	86-96	keratin 20	Homo sapiens	42-46
25276866-0	2014	Rituximab-Au nanoprobes for simultaneous dark-field imaging and DAB staining of CD20 over-expressed on Raji cells.	rituximab-au	0-12	keratin 20	Homo sapiens	80-84
25276866-1	2014	A novel dual-modal cell immunodetection method based on both dark-field imaging and catalysis functions of gold nanoparticles has been established, where the Rituximab-Au conjugates were used as nanoprobes to label and image specifically the CD20 overexpressed on the surface of malignant lymphoma cells of Raji with high affinity.	Gold	168-170	keratin 20	Homo sapiens	242-246
26489498-2	2015	Rituximab, the most widely used anti-CD20 antibody in routine clinical practice, led not only to improvement of progression-free survival, but also to improvement of overall survival in previously untreated patients with good performance status in combination with fludarabine and cyclophosphamide.	fludarabine	265-276	keratin 20	Homo sapiens	37-41
26489498-2	2015	Rituximab, the most widely used anti-CD20 antibody in routine clinical practice, led not only to improvement of progression-free survival, but also to improvement of overall survival in previously untreated patients with good performance status in combination with fludarabine and cyclophosphamide.	Cyclophosphamide	281-297	keratin 20	Homo sapiens	37-41
26489498-4	2015	Rituximab and the newest anti-CD20 antibody obinutuzumab in combination with chlorambucil, as compared with chlorambucil alone, prolonged overall survival in previously untreated patients with significant comorbidities, and the combination of anti-CD20 antibody with chlorambucil has become the standard regimen in this group of patients.	Chlorambucil	77-89	keratin 20	Homo sapiens	248-252
25953541-3	2015	Chitosan was conjugated with an anti-CD20 polyclonal antibody (pAbCD20) by the formation of covalent amide bonds.	Amides	101-106	keratin 20	Homo sapiens	37-41
25762106-1	2015	Manufacturing of 64Cu-1,4,7,10-tetraazacyclododecane-N,N",N"",N"""-tetraacetic acid (DOTA)-rituximab injection under good manufacturing practices (GMP) was validated for imaging of patients with CD20+ B-cell non-Hodgkin lymphoma.	64cu-1,4,7,10-tetraazacyclododecane-n,n",n"",n"""-tetraacetic acid	17-83	keratin 20	Homo sapiens	195-199
25762106-1	2015	Manufacturing of 64Cu-1,4,7,10-tetraazacyclododecane-N,N",N"",N"""-tetraacetic acid (DOTA)-rituximab injection under good manufacturing practices (GMP) was validated for imaging of patients with CD20+ B-cell non-Hodgkin lymphoma.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	85-89	keratin 20	Homo sapiens	195-199
25538692-0	2014	Antifungal amphiphilic aminoglycoside K20: bioactivities and mechanism of action.	Aminoglycosides	23-37	keratin 20	Homo sapiens	38-41
25538692-1	2014	K20 is a novel amphiphilic antifungal aminoglycoside that is synthetically derived from the antibiotic kanamycin A.	Aminoglycosides	38-52	keratin 20	Homo sapiens	0-3
25538692-1	2014	K20 is a novel amphiphilic antifungal aminoglycoside that is synthetically derived from the antibiotic kanamycin A.	Kanamycin	103-114	keratin 20	Homo sapiens	0-3
25538692-9	2014	With fluorescein isothiocyanate (FITC), 20-25 mg/L K20 caused staining of &gt;95% of C. neoformans and Fusarium graminearum cells and at 31.3 mg/L caused rapid leakage (30-80% in 15 min) of calcein from preloaded small unilamellar lipid vesicles.	Fluorescein-5-isothiocyanate	5-31	keratin 20	Homo sapiens	51-54
25538692-9	2014	With fluorescein isothiocyanate (FITC), 20-25 mg/L K20 caused staining of &gt;95% of C. neoformans and Fusarium graminearum cells and at 31.3 mg/L caused rapid leakage (30-80% in 15 min) of calcein from preloaded small unilamellar lipid vesicles.	Fluorescein-5-isothiocyanate	33-37	keratin 20	Homo sapiens	51-54
25538692-9	2014	With fluorescein isothiocyanate (FITC), 20-25 mg/L K20 caused staining of &gt;95% of C. neoformans and Fusarium graminearum cells and at 31.3 mg/L caused rapid leakage (30-80% in 15 min) of calcein from preloaded small unilamellar lipid vesicles.	fluorexon	190-197	keratin 20	Homo sapiens	51-54
25538692-12	2014	K20 is a novel amphiphilic aminoglycoside amenable to scalable production and a potential lead antifungal for therapeutic and crop protection applications.	Aminoglycosides	27-41	keratin 20	Homo sapiens	0-3
25082646-1	2014	INTRODUCTION: Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX).	Methotrexate	141-153	keratin 20	Homo sapiens	51-55
25088934-7	2014	The ability of antibody to suppress the growth of CD20 overexpressing Raji cells was tested by MTT assay.	monooxyethylene trimethylolpropane tristearate	95-98	keratin 20	Homo sapiens	50-54
25042202-0	2014	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.	ibrutinib	15-24	keratin 20	Homo sapiens	143-147
25440606-2	2014	Two products targeting the CD20 antigen are approved in the treatment of non-Hodgkin B-cell lymphoma (NHBL): iodine 131-tositumomab and yttrium 90-ibritumomab tiuxetan.	ibritumomab tiuxetan	136-167	keratin 20	Homo sapiens	27-31
24283753-0	2014	The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	30-36	keratin 20	Homo sapiens	154-158
25271635-9	2014	Flow cytometric analysis of PBMCs revealed that CD3+ were more affected than CD20+ cells to apopotosis by cinnamaldehyde.	cinnamaldehyde	106-120	keratin 20	Homo sapiens	77-81
25081540-6	2014	The CK20-positive rates of these 3 location types differed significantly (peri-AMP type, 50.6% +- 21.0%; extended type, 35.4% +- 18.6%; intra-AMP type, 6.9% +- 6.3%).	peri	74-78	keratin 20	Homo sapiens	4-8
25081540-6	2014	The CK20-positive rates of these 3 location types differed significantly (peri-AMP type, 50.6% +- 21.0%; extended type, 35.4% +- 18.6%; intra-AMP type, 6.9% +- 6.3%).	Adenosine Monophosphate	79-82	keratin 20	Homo sapiens	4-8
25081540-7	2014	The CK20-positive rate for intestinal-type tumors of the intra-AMP location type was lower than that of the peri-AMP location type.	Adenosine Monophosphate	63-66	keratin 20	Homo sapiens	4-8
25081540-7	2014	The CK20-positive rate for intestinal-type tumors of the intra-AMP location type was lower than that of the peri-AMP location type.	peri-amp	108-116	keratin 20	Homo sapiens	4-8
24852241-8	2014	Immunohistochemical analysis showed that the LP cells in all cases were positive for CD20, CD79a, PAX5, OCT2, and CD45 and were negative for CD15.	leucylproline	45-47	keratin 20	Homo sapiens	85-89
25042202-0	2014	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.	Prednisone	89-99	keratin 20	Homo sapiens	143-147
25042202-3	2014	We investigated the safety and efficacy of ibrutinib in combination with R-CHOP for patients with previously untreated CD20-positive B-cell non-Hodgkin lymphoma.	ibrutinib	43-52	keratin 20	Homo sapiens	119-123
24956063-3	2014	Chitosan was covalently conjugated with anti-CD20 polyclonal antibody (pAbCD20) via formation of amide bonds between amines and carboxyl groups.	Amides	97-102	keratin 20	Homo sapiens	45-49
24956063-3	2014	Chitosan was covalently conjugated with anti-CD20 polyclonal antibody (pAbCD20) via formation of amide bonds between amines and carboxyl groups.	Amines	117-123	keratin 20	Homo sapiens	45-49
24652202-9	2014	Ligplot shows hydrogen bondings (S16, S17, V18, G19, K20, T21, S22, S31, T33, A35, S38, T39 and G65) and hydrophobic interacting residues (F25, F32, P34, F36, V37, D62 and A64) with the GTP ligands in the binding site of Rab3A protein.	Hydrogen	14-22	keratin 20	Homo sapiens	53-56
24948624-0	2014	CD20 antibodies induce production and release of reactive oxygen species by neutrophils.	Reactive Oxygen Species	49-72	keratin 20	Homo sapiens	0-4
24685706-7	2014	Anti-CD20 (Rituximab)-painted RBCs efficiently (over 90%) depleted CD19+/CD20+/CD45+ human lymphoma cells in mantle cell lymphoma (MCL) JeKo-1 model, while the same amount of rituximab-lipid (2mug/mouse) was much less efficient in lymphoma cell depletion.	rituximab-lipid	175-190	keratin 20	Homo sapiens	5-9
24528507-0	2014	CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.	Bortezomib	64-74	keratin 20	Homo sapiens	0-4
24458483-6	2014	In a novel finding, robust NCS formation on CD20 was dependent on a 4 ng/mL progesterone threshold but did not correlate linearly with serum progesterone levels.	Progesterone	76-88	keratin 20	Homo sapiens	44-48
24982661-0	2014	TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.	Oligodeoxyribonucleotides	17-37	keratin 20	Homo sapiens	81-85
24727089-11	2014	The mean percentage of total cells reacting with serum ATG from ten patients compared to fresh ATG (100%) was 44% of CD4 positive and 58% of CD8 positive T-lymphocytes, 41% of CD56 positive NK-cells, 83% of CD20 positive B-lymphocytes and 98% of CD14 positive monocytes.	atg	55-58	keratin 20	Homo sapiens	207-211
24183980-0	2014	Comment on "pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19(+)CD20(+)CD3(-)CD70(-)CD27(+)IgM(+)CD43(+)CD5(+/-)".	Polysaccharides	25-39	keratin 20	Homo sapiens	136-140
24519895-4	2014	Moreover, acadesine was highly synergistic, both in vitro and in vivo, with the anti-CD20 monoclonal antibody rituximab, commonly used in combination therapy for MCL.	acadesine	10-19	keratin 20	Homo sapiens	85-89
24486518-1	2014	The anti CD20 antibody Rituximab was conjugated with para isothiocyanato benzyl diethylene triamine penta acetic acid (p-NCS-Bz-DTPA) and subsequent radiolabeling with (99m)Tc was carried out via the (99m)Tc carbonyl synthon.	para isothiocyanato benzyl diethylene triamine penta acetic acid	53-117	keratin 20	Homo sapiens	9-13
24486518-1	2014	The anti CD20 antibody Rituximab was conjugated with para isothiocyanato benzyl diethylene triamine penta acetic acid (p-NCS-Bz-DTPA) and subsequent radiolabeling with (99m)Tc was carried out via the (99m)Tc carbonyl synthon.	p-ncs-bz-dtpa	119-132	keratin 20	Homo sapiens	9-13
23903896-0	2014	Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.	auristatin	114-124	keratin 20	Homo sapiens	46-50
23903896-3	2014	In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl auristatin E (MMAE) through a cathepsin-B-cleavable valine-citrulline (vc) dipeptide linkage to form OFA-vcMMAE and the anti-tumor activity of OFA-vcMMAE against CD20-positive B lymphoma cells are then evaluated in vitro and in vivo.	monomethyl auristatin E	114-137	keratin 20	Homo sapiens	63-67
23903896-3	2014	In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl auristatin E (MMAE) through a cathepsin-B-cleavable valine-citrulline (vc) dipeptide linkage to form OFA-vcMMAE and the anti-tumor activity of OFA-vcMMAE against CD20-positive B lymphoma cells are then evaluated in vitro and in vivo.	monomethyl auristatin E	114-137	keratin 20	Homo sapiens	287-291
23903896-3	2014	In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl auristatin E (MMAE) through a cathepsin-B-cleavable valine-citrulline (vc) dipeptide linkage to form OFA-vcMMAE and the anti-tumor activity of OFA-vcMMAE against CD20-positive B lymphoma cells are then evaluated in vitro and in vivo.	valine-citrulline	177-194	keratin 20	Homo sapiens	63-67
23903896-3	2014	In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl auristatin E (MMAE) through a cathepsin-B-cleavable valine-citrulline (vc) dipeptide linkage to form OFA-vcMMAE and the anti-tumor activity of OFA-vcMMAE against CD20-positive B lymphoma cells are then evaluated in vitro and in vivo.	Polyvinyl Chloride	196-198	keratin 20	Homo sapiens	63-67
23903896-3	2014	In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl auristatin E (MMAE) through a cathepsin-B-cleavable valine-citrulline (vc) dipeptide linkage to form OFA-vcMMAE and the anti-tumor activity of OFA-vcMMAE against CD20-positive B lymphoma cells are then evaluated in vitro and in vivo.	Dipeptides	200-209	keratin 20	Homo sapiens	63-67
24056738-7	2014	CD20Bi aATC infusions induced specific cytotoxicity directed at lymphoma targets.	aatc	7-11	keratin 20	Homo sapiens	0-4
25313353-9	2014	Lenalidomide also upregulated CD20 expression on leukemia cells and, accordingly, it had a synergistic effect with rituximab on promoting antibody-dependent cell-mediated cytotoxicity against primary leukemia cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	30-34
24189269-7	2014	Higher reactive oxygen species (ROS) expelling and in vitro colony formation activities were detected in CD20- CD138- cells than in CD20+ CD138- and CD20+ CD138+ cells.	Reactive Oxygen Species	7-30	keratin 20	Homo sapiens	105-109
24189269-7	2014	Higher reactive oxygen species (ROS) expelling and in vitro colony formation activities were detected in CD20- CD138- cells than in CD20+ CD138- and CD20+ CD138+ cells.	Reactive Oxygen Species	32-35	keratin 20	Homo sapiens	132-136
22633802-12	2014	The combination of CK20 and Ki-67 showed significantly worse RFS (p=0.026), PFS (p=0.003), and CSS (p&lt;0.001) in tumours with a high proliferation index and abnormal CK20 expression.	thiocysteine	95-98	keratin 20	Homo sapiens	19-23
24189269-7	2014	Higher reactive oxygen species (ROS) expelling and in vitro colony formation activities were detected in CD20- CD138- cells than in CD20+ CD138- and CD20+ CD138+ cells.	Reactive Oxygen Species	7-30	keratin 20	Homo sapiens	132-136
24189269-7	2014	Higher reactive oxygen species (ROS) expelling and in vitro colony formation activities were detected in CD20- CD138- cells than in CD20+ CD138- and CD20+ CD138+ cells.	Reactive Oxygen Species	32-35	keratin 20	Homo sapiens	132-136
24189269-11	2014	The production of all three subpopulations, the efficient ROS expelling and in vitro colony-forming activities, and the resistance to apoptosis suggested that the CD20- CD138- cell might be a candidate of CICs in WM.	Reactive Oxygen Species	58-61	keratin 20	Homo sapiens	163-167
24189269-7	2014	Higher reactive oxygen species (ROS) expelling and in vitro colony formation activities were detected in CD20- CD138- cells than in CD20+ CD138- and CD20+ CD138+ cells.	Reactive Oxygen Species	7-30	keratin 20	Homo sapiens	132-136
24189269-7	2014	Higher reactive oxygen species (ROS) expelling and in vitro colony formation activities were detected in CD20- CD138- cells than in CD20+ CD138- and CD20+ CD138+ cells.	Reactive Oxygen Species	32-35	keratin 20	Homo sapiens	105-109
25379535-2	2014	In a clinical field, two successful examples of this treatment protocol are currently extended by (90)Y-ibritumomab tiuxetan (Zevalin) and (131)I-tositumomab (Bexxar), both of which are anti-CD20 monoclonal antibodies coupled to cytotoxic radioisotopes and are approved for the treatment of non-Hodgkin lymphoma patients.	ibritumomab tiuxetan	104-124	keratin 20	Homo sapiens	191-195
24655971-0	2014	Usefulness and safety of high-dose mizoribine on ABO-incompatible living related kidney transplantation using anti-CD20 and anti-CD25 antibodies without splenectomy: 3-year results.	mizoribine	35-45	keratin 20	Homo sapiens	115-119
23911852-0	2013	Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19+CD20+CD3-CD70-CD27+IgM+CD43+CD5+/-.	pneumococcal polysaccharide	0-27	keratin 20	Homo sapiens	122-126
23927993-8	2013	Among patients receiving bortezomib-based treatment, patients harboring t(11;14) without CD20 expression had a significantly shortened PFS (11.0 versus 43.0 months, p=0.005) and OS (16.5 versus 54.0 months, p=0.016) compared with patients displaying t(11;14) with CD20.	Bortezomib	25-35	keratin 20	Homo sapiens	89-93
23927993-8	2013	Among patients receiving bortezomib-based treatment, patients harboring t(11;14) without CD20 expression had a significantly shortened PFS (11.0 versus 43.0 months, p=0.005) and OS (16.5 versus 54.0 months, p=0.016) compared with patients displaying t(11;14) with CD20.	Bortezomib	25-35	keratin 20	Homo sapiens	264-268
24098639-0	2013	New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.	Chlorambucil	82-94	keratin 20	Homo sapiens	126-130
24098639-0	2013	New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.	Hydroxychloroquine	95-113	keratin 20	Homo sapiens	126-130
24098639-3	2013	In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody.	Hydroxychloroquine	96-114	keratin 20	Homo sapiens	197-201
24098639-3	2013	In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody.	Chlorambucil	119-131	keratin 20	Homo sapiens	197-201
24098639-8	2013	In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab.	Hydroxychloroquine	84-102	keratin 20	Homo sapiens	53-57
24098639-8	2013	In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab.	Chlorambucil	107-119	keratin 20	Homo sapiens	53-57
24098639-9	2013	These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.	Hydroxychloroquine	78-96	keratin 20	Homo sapiens	50-54
24098639-9	2013	These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.	Chlorambucil	101-113	keratin 20	Homo sapiens	50-54
24097872-2	2013	EXPERIMENTAL DESIGN: The engineered FN3(CD20) and FN3(WT) were produced in Escherichia coli cells at 2 to 5 mg/L, conjugated to DOTA, labeled with (64)Cu, and used for PET imaging of huCD20 expression in B cells.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	128-132	keratin 20	Homo sapiens	40-44
24348405-3	2013	We present a case of IOID that was successfully treated with the anti-CD20 monoclonal antibody rituximab following failed steroid sparing with conventional second-line immunosuppressive agents.	Steroids	122-129	keratin 20	Homo sapiens	70-74
24490292-6	2013	RESULT: Patients with CRS had higher infiltration of the B lymphocytes (CD20) and T lymphocyte subsets (CD4, CD88) than the patients of the control group (P &lt; 0.05).	Chromium	22-25	keratin 20	Homo sapiens	72-76
23583086-8	2013	Finally, PGE2 and beraprost enhanced the generation of both CD20-CD38+ plasma cells and CD20+CD38- memory B cells from GC B cells.	Dinoprostone	9-13	keratin 20	Homo sapiens	60-64
23583086-8	2013	Finally, PGE2 and beraprost enhanced the generation of both CD20-CD38+ plasma cells and CD20+CD38- memory B cells from GC B cells.	Dinoprostone	9-13	keratin 20	Homo sapiens	88-92
23911852-0	2013	Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19+CD20+CD3-CD70-CD27+IgM+CD43+CD5+/-.	Polysaccharides	13-27	keratin 20	Homo sapiens	122-126
23911852-6	2013	We show that 7 days post-immunization the majority of pneumococcal polysaccharide-selected IgM(+) memory cells (PPS14(+) 56.5%, PPS23F(+) 63.8%) were CD19(+)CD20(+)CD27(+)IgM(+)CD43(+)CD5(+/-)CD70(-), which was significantly increased compared to pre-immunization levels.	Polysaccharides	67-81	keratin 20	Homo sapiens	157-161
23529012-1	2013	A phase I trial of infusing anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) armed activated T cells (aATC) was conducted in high-risk/refractory non-Hodgkin"s lymphoma patients to determine whether aATC infusions are safe, affect immune recovery, and induce an antilymphoma effect.	aatc	103-107	keratin 20	Homo sapiens	44-48
23926879-8	2013	The effects of Ca(2+) and Mn(2+) ions on the Rituximab-Raji cell interaction were also studied providing the enhanced QCM signals, in particular with Ca(2+), further indicating that CD20 is a calcium ion channel that can transport these metal ions into the cells and accelerate the cell lysis induced by Rituximab.	Manganese(2+)	26-32	keratin 20	Homo sapiens	182-186
23926879-8	2013	The effects of Ca(2+) and Mn(2+) ions on the Rituximab-Raji cell interaction were also studied providing the enhanced QCM signals, in particular with Ca(2+), further indicating that CD20 is a calcium ion channel that can transport these metal ions into the cells and accelerate the cell lysis induced by Rituximab.	Metals	237-242	keratin 20	Homo sapiens	182-186
23639298-8	2013	As a consequence, the ADA method was modified to minimize the matrix interference caused by CD20(+) CMFs and, then, validated for sample testing.	N-(2-acetamido)iminodiacetic acid	22-25	keratin 20	Homo sapiens	92-96
23603515-0	2013	Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels.	Cholesterol	98-109	keratin 20	Homo sapiens	35-39
23875170-3	2013	Today, two products targeting the CD20 antigen are approved: (131)I-tositumomab (Bexxar( )), and (90)Y-ibritumomab tiuxetan (Zevalin( )).	ibritumomab tiuxetan	103-123	keratin 20	Homo sapiens	34-38
23471750-2	2013	PROCEDURES: Zr-rituximab (2.6 MBq) was tail vein-injected into transgenic mice that express the human CD20 on their B cells (huCD20TM).	Zirconium	12-14	keratin 20	Homo sapiens	102-106
23919117-5	2013	METHODS: In this study, we have determined the expression titer of monoclonal antibody against human CD20 using soy extract, Essential Amino Acid, Non-Essential Amino Acid, Panexin NTS, Peptone, Yeast extract, Insulin-transferrin selenite, Human Serum Albumin, Bovine Serum Albumin, Lipid, and two commercially available supplements, Power and Xtreme feed.	Amino Acids, Essential	125-145	keratin 20	Homo sapiens	101-105
23298674-3	2013	METHODS: Iron oxide nanoparticles coated with a copolymer of chitosan-grafted polyethylene glycol (NPs) were conjugated with an anti-CD20 single-chain variable fragment-streptavidin fusion protein (FP), and optically activated with Oregon Green 488.	ferric oxide	9-19	keratin 20	Homo sapiens	133-137
23298674-3	2013	METHODS: Iron oxide nanoparticles coated with a copolymer of chitosan-grafted polyethylene glycol (NPs) were conjugated with an anti-CD20 single-chain variable fragment-streptavidin fusion protein (FP), and optically activated with Oregon Green 488.	Polyethylene Glycols	78-97	keratin 20	Homo sapiens	133-137
23298674-3	2013	METHODS: Iron oxide nanoparticles coated with a copolymer of chitosan-grafted polyethylene glycol (NPs) were conjugated with an anti-CD20 single-chain variable fragment-streptavidin fusion protein (FP), and optically activated with Oregon Green 488.	Oregon Green 488 carboxylic acid	232-248	keratin 20	Homo sapiens	133-137
23765188-15	2013	CONCLUSION: Myeloablative RIT with 131I-rituximab followed by ASCT is feasible, well-tolerated and effective in high risk CD20+ NHL.	asct	62-66	keratin 20	Homo sapiens	122-126
23462143-0	2013	Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report.	5-azacytidin	15-27	keratin 20	Homo sapiens	58-62
23462143-0	2013	Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report.	5-azacytidin	15-27	keratin 20	Homo sapiens	66-70
23530878-0	2013	Phase I study of a modified regimen of 90Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.	90yttrium-ibritumomab tiuxetan	39-69	keratin 20	Homo sapiens	123-127
23144195-1	2013	The treatment of choice in steroid-resistant immune thrombocytopenia is still controversial due to the recent advent of new drugs (anti-CD20 antibodies and thrombopoietin mimetics) that have encouraged a generalized tendency to delay splenectomy.	Steroids	27-34	keratin 20	Homo sapiens	136-140
23710950-13	2013	In nonfungal CRS cases, CD20+ lymphocytes (B lymphocytes) predominated (p &lt; 0.001).	3-cresol	13-16	keratin 20	Homo sapiens	24-28
23341189-2	2013	Previous reports suggest that decreased CD20 and/or CD19 expression by flow cytometry is relatively common in DHL and may help to identify cases requiring additional cytogenetic analysis.	Cysteamine	110-113	keratin 20	Homo sapiens	40-44
23700066-8	2013	The key role of methotrexate and its optimal risk adapted dose and administration schedule for treatment of mature B-cell neoplasm"s could be enlightened and the first phase 2 study proving the activity of the anti-CD20 monoclonal antibody Rituximab as targeted therapy for pediatric B-NHL was successfully conducted.	Methotrexate	16-28	keratin 20	Homo sapiens	215-219
23612383-0	2013	Transient effect of anti-CD20 therapy in a child with 22q11.2 deletion syndrome and severe steroid refractory cytopenias: a case report.	Steroids	91-98	keratin 20	Homo sapiens	25-29
23347903-4	2013	HCL-v expressed bright CD20, bright CD22, CD11c(100%), CD103(100%), dim(40%) or negative(60%) CD123, and uniformly lacked CD25(100%).	hcl-v	0-5	keratin 20	Homo sapiens	23-27
23295790-12	2013	This and the manageable toxicity profile suggest that R-INO may be a promising option for CD20(+)/CD22(+) B-cell NHL.	r-ino	54-59	keratin 20	Homo sapiens	90-94
23121194-5	2013	On the other hand, anti-CD 20 mAb-PEG-SN-38 via carbamate-bond as conventional immunoconjugate, enabled SN-38 to be released by a carboxylesterase inside of the tumor cell following the internalization, showed strong anti-tumor activity against malignant lymphoma as hypervascular and stroma-poor tumor.	Irinotecan	104-109	keratin 20	Homo sapiens	24-29
23121194-5	2013	On the other hand, anti-CD 20 mAb-PEG-SN-38 via carbamate-bond as conventional immunoconjugate, enabled SN-38 to be released by a carboxylesterase inside of the tumor cell following the internalization, showed strong anti-tumor activity against malignant lymphoma as hypervascular and stroma-poor tumor.	Polyethylene Glycols	34-37	keratin 20	Homo sapiens	24-29
23305345-0	2013	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.	Bortezomib	11-21	keratin 20	Homo sapiens	58-62
23121194-5	2013	On the other hand, anti-CD 20 mAb-PEG-SN-38 via carbamate-bond as conventional immunoconjugate, enabled SN-38 to be released by a carboxylesterase inside of the tumor cell following the internalization, showed strong anti-tumor activity against malignant lymphoma as hypervascular and stroma-poor tumor.	Irinotecan	38-43	keratin 20	Homo sapiens	24-29
23121194-5	2013	On the other hand, anti-CD 20 mAb-PEG-SN-38 via carbamate-bond as conventional immunoconjugate, enabled SN-38 to be released by a carboxylesterase inside of the tumor cell following the internalization, showed strong anti-tumor activity against malignant lymphoma as hypervascular and stroma-poor tumor.	Carbamates	48-57	keratin 20	Homo sapiens	24-29
23474846-7	2013	Breaking radio-/ chemoresistance in NHL cells using [Bi-213]anti-CD20 depends on caspase activation as demonstrated by complete inhibition of [Bi-213]anti-CD20-induced apoptosis with zVAD.fmk, a specific inhibitor of caspases activation.	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	183-187	keratin 20	Homo sapiens	65-69
23474846-7	2013	Breaking radio-/ chemoresistance in NHL cells using [Bi-213]anti-CD20 depends on caspase activation as demonstrated by complete inhibition of [Bi-213]anti-CD20-induced apoptosis with zVAD.fmk, a specific inhibitor of caspases activation.	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	183-187	keratin 20	Homo sapiens	155-159
23256681-10	2013	EXPERT OPINION: Rituximab, the prototype anti-CD20 mAb, forms the core of CIT in CLL.	cit	74-77	keratin 20	Homo sapiens	46-50
23305345-6	2013	CONCLUSIONS: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.	Bortezomib	67-70	keratin 20	Homo sapiens	133-137
23305345-6	2013	CONCLUSIONS: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.	Bortezomib	207-210	keratin 20	Homo sapiens	133-137
23357165-2	2013	METHODS: Twenty-three patients with Luminex-detected DSA were successfully desensitized by anti-CD20 therapy and immunoadsorption (N = 19) or plasmapheresis (N = 4) and received a kidney transplant from a living donor.	luminex	36-43	keratin 20	Homo sapiens	96-100
23573362-3	2013	At present, standard first line treatment for DLBCL patients is the antracycline-based chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP).	antracycline	68-80	keratin 20	Homo sapiens	207-211
23165478-3	2013	In an attempt to diminish their off-target prosurvival and proinflammatory effects and specific delivery, as a proof of principle, in the present study, we developed an Ab-targeted liposomal delivery strategy using a clinically relevant CD20 Ab (rituximab)-conjugated lipopolyplex nanoparticle (RIT-INP)- and Bcl-2-targeted antisense G3139 as archetypical antisense therapeutics.	lipopolyplex	268-280	keratin 20	Homo sapiens	237-241
23165478-3	2013	In an attempt to diminish their off-target prosurvival and proinflammatory effects and specific delivery, as a proof of principle, in the present study, we developed an Ab-targeted liposomal delivery strategy using a clinically relevant CD20 Ab (rituximab)-conjugated lipopolyplex nanoparticle (RIT-INP)- and Bcl-2-targeted antisense G3139 as archetypical antisense therapeutics.	rit-inp	295-302	keratin 20	Homo sapiens	237-241
23165478-3	2013	In an attempt to diminish their off-target prosurvival and proinflammatory effects and specific delivery, as a proof of principle, in the present study, we developed an Ab-targeted liposomal delivery strategy using a clinically relevant CD20 Ab (rituximab)-conjugated lipopolyplex nanoparticle (RIT-INP)- and Bcl-2-targeted antisense G3139 as archetypical antisense therapeutics.	oblimersen	334-339	keratin 20	Homo sapiens	237-241
23288643-9	2013	Epigenetic therapy with the DNA hypomethylating agent 5-aza-2-deoxycytidine can also cause restoration of cell surface expression of the CD20 protein and increase rituximab sensitivity in vitro.	Decitabine	54-75	keratin 20	Homo sapiens	137-141
23357165-2	2013	METHODS: Twenty-three patients with Luminex-detected DSA were successfully desensitized by anti-CD20 therapy and immunoadsorption (N = 19) or plasmapheresis (N = 4) and received a kidney transplant from a living donor.	dsa	53-56	keratin 20	Homo sapiens	96-100
24099423-3	2013	In this article we describe the efficacy of 131I-rituximab in CD20-expressing Raji cells.	Iodine-131	44-48	keratin 20	Homo sapiens	62-66
23252565-6	2013	In addition, small modular immunopharmaceuticals - TRU-015 (anti-CD20) and TRU-016 (anti-CD37) - that retain Fc-mediated effector functions have been developed and investigated in preclinical studies and clinical trials.	tru	51-54	keratin 20	Homo sapiens	65-69
23040543-1	2013	Targeted therapies, such as those using imatinib and rituximab, have revolutionized the treatment of Philadelphia chromosome-positive and CD20-positive acute lymphoblastic leukemia (ALL) respectively, yet these therapies are effective in only a subset of patients and remission is generally not durable.	Imatinib Mesylate	40-48	keratin 20	Homo sapiens	138-142
22542823-0	2013	Evaluation of SERS labeling of CD20 on CLL cells using optical microscopy and fluorescence flow cytometry.	sers	14-18	keratin 20	Homo sapiens	31-35
22542823-3	2013	We report and evaluate the use of surface-enhanced Raman scattering (SERS) gold NPs (AuNPs) conjugated to therapeutic rituximab antibodies for selective targeting of CD20 molecules.	sers	69-73	keratin 20	Homo sapiens	166-170
22542823-5	2013	The effective targeting of CD20 on chronic lymphocytic leukemia cells by rituximab-conjugated SERS AuNPs was evaluated by dark-field imaging, Raman spectroscopy, and flow cytometry with both competitive binding and fluorescence detection procedures.	sers	94-98	keratin 20	Homo sapiens	27-31
22948319-1	2013	BACKGROUND: Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children.	Steroids	96-103	keratin 20	Homo sapiens	31-35
22948319-1	2013	BACKGROUND: Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children.	Steroids	118-125	keratin 20	Homo sapiens	31-35
22890585-6	2013	To measure the CD20-rituximab interaction forces, the polyethylene glycol (PEG) linker was used to link rituximab onto the AFM tip and the verification experiments of the functionalized probe indicated that rituximab molecules were successfully linked onto the AFM tip.	Polyethylene Glycols	54-73	keratin 20	Homo sapiens	15-19
22249209-8	2012	Of the 105 patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy, those who were CD20 negative (FCM) showed significantly inferior overall (hazard ratios (HR): 6.79, 95% CI: 1.32-34.96, p = 0.04) and progression-free survival (HR: 7.3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal.	Cyclophosphamide	48-64	keratin 20	Homo sapiens	133-137
22563760-2	2013	Adjunction of the monoclonal anti-CD20 antibody rituximab (R-ACVBP) was recently found to be superior to ACVBP alone.	r-acvbp	59-66	keratin 20	Homo sapiens	34-38
22563760-2	2013	Adjunction of the monoclonal anti-CD20 antibody rituximab (R-ACVBP) was recently found to be superior to ACVBP alone.	acvbp	61-66	keratin 20	Homo sapiens	34-38
23158095-3	2012	Radioimmunotherapy (RIT) with an anti-CD20 antibody linked to iodine-131 or to yttrium-90 has emerged as well-tolerated treatment after induction.	Iodine-131	62-72	keratin 20	Homo sapiens	38-42
23158095-3	2012	Radioimmunotherapy (RIT) with an anti-CD20 antibody linked to iodine-131 or to yttrium-90 has emerged as well-tolerated treatment after induction.	Yttrium-90	79-89	keratin 20	Homo sapiens	38-42
22982241-0	2012	Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle.	Calcium	48-55	keratin 20	Homo sapiens	14-18
23436965-0	2012	Everolimus for the treatment of CD20+ diffuse large B-cell lymphoma in a renal allograft recipient.	Everolimus	0-10	keratin 20	Homo sapiens	32-36
22955077-1	2012	99Y-ibritumomab tiuxetan (Zevalin) is a CD20-targeted radioimmunotherapy for the treatment of B-cell non-Hodgkin lymphoma approved by the FDA in 2002.	99y-ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	40-44
22231277-1	2012	PURPOSE: This study aims to evaluate (64)Cu-DOTA-rituximab (PETRIT) in a preclinical transgenic mouse model expressing human CD20 for potential clinical translation.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	41-48	keratin 20	Homo sapiens	125-129
23606931-2	2012	The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in difficult to treat patients with chronic lymphocytic leukemia, namely those resistant or refractory to fludarabine and alemtuzumab and has now been licensed for this uncommon indication.	fludarabine	194-205	keratin 20	Homo sapiens	21-25
22849322-3	2012	Double immunohistochemical staining of CD20 and CD27 was carried out on paraffin-embedded SG tissue from 10 pSS patients to distinguish CD20(+)/CD27(+) memory B cells, and identify the CD20(+) glandular B cell zones (BCZ).	Paraffin	72-80	keratin 20	Homo sapiens	39-43
21805176-2	2012	Rituximab (RTX), a chimeric monoclonal antibody against the CD20 molecule expressed on the surface of mature B cells that has been approved for the treatment of NHL, has been used to treat pSS-associated lymphoma.	pss	189-192	keratin 20	Homo sapiens	60-64
22721383-6	2012	After combining with either adriamycin or cyclophosphamide, the binding capacity of R to the CD20 antigen was equivalent to controls, and no molecular changes in adriamycin and cyclophosphamide were detected after combination with R. Twenty-one cases of DLBCL were treated safely with concurrent administration of R and CHOP.	Doxorubicin	28-38	keratin 20	Homo sapiens	93-97
22721383-6	2012	After combining with either adriamycin or cyclophosphamide, the binding capacity of R to the CD20 antigen was equivalent to controls, and no molecular changes in adriamycin and cyclophosphamide were detected after combination with R. Twenty-one cases of DLBCL were treated safely with concurrent administration of R and CHOP.	Cyclophosphamide	42-58	keratin 20	Homo sapiens	93-97
22888081-3	2012	CK20 immunostaining was performed on archived papanicolaou stained urine cytology smears in 34 cases (27 bladder carcinoma and 7 negative controls).	papanicolaou	46-58	keratin 20	Homo sapiens	0-4
22395998-4	2012	METHODS: In 108 patients with colorectal liver metastases, the presence of DTC in the peripheral blood and bone marrow was detected with CK20 RT-PCR.	dtc	75-78	keratin 20	Homo sapiens	137-141
22249209-8	2012	Of the 105 patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy, those who were CD20 negative (FCM) showed significantly inferior overall (hazard ratios (HR): 6.79, 95% CI: 1.32-34.96, p = 0.04) and progression-free survival (HR: 7.3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal.	Doxorubicin	66-77	keratin 20	Homo sapiens	133-137
22249209-8	2012	Of the 105 patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy, those who were CD20 negative (FCM) showed significantly inferior overall (hazard ratios (HR): 6.79, 95% CI: 1.32-34.96, p = 0.04) and progression-free survival (HR: 7.3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal.	Vincristine	79-90	keratin 20	Homo sapiens	133-137
22249209-8	2012	Of the 105 patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy, those who were CD20 negative (FCM) showed significantly inferior overall (hazard ratios (HR): 6.79, 95% CI: 1.32-34.96, p = 0.04) and progression-free survival (HR: 7.3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal.	Prednisolone	96-108	keratin 20	Homo sapiens	133-137
22315496-4	2012	Thus, only a small population of CD20(dim+) cells (0.3%) in the RPMI-8226 cell line was found.	rpmi	64-68	keratin 20	Homo sapiens	33-37
22252477-8	2012	When an anti-human CD20 antibody protein is stably expressed in one CHO-DUKX-Lec1 line, it is confirmed that N-glycans are predominantly Man(5) GlcNAc(2) and they do not contain an alpha1,6-fucose linked to the innermost GlcNAc.	n-glycans	109-118	keratin 20	Homo sapiens	19-23
22252477-8	2012	When an anti-human CD20 antibody protein is stably expressed in one CHO-DUKX-Lec1 line, it is confirmed that N-glycans are predominantly Man(5) GlcNAc(2) and they do not contain an alpha1,6-fucose linked to the innermost GlcNAc.	alpha1,6-fucose	181-196	keratin 20	Homo sapiens	19-23
22252477-8	2012	When an anti-human CD20 antibody protein is stably expressed in one CHO-DUKX-Lec1 line, it is confirmed that N-glycans are predominantly Man(5) GlcNAc(2) and they do not contain an alpha1,6-fucose linked to the innermost GlcNAc.	2-acetamido-2-deoxy-4-O-(beta-2-acetamid-2-deoxyglucopyranosyl)glucopyranose	144-150	keratin 20	Homo sapiens	19-23
22269114-9	2012	Our data support fludarabine, cyclophosphamide, and rituximab-based nonablative conditioning allo-SCT in CD20(+) B-cell lymphoid malignancies and it is time to compare this regimen with an alternative reduced-intensity conditioning regimen in B-cell malignancies.	fludarabine	17-28	keratin 20	Homo sapiens	105-109
22237846-1	2012	PURPOSE: Radioimmunotherapy with (90)Y-ibritumomab tiuxetan has been used successfully used in the treatment of CD20-positive non-Hodgkin"s lymphoma (NHL).	y-ibritumomab tiuxetan	37-59	keratin 20	Homo sapiens	112-116
23586828-7	2012	In this study, we selected three candidate epitopes within the extra membrane loop of hCD20 with the aid of five immunoinformatics predictor web servers and evaluated mouse humoral response to keyhole-limpet-hemocyaninconjugated peptides, and P4 and P5 peptides (the extracellular loop of hCD20 without and with a disulfide bond, respectively).	Disulfides	314-323	keratin 20	Homo sapiens	86-91
22443503-12	2012	Rituximab, an anti-CD20 antibody that specifically depletes B lymphocytes, can be an effective treatment strategy for patients with steroid-refractory, B cell-predominant lymphocytic hypophysitis.	Steroids	132-139	keratin 20	Homo sapiens	19-23
22350416-4	2012	In this study, we developed a mathematical model that integrates temporal patterns of drug exposure, receptor occupancy, and signal transduction to predict the effects of the CD20 agonist rituximab in combination with rhApo2L/TNF-related apoptosis inducing ligand or fenretinide, a cytotoxic retinoid, upon growth kinetics in non-Hodgkin lymphoma xenografts.	Fenretinide	267-278	keratin 20	Homo sapiens	175-179
22712014-0	2012	Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine.	Cladribine	121-131	keratin 20	Homo sapiens	57-61
22354003-4	2012	Here, we reveal that the induction of PCD by these mAbs, including the type II anti-CD20 mAb GA101 (obinutuzumab), directly correlates with their ability to produce reactive oxygen species (ROS) in human B-lymphoma cell lines and primary B-cell chronic lymphocytic leukemia cells.	Reactive Oxygen Species	165-188	keratin 20	Homo sapiens	84-88
22354003-4	2012	Here, we reveal that the induction of PCD by these mAbs, including the type II anti-CD20 mAb GA101 (obinutuzumab), directly correlates with their ability to produce reactive oxygen species (ROS) in human B-lymphoma cell lines and primary B-cell chronic lymphocytic leukemia cells.	Reactive Oxygen Species	190-193	keratin 20	Homo sapiens	84-88
22171982-3	2012	Lenalidomide, an immunomodulator, is clinically effective in CLL and can enhance the anti-CLL effects of CD20 targeting monoclonal antibody, rituximab.	Lenalidomide	0-12	keratin 20	Homo sapiens	105-109
22475423-7	2012	Either of 2 anti-CD20 monoclonal antibodies, one labeled with indium for imaging or (90)Y for radiotherapy or a second labeled with (131)I for both imaging and radiotherapy, is used for salvage and first-line therapy of multifocal non-Hodgkin lymphoma.	Indium	62-68	keratin 20	Homo sapiens	17-21
22271448-4	2012	The juxtaposition of CD20 and CD74 on MCL cells by the HexAbs resulted in homotypic adhesion and triggered intracellular changes that include loss of mitochondrial transmembrane potential, production of reactive oxygen species, rapid and sustained phosphorylation of ERKs and JNK, down-regulation of pAkt and Bcl-xL, actin reorganization, and lysosomal membrane permeabilization, culminating in cell death.	Reactive Oxygen Species	203-226	keratin 20	Homo sapiens	21-25
22271448-6	2012	Such bispecific HexAbs may constitute a new class of therapeutic agents for improved cancer immunotherapy, as shown here for MCL and other CD20(+)/CD74(+) malignancies.	hexabs	16-22	keratin 20	Homo sapiens	139-143
22493352-0	2012	CK20 expression enhances the invasiveness of tamoxifen-resistant MCF-7 cells.	Tamoxifen	45-54	keratin 20	Homo sapiens	0-4
22493352-2	2012	However, little is known about CK20 expression and tumor metastasis in tamoxifen-resistant MCF-7 (TRM-7) breast cancer cells.	Tamoxifen	71-80	keratin 20	Homo sapiens	31-35
22493352-6	2012	Our findings suggest that PPARgamma-dependent CK20 expression enhances the metastatic potential of MCF-7 breast cancer cells and may be a potential therapeutic target in tamoxifen-resistant breast cancer.	Tamoxifen	170-179	keratin 20	Homo sapiens	46-50
22350416-4	2012	In this study, we developed a mathematical model that integrates temporal patterns of drug exposure, receptor occupancy, and signal transduction to predict the effects of the CD20 agonist rituximab in combination with rhApo2L/TNF-related apoptosis inducing ligand or fenretinide, a cytotoxic retinoid, upon growth kinetics in non-Hodgkin lymphoma xenografts.	Retinoids	292-300	keratin 20	Homo sapiens	175-179
21827339-3	2012	We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) for patients with previously untreated advanced-stage indolent CD20-positive B-cell lymphoma according to the Working Formulation and World Health Organization classification.	R-tetrahydropapaverine HCl	99-104	keratin 20	Homo sapiens	173-177
22507801-2	2012	Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival.	cit	20-23	keratin 20	Homo sapiens	40-44
22288884-0	2012	Biological activity of anti-CD20 multivalent HPMA copolymer-Fab" conjugates.	copolymer	50-59	keratin 20	Homo sapiens	28-32
22288884-1	2012	High-molecular-weight, branched N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesized and conjugated with Fab" fragments of the anti-CD20 antibody, 1F5.	hpma) copolymers	67-83	keratin 20	Homo sapiens	148-152
22405566-6	2012	SMA group also had a higher percentage of CD20+ B cells (26.8 +- 9.7SD vs 20.9 +- 9.01 SD in the UM) (P = 0.03), indicating considerable polyclonal B-cell activation.	sma	0-3	keratin 20	Homo sapiens	42-46
22130422-11	2012	CONCLUSIONS: We propose that CD20 dissociation from the BCR signalosome is pivotal to BCR-mediated calcium mobilization in the cytosol.	Calcium	99-106	keratin 20	Homo sapiens	29-33
22058197-0	2012	Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.	Sphingolipids	21-34	keratin 20	Homo sapiens	57-61
21827339-7	2012	The R-THP-COP regimen appears very effective for patients with previously untreated advanced-stage indolent CD20-positive B-cell lymphoma.	R-tetrahydropapaverine HCl	4-9	keratin 20	Homo sapiens	108-112
21827339-7	2012	The R-THP-COP regimen appears very effective for patients with previously untreated advanced-stage indolent CD20-positive B-cell lymphoma.	Creatinolfosfate	10-13	keratin 20	Homo sapiens	108-112
21827339-8	2012	The present results indicate the need for randomized trials of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) and R-THP-COP among patients with CD20-positive indolent lymphoma.	r-thp-cop	147-156	keratin 20	Homo sapiens	177-181
21953334-4	2012	Based on these findings, three patients with active refractory TA were treated with B cell depletion therapy (BCDT) using monoclonal anti-CD20 antibodies (rituximab).	bcdt	110-114	keratin 20	Homo sapiens	138-142
21564352-2	2012	To our knowledge, this is the first case report of a patient who developed simultaneously subacute cutaneous lupus erythematosus and a small CD20+ B-cell clone because of chronic HCV infection and relapse after standard of care therapy (pegylated interferon plus ribavirin).	Ribavirin	263-272	keratin 20	Homo sapiens	141-145
22116821-5	2012	Splenic DEX-specific plasmablasts were located in the red pulp with persisting DEX-associated CD11c(+) dendritic cells 90 d after immunization, whereas DEX was not detected in the bone marrow after 28 d. Selective depletion of short-lived DEX-specific plasmablasts and memory B1b B cells using cyclophosphamide and anti-CD20 treatment had a minimal impact on the maintenance of serum anti-DEX Abs.	dex	8-11	keratin 20	Homo sapiens	320-324
22591390-2	2012	Two large randomized trials demonstrated superiority of chemoimmunotherapy combining fludarabine and cyclophosphamide with monoclonal anti-CD20 antibody rituximab (FCR) over fludarabine and cyclophosphamide (FC) alone in first line and relapse; this lead to establishment of FCR regimen as new gold standard in younger and physically fit patients.	Fc(alpha) receptor	164-166	keratin 20	Homo sapiens	139-143
22178408-2	2012	A method for the quantification of the anti-CD20 drug in human DBS was developed and validated.	dbs	63-66	keratin 20	Homo sapiens	44-48
22178408-5	2012	RESULTS: The assay range of the anti-CD20 drug standards in DBS was 100-2500ng/mL.	dbs	60-63	keratin 20	Homo sapiens	37-41
22178408-10	2012	Furthermore, the storage stability of the anti-CD20 drug on DBS cards was tested at various conditions.	dbs	60-63	keratin 20	Homo sapiens	47-51
22178408-11	2012	It was found that the anti-CD20 drug was stable for one week in DBS stored at room temperature.	dbs	64-67	keratin 20	Homo sapiens	27-31
22178408-14	2012	DISCUSSION: Our results demonstrated a successful use of DBS technique in ELISA quantification of an anti-CD20 monoclonal antibody drug in human blood.	dbs	57-60	keratin 20	Homo sapiens	106-110
21918174-1	2011	PURPOSE: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complement-dependent cytotoxicity (CDC) than rituximab.	fludarabine	80-91	keratin 20	Homo sapiens	31-35
21745212-5	2012	Cytotoxicity was optimal when CBATCs were armed with 50 ng of CD20Bi/10(6) cells.	cbatcs	30-36	keratin 20	Homo sapiens	62-66
21745212-7	2012	At an effector-to-target ratio of 25:1, the mean cytotoxicities of CBATCs armed with Her2Bi or CD20Bi were 40% (n=4) and 30% (n=4), respectively.	cbatcs	67-73	keratin 20	Homo sapiens	95-99
21917310-8	2011	When the NA/S sub-population was cultured back onto PDMS it resulted in the further enrichment of CD20+ CD271+ cells to 14.7%.	Sulfur	12-13	keratin 20	Homo sapiens	98-102
22064461-3	2011	Although many tumor-associated antigens have been identified as possible targets for radioimmunotherapy of patients with hematological or solid tumors, clinical success has so far been achieved mostly with radiolabeled antibodies against CD20 ((131)I-tositumomab and (90)Y-ibritumomab tiuxetan) for the treatment of lymphoma.	tiuxetan	285-293	keratin 20	Homo sapiens	238-242
21821153-3	2011	The treatment of MCs syndrome is generally based on antiviral drugs and/or immunosuppressors, among which rituximab, an anti-CD20 monoclonal antibody, has been usefully employed for both cutaneous and visceral MCs organ involvement.	mcs	17-20	keratin 20	Homo sapiens	125-129
22039078-9	2012	Thus, Emab-SN-38 is active in lymphoma and leukemia at doses well below toxic levels and therefore represents a new promising agent with therapeutic potential alone or combined with anti-CD20 antibody therapy.	emab-sn-38	6-16	keratin 20	Homo sapiens	187-191
22615937-5	2012	Palmitoylation of CD20 and CD23 was confirmed by heterologous expression of alanine mutants coupled with bioorthogonal metabolic labeling.	Alanine	76-83	keratin 20	Homo sapiens	18-22
22310599-0	2012	The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.	mizoribine	37-47	keratin 20	Homo sapiens	102-106
22566872-9	2011	Removal of CpG ODN during differentiation induced a decrease in the CD20+ plasmablastic population, and, conversely, stimulation of CD40L-induced pre-plasmablasts with CpG ODN increased the population of CD20+CD38+ PBs.	pbs	215-218	keratin 20	Homo sapiens	204-208
21856867-1	2011	Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (&gt; 5 cm) lymph nodes (BF-ref).	fludarabine	203-214	keratin 20	Homo sapiens	22-26
21909699-5	2011	CD20, B-lymphocyte, was decreased in the tocilizumab group compared with the MTX group significantly.	Methotrexate	77-80	keratin 20	Homo sapiens	0-4
21909699-10	2011	These findings indicate that the inhibition of CD20, CD29, and JNK in MAPK may be involved in the efficacy of tocilizumab compared with MTX treatment in RA.	Methotrexate	136-139	keratin 20	Homo sapiens	47-51
21624007-2	2011	The present dose-escalation study evaluated the safety, efficacy, and pharmacokinetics of bendamustine hydrochloride in combination with rituximab in patients with relapsed/refractory, CD20-positive, aggressive B-NHL.	Bendamustine Hydrochloride	90-116	keratin 20	Homo sapiens	185-189
21471566-1	2011	OBJECTIVE: To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).	Steroids	118-125	keratin 20	Homo sapiens	71-75
21819314-6	2011	EXPERT OPINION: A single course of the chimeric humanized anti-CD20 antibody rituximab was effective in reducing disease activity in pSS patients for about six to nine months.	pss	133-136	keratin 20	Homo sapiens	63-67
21474325-4	2011	This method seems to be an appropriate alternative for the production of [(177)Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.	Lutetium-177	75-82	keratin 20	Homo sapiens	93-97
21474325-4	2011	This method seems to be an appropriate alternative for the production of [(177)Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	83-87	keratin 20	Homo sapiens	93-97
21639584-2	2011	Our specific apparatus mixes two excitation radiations by means of an acousto-optics tunable filter to properly control fluorescence emission of phycoerythrin cyanin 5 (PC5) conjugated to antibodies (anti-CD20 or anti-CRTH2) and Thiazole Orange.	cyanin 5	159-167	keratin 20	Homo sapiens	205-209
21842694-6	2011	Because CD20 immunostaining was positive, the patient received 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) without any signs of major toxicity.	Cyclophosphamide	90-106	keratin 20	Homo sapiens	8-12
21842694-6	2011	Because CD20 immunostaining was positive, the patient received 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) without any signs of major toxicity.	Doxorubicin	108-119	keratin 20	Homo sapiens	8-12
21842694-6	2011	Because CD20 immunostaining was positive, the patient received 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) without any signs of major toxicity.	Vincristine	121-132	keratin 20	Homo sapiens	8-12
21842694-6	2011	Because CD20 immunostaining was positive, the patient received 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) without any signs of major toxicity.	Prednisolone	138-150	keratin 20	Homo sapiens	8-12
21571787-1	2011	UNLABELLED: Targeted radioimmunotherapy with (90)Y-labeled ibritumomab tiuxetan is a novel therapeutic approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL).	ibritumomab tiuxetan	59-79	keratin 20	Homo sapiens	116-120
21658657-3	2011	Rituximab, a monoclonal antibody that targets the CD20 marker on B cells, is an effective and well-reported treatment for PCBCL.	pcbcl	122-127	keratin 20	Homo sapiens	50-54
21595596-1	2011	Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved for the treatment of chronic lymphocytic leukemia refractory to alemtuzumab and fludarabine.	fludarabine	150-161	keratin 20	Homo sapiens	27-31
21533122-9	2011	We propose that CD20(+)CD5(+)sIgM(+) lymphocytes producing anti-carbohydrate antibodies with anti-tumor activity, might contribute to the response to imatinib treatment.	Carbohydrates	64-76	keratin 20	Homo sapiens	16-20
21533122-9	2011	We propose that CD20(+)CD5(+)sIgM(+) lymphocytes producing anti-carbohydrate antibodies with anti-tumor activity, might contribute to the response to imatinib treatment.	Imatinib Mesylate	150-158	keratin 20	Homo sapiens	16-20
21575926-0	2011	(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma.	ibritumomab tiuxetan	6-26	keratin 20	Homo sapiens	165-169
21486448-6	2011	RESULTS: The range of CD20 expression in different B-cell lymphomas was very broad, varying from 2 737 to 115 623 MESF in CLL and 3 549 to 679 577 MESF in DLBCL.	mesf	114-118	keratin 20	Homo sapiens	22-26
21486448-6	2011	RESULTS: The range of CD20 expression in different B-cell lymphomas was very broad, varying from 2 737 to 115 623 MESF in CLL and 3 549 to 679 577 MESF in DLBCL.	mesf	147-151	keratin 20	Homo sapiens	22-26
21436340-1	2011	Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma.	Iodine-131	16-28	keratin 20	Homo sapiens	112-116
21436340-1	2011	Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma.	bexaar	42-48	keratin 20	Homo sapiens	112-116
21727772-0	2011	Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab).	Steroids	24-31	keratin 20	Homo sapiens	115-120
21257813-5	2011	The results suggest that the corresponding residues (K20, A21, T23, N27, and A34, respectively) in pediocin PA-1 might be involved in interactions between pediocin PA-1 and its receptor.	pa-1	108-112	keratin 20	Homo sapiens	53-56
21257813-8	2011	The positive charge in K20 and the polar amide group in N27 appeared to interact with electronegative groups, since the replacement of these two residues with a positive (Arg) residue was well tolerated, while replacement with a negative (Asp) residue was detrimental to the bacteriocin activity.	Arginine	171-174	keratin 20	Homo sapiens	23-26
21257813-8	2011	The positive charge in K20 and the polar amide group in N27 appeared to interact with electronegative groups, since the replacement of these two residues with a positive (Arg) residue was well tolerated, while replacement with a negative (Asp) residue was detrimental to the bacteriocin activity.	Aspartic Acid	239-242	keratin 20	Homo sapiens	23-26
21257813-9	2011	K20 was in a less constrained environment than N27, since the replacement of K20 with a large hydrophobic (Leu) residue was tolerated fairly well and to a greater extent than N27.	Leucine	107-110	keratin 20	Homo sapiens	0-3
21257813-9	2011	K20 was in a less constrained environment than N27, since the replacement of K20 with a large hydrophobic (Leu) residue was tolerated fairly well and to a greater extent than N27.	Leucine	107-110	keratin 20	Homo sapiens	77-80
21155758-7	2011	Treatment of whole blood samples from CLL patients with a CpG-containing oligonucleotide increased CD20 expression on CLL cells and GA101-dependent B cell depletion.	Oligonucleotides	73-88	keratin 20	Homo sapiens	99-103
21298041-6	2011	RESULTS: In univariate analyses, increased numbers of CD4+ (P = 0.008) and CD20+ (P = 0.006) lymphocytes in tumor correlated significantly with an improved disease-specific survival (DSS) in patients with wide resection margins (n = 108).	dss	183-186	keratin 20	Homo sapiens	75-79
21298041-8	2011	In multivariate analyses, a high number of CD20+ lymphocytes (HR = 5.5, CI 95%  = 1.6-18.6, P = 0.006) in the tumor was an independent positive prognostic factor for DSS in patients with wide resections margins.	dss	166-169	keratin 20	Homo sapiens	43-47
21416325-7	2011	MTT assay revealed potent cytotoxicity of scFv-LDP-AE to CD20-positive Raji and Daudi cells, with IC(50) values of 1.21x10(-11) and 6.24x10(-11) mol L(-1), respectively.	monooxyethylene trimethylolpropane tristearate	0-3	keratin 20	Homo sapiens	57-61
21352561-5	2011	The anti CD20 antibody Rituximab (Mabthera ) has shown to be effective in systemic therapy of FL in primary treatment, relapse and maintenance therapy.	fl	94-96	keratin 20	Homo sapiens	9-13
21454214-13	2011	Bendamustine is active and produces durable responses in previously treated WM, both as monotherapy and with CD20-directed monoclonal antibodies.	Bendamustine Hydrochloride	0-12	keratin 20	Homo sapiens	109-113
21246311-0	2011	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.	Busulfan	12-20	keratin 20	Homo sapiens	146-150
21246311-0	2011	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.	fludarabine	25-36	keratin 20	Homo sapiens	146-150
21113055-3	2011	The introduction of imatinib and rituximab has changed the mortality rates associated with chronic myeloid leukemia and CD20-positive lymphoma, respectively.	Imatinib Mesylate	20-28	keratin 20	Homo sapiens	120-124
21496404-8	2011	There was a statistically significant difference for the Midline Estimating Statistic of Rhythm (MESOR) of CD3 (p=0.001), CD25 (p=0.003) and gammadelta-TCR-expressing cells (p=0.004), higher in the elderly, and for the MESOR of HLA-DR (p=0.002) and CD20 (p=0.002) higher in the young and middle-aged subjects.	midline	57-64	keratin 20	Homo sapiens	249-253
22287865-2	2011	Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe for the treatment of CLL refractory to alemtuzumab and fludarabine.	fludarabine	146-157	keratin 20	Homo sapiens	27-31
21034409-10	2010	Ibritumomab Tiuxetan and Tositumomab are murine anti-CD20 monoclonal antibodies, not chimeric antibodies.	ibritumomab tiuxetan	0-20	keratin 20	Homo sapiens	53-57
21339937-5	2010	On the basis of these findings, the US Food and Drug Administration (FDA) recently approved rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed/refractory or previously untreated CD20-postive CLL.	Cyclophosphamide	138-154	keratin 20	Homo sapiens	234-238
21084053-3	2010	Herein, we report a 75-year-old female patient with infiltrative CD20 (+) B-cell lymphoma who underwent 4 consecutive courses of chemotherapy with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) and after 12 sessions became free from hemodialysis in good general condition.	r-cvp	147-152	keratin 20	Homo sapiens	65-69
21084053-3	2010	Herein, we report a 75-year-old female patient with infiltrative CD20 (+) B-cell lymphoma who underwent 4 consecutive courses of chemotherapy with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) and after 12 sessions became free from hemodialysis in good general condition.	Vincristine	183-194	keratin 20	Homo sapiens	65-69
21084053-3	2010	Herein, we report a 75-year-old female patient with infiltrative CD20 (+) B-cell lymphoma who underwent 4 consecutive courses of chemotherapy with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) and after 12 sessions became free from hemodialysis in good general condition.	Prednisone	200-210	keratin 20	Homo sapiens	65-69
20069333-6	2010	CK20 expression was positively expressed in 103/154 (66.9%) of BCa and 2/30 (6.67%) of normal bladder tissues, respectively.	alpha-bromocinnamaldehyde	63-66	keratin 20	Homo sapiens	0-4
20696244-5	2010	RAFT polymerisation facilitated the synthesis of semitelechelic copolymers, which were used in the synthesis of monoclonal anti-CD20 antibody-polymer-drug conjugate designed for cell-specific tumour targeting.	copolymers	64-74	keratin 20	Homo sapiens	128-132
20304086-5	2010	In 2 FDA-authorized trials, patients with recurrent diffuse large cell lymphoma were treated with cloned CD8(+) CTLs expressing a CD20-specific CAR (along with NeoR) after autologous hematopoietic stem cell transplantation, and patients with refractory follicular lymphoma were treated with polyclonal T cell preparations expressing a CD19-specific CAR (along with HyTK, a fusion of hygromycin resistance and HSV-1 thymidine kinase suicide genes) and low-dose s.c. recombinant human interleukin-2.	hygromycin A	383-393	keratin 20	Homo sapiens	130-134
20724476-6	2010	Notably, analysis of small molecule p38 inhibitors on K8-Ser(73) phosphorylation also demonstrated reduced phosphorylations of keratins K18-Ser(52) and K20-Ser(13) but not of K8-Ser(431) or K18-Ser(33).	Serine	57-60	keratin 20	Homo sapiens	152-155
20724476-7	2010	Interestingly, K18-Ser(52) and K20-Ser(13) are not directly phosphorylated by p38 in vitro, but by MK2.	Serine	35-38	keratin 20	Homo sapiens	31-34
20724476-8	2010	Furthermore, anisomycin-stimulated phosphorylations of K20-Ser(13) and K18-Ser(52) are inhibited by small molecule inhibitors of both p38 and MK2.	Anisomycin	13-23	keratin 20	Homo sapiens	55-58
20724476-8	2010	Furthermore, anisomycin-stimulated phosphorylations of K20-Ser(13) and K18-Ser(52) are inhibited by small molecule inhibitors of both p38 and MK2.	Serine	59-62	keratin 20	Homo sapiens	55-58
20724476-9	2010	MK2 knockdown in HT29 cells leads to reduced K20-Ser(13) phosphorylation, which further supports the notion that MK2 is responsible for K20 phosphorylation in vivo.	Serine	49-52	keratin 20	Homo sapiens	45-48
20724476-9	2010	MK2 knockdown in HT29 cells leads to reduced K20-Ser(13) phosphorylation, which further supports the notion that MK2 is responsible for K20 phosphorylation in vivo.	Serine	49-52	keratin 20	Homo sapiens	136-139
20069333-9	2010	Pathologic findings demonstrated that the intensity of CK20 and Ki-67 staining in cancerous tissues was associated significantly with tumor grades (p = 0.03, p &lt; 0.01), distant metastasis (both p &lt; 0.01) and TNM grades (p = 0.01, p = 0.03) of BCa.	alpha-bromocinnamaldehyde	249-252	keratin 20	Homo sapiens	55-59
20574159-2	2010	Therefore, proteasome inhibitors including the clinically approved bortezomib might influence the levels of CD20, a rituximab target antigen.	Bortezomib	67-77	keratin 20	Homo sapiens	108-112
20660823-1	2010	PURPOSE: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone).	Cyclophosphamide	262-278	keratin 20	Homo sapiens	34-38
20660823-1	2010	PURPOSE: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone).	Vincristine	280-291	keratin 20	Homo sapiens	34-38
20660823-1	2010	PURPOSE: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone).	Doxorubicin	293-304	keratin 20	Homo sapiens	34-38
20660823-1	2010	PURPOSE: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone).	Dexamethasone	306-319	keratin 20	Homo sapiens	34-38
20425050-6	2010	The latter stained as B cells (CD20), enabling a diagnosis of B-cell lymphoma, and the condition responded fully to high-dose methotrexate.	Methotrexate	126-138	keratin 20	Homo sapiens	31-35
20590521-2	2010	I-131 tositumomab is a radiommunoconjugate of (131)I and the anti-CD20 monoclonal antibody tositumomab.	Iodine-131	0-5	keratin 20	Homo sapiens	66-70
20101022-6	2010	The ability of IMMU-114 to induce activation of ERK and JNK signaling correlated with cytotoxicity and differentiates the mechanism of action of IMMU-114 from monoclonal antibodies against CD20 and CD74.	IMMU-114	15-23	keratin 20	Homo sapiens	189-193
20101022-6	2010	The ability of IMMU-114 to induce activation of ERK and JNK signaling correlated with cytotoxicity and differentiates the mechanism of action of IMMU-114 from monoclonal antibodies against CD20 and CD74.	IMMU-114	145-153	keratin 20	Homo sapiens	189-193
20435928-1	2010	Anti-CD20 B cell depletion therapy (BCDT) is very effective for some patients with rheumatoid arthritis (RA); however the pathogenic role of B lymphocytes in RA and the primary targets of BCDT are unknown.	bcdt	36-40	keratin 20	Homo sapiens	5-9
20435928-1	2010	Anti-CD20 B cell depletion therapy (BCDT) is very effective for some patients with rheumatoid arthritis (RA); however the pathogenic role of B lymphocytes in RA and the primary targets of BCDT are unknown.	bcdt	188-192	keratin 20	Homo sapiens	5-9
20200358-0	2010	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.	Bortezomib	0-10	keratin 20	Homo sapiens	29-33
20200358-6	2010	Short-term (24 hours) incubation of Raji cells with 10 or 20 nM bortezomib did not change surface CD20 levels, but sensitized CD20(+) lymphoma cells to R-CDC.	Bortezomib	64-74	keratin 20	Homo sapiens	126-130
20200358-7	2010	Prolonged (48 hours) incubation with 20 nM bortezomib, or incubation with 50 nM bortezomib for 24 hours led to a significant decrease in surface CD20 levels as well as R-CDC.	Bortezomib	43-53	keratin 20	Homo sapiens	145-149
20200358-7	2010	Prolonged (48 hours) incubation with 20 nM bortezomib, or incubation with 50 nM bortezomib for 24 hours led to a significant decrease in surface CD20 levels as well as R-CDC.	Bortezomib	80-90	keratin 20	Homo sapiens	145-149
20393401-5	2010	The clinical outcomes of CD20 or CD38 B cells were evaluated with late-onset and repeated ACR, steroid resistance, incomplete recovery after rejection treatment, and allograft survival.	Steroids	95-102	keratin 20	Homo sapiens	25-29
20460536-0	2010	Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.	Itraconazole	24-36	keratin 20	Homo sapiens	113-117
20460536-6	2010	At the molecular level, recruitment of CD20 to lipid rafts is inhibited in the presence of itraconazole.	Itraconazole	91-103	keratin 20	Homo sapiens	39-43
20460536-9	2010	The finding that itraconazole also abolished the cytotoxic effects of other therapeutic antibodies directed against lipid raft-associated molecules (i.e., CD20 and CD52) but not those against the non-raft-associated molecule CD33 further supported our proposed mechanism of action.	Itraconazole	17-29	keratin 20	Homo sapiens	155-159
20077379-16	2010	CONCLUSION: Severe autoantibody TTP can be successfully treated by administering rituximanb, an anti-CD20 antibody, in addition to the standard treatment with plasmapheresis.	rituximanb	81-91	keratin 20	Homo sapiens	101-105
20119714-3	2010	The purpose of this report is to describe the successful treatment of gemcitabine-induced TTP/HUS with rituximab, a CD20 monoclonal antibody that has been used for the treatment of refractory idiopathic TTP/HUS.	gemcitabine	70-81	keratin 20	Homo sapiens	116-120
21696056-2	2010	Despite initial treatment with CD20 antibody rituximab and intravenous immunoglobulin, the patient presented with a steady increase in serum creatinine and de novo proteinuria.	Creatinine	141-151	keratin 20	Homo sapiens	31-35
20335656-0	2010	Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.	Cyclosporine	79-91	keratin 20	Homo sapiens	11-15
20335656-4	2010	Furthermore, CD20+ B cell depletion therapy combined with the calcineurin inhibitor cyclosporine A (CsA) prolonged median primary graft survival relative to treatment with alphaCD20 or CsA alone.	alphacd20	172-181	keratin 20	Homo sapiens	13-17
20335656-4	2010	Furthermore, CD20+ B cell depletion therapy combined with the calcineurin inhibitor cyclosporine A (CsA) prolonged median primary graft survival relative to treatment with alphaCD20 or CsA alone.	Cyclosporine	185-188	keratin 20	Homo sapiens	13-17
20412709-2	2010	Anti-CD20 monoclonal antibody, rituximab (RTX) has already been used with good results in MC in preliminary studies.	Methylcholanthrene	90-92	keratin 20	Homo sapiens	5-9
20194866-0	2010	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.	fludarabine	49-60	keratin 20	Homo sapiens	27-31
20620977-4	2010	The most recent antibody to be approved by regulatory agencies is ofatumumab, a new anti-CD20 antibody, with efficacy in patients whose disease is refractory to both fludarabine and alemtuzumab.	fludarabine	166-177	keratin 20	Homo sapiens	89-93
19930155-9	2010	Importantly, hOUBM6 exhibited cellular cytotoxicity against diffuse, large B cells that are less effectively depleted by rituximab and also exhibited effective cytotoxicity against tumor cells from human CD20(+) leukemia and lymphoma patients.	houbm6	13-19	keratin 20	Homo sapiens	204-208
20425394-5	2010	Second-generation monoclonal anti-CD20 antibodies in clinical trials include ofatumumab, which demonstrated activity in fludarabine-refractory patients with bulky lymphadenopathy.	fludarabine	120-131	keratin 20	Homo sapiens	34-38
19350237-7	2009	RESULTS: The immunological binding properties of DOTA-rituximab to the CD20 antigen were found to be retained after conjugation with up to four chelators.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	49-53	keratin 20	Homo sapiens	71-75
19952958-4	2010	Intracellular calcium release was triggered via a signaling pathway distinct from the lipid raft-dependent and src family kinase-dependent pathway that is activated by CD20 hypercrosslinking or B-cell receptor association.	Calcium	14-21	keratin 20	Homo sapiens	168-172
19922338-1	2009	A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation.	VAD I protocol	153-156	keratin 20	Homo sapiens	209-213
19922338-1	2009	A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation.	Melphalan	171-180	keratin 20	Homo sapiens	209-213
20641565-0	2004	(124)I/(64)Cu-Labeled anti-CD20 minibody The B cell differentiation antigen (CD20) is a transmembrane, non-glycosylated, hydrophobic protein that is characteristically expressed in more than 90% of non-Hodgkin lymphoma (NHL) tumors.	Copper	11-13	keratin 20	Homo sapiens	27-31
20641565-0	2004	(124)I/(64)Cu-Labeled anti-CD20 minibody The B cell differentiation antigen (CD20) is a transmembrane, non-glycosylated, hydrophobic protein that is characteristically expressed in more than 90% of non-Hodgkin lymphoma (NHL) tumors.	Copper	11-13	keratin 20	Homo sapiens	77-81
20641565-1	2004	Although the exact cellular functions of CD20 are not known, it is believed to play a role in B cell growth, activation, and maintenance of cellular calcium homeostasis (1).	Calcium	149-156	keratin 20	Homo sapiens	41-45
20641565-3	2004	For enhanced efficacy, radionuclide-coupled anti-CD20 Abs tositumomab ((131)I labeled) or ibritumomab ((90)Y conjugated) were also respectively approved by the FDA for the treatment of NHL and are commercially available in the United States.	Radioisotopes	23-35	keratin 20	Homo sapiens	49-53
20641768-1	2004	Although the exact cellular functions of CD20 are not known, it is believed to play a role in B cell growth, activation, and maintenance of cellular calcium homeostasis (1).	Calcium	149-156	keratin 20	Homo sapiens	41-45
20641768-3	2004	For enhanced efficacy, radionuclide-coupled anti-CD20 Abs tositumomab ((131)I labeled) or ibritumomab ((90)Y conjugated) were also respectively approved by the FDA for the treatment of NHL and are commercially available in the United States.	Radioisotopes	23-35	keratin 20	Homo sapiens	49-53
19632282-0	2009	HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting.	hpma copolymer	0-14	keratin 20	Homo sapiens	44-48
19632282-2	2009	Synthesis, physicochemical and biological properties and preliminary anticancer activity of new star-shaped polymer-doxorubicin (DOX) conjugates targeted with anti-CD20 monoclonal antibody were investigated.	polymer-doxorubicin	108-127	keratin 20	Homo sapiens	164-168
19679402-2	2009	METHODS AND MATERIALS: CD20-positive lymphoma cell lines were treated with (227)Th-DOTA-rituximab for 1-5 weeks.	th-dota	80-87	keratin 20	Homo sapiens	23-27
19833600-2	2009	Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies and has been demonstrated effective in combination with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone).	Doxorubicin	234-245	keratin 20	Homo sapiens	21-25
19833600-2	2009	Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies and has been demonstrated effective in combination with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone).	Vincristine	247-258	keratin 20	Homo sapiens	21-25
19833600-2	2009	Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies and has been demonstrated effective in combination with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone).	Prednisolone	264-276	keratin 20	Homo sapiens	21-25
19690034-10	2009	The ratio achieved with the (64)Cu-DOTA-minibody at 19 h was about 5-fold lower because of higher residual background activity in CD20-negative tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	32-39	keratin 20	Homo sapiens	130-134
19278954-3	2009	Here we report that, in association with the CD20(+)-specific mAb rituximab (RTX), the synthetic PAg bromohydrin pyrophosphate (BrHPP) increased TCRVgamma9(+) cell binding to CD20(+) lymphoma cells in vitro.	pag bromohydrin pyrophosphate	97-126	keratin 20	Homo sapiens	45-49
19409431-3	2009	Tailor-designed l-lysine peptides (K4 and K20) were employed to modify the surface charge of PLGA foams using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide cross linkers and the effects of charge modification of PLGA were examined in three main aspects: DNA adsorption, DNA release properties and DNA transfection.	Lysine	18-24	keratin 20	Homo sapiens	42-45
19409431-3	2009	Tailor-designed l-lysine peptides (K4 and K20) were employed to modify the surface charge of PLGA foams using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide cross linkers and the effects of charge modification of PLGA were examined in three main aspects: DNA adsorption, DNA release properties and DNA transfection.	Ethyldimethylaminopropyl Carbodiimide	110-155	keratin 20	Homo sapiens	42-45
19409431-3	2009	Tailor-designed l-lysine peptides (K4 and K20) were employed to modify the surface charge of PLGA foams using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide cross linkers and the effects of charge modification of PLGA were examined in three main aspects: DNA adsorption, DNA release properties and DNA transfection.	N-hydroxysuccinimide	160-180	keratin 20	Homo sapiens	42-45
19427037-2	2009	The success of anti-CD20 antibody drugs such as Rituximab, Ibritumomab, and Tositumomab has promoted the development of new generation of anti-CD20 antibodies for therapeutic applications.	ibritumomab tiuxetan	59-70	keratin 20	Homo sapiens	20-24
19427037-2	2009	The success of anti-CD20 antibody drugs such as Rituximab, Ibritumomab, and Tositumomab has promoted the development of new generation of anti-CD20 antibodies for therapeutic applications.	ibritumomab tiuxetan	59-70	keratin 20	Homo sapiens	143-147
19427037-7	2009	Structure analysis and comparison with other antibodies suggest that the hydrophobic periphery might interact with the epitope on CD20 that is enriched with hydrophobic residues and very close to cell membrane, and the positively charged bottom might interact with Glu(150) of CD20 which is the only negatively charged residue within the epitope.	Glutamic Acid	265-268	keratin 20	Homo sapiens	130-134
19427037-7	2009	Structure analysis and comparison with other antibodies suggest that the hydrophobic periphery might interact with the epitope on CD20 that is enriched with hydrophobic residues and very close to cell membrane, and the positively charged bottom might interact with Glu(150) of CD20 which is the only negatively charged residue within the epitope.	Glutamic Acid	265-268	keratin 20	Homo sapiens	277-281
19111631-5	2009	Within the acute rejection group, a positive staining for CD20 was not associated with graft loss, steroid resistance or lack of return to basal creatinine after treatment, but was associated with higher serum creatinine at 3 and 6 months, 1 and 2 years after the acute episode (p&lt;0.05).	Creatinine	145-155	keratin 20	Homo sapiens	58-62
19111631-5	2009	Within the acute rejection group, a positive staining for CD20 was not associated with graft loss, steroid resistance or lack of return to basal creatinine after treatment, but was associated with higher serum creatinine at 3 and 6 months, 1 and 2 years after the acute episode (p&lt;0.05).	Creatinine	210-220	keratin 20	Homo sapiens	58-62
19111631-7	2009	Patients with clusters of CD20+ cells &gt;50/HPF had higher serum creatinine after 2 years of follow up.	Creatinine	66-76	keratin 20	Homo sapiens	26-30
19246561-8	2009	Interestingly, when CD20-negative cells were treated with 5-aza-2"-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both cell surface expression of the CD20 protein and rituximab sensitivity.	Decitabine	58-80	keratin 20	Homo sapiens	20-24
19246561-8	2009	Interestingly, when CD20-negative cells were treated with 5-aza-2"-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both cell surface expression of the CD20 protein and rituximab sensitivity.	Decitabine	58-80	keratin 20	Homo sapiens	109-113
19246561-8	2009	Interestingly, when CD20-negative cells were treated with 5-aza-2"-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both cell surface expression of the CD20 protein and rituximab sensitivity.	Decitabine	58-80	keratin 20	Homo sapiens	109-113
19556825-0	2009	Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera.	Methotrexate	77-89	keratin 20	Homo sapiens	126-130
19278954-3	2009	Here we report that, in association with the CD20(+)-specific mAb rituximab (RTX), the synthetic PAg bromohydrin pyrophosphate (BrHPP) increased TCRVgamma9(+) cell binding to CD20(+) lymphoma cells in vitro.	pag bromohydrin pyrophosphate	97-126	keratin 20	Homo sapiens	175-179
19278954-3	2009	Here we report that, in association with the CD20(+)-specific mAb rituximab (RTX), the synthetic PAg bromohydrin pyrophosphate (BrHPP) increased TCRVgamma9(+) cell binding to CD20(+) lymphoma cells in vitro.	bromohydrin pyrophosphate	128-133	keratin 20	Homo sapiens	45-49
19278954-3	2009	Here we report that, in association with the CD20(+)-specific mAb rituximab (RTX), the synthetic PAg bromohydrin pyrophosphate (BrHPP) increased TCRVgamma9(+) cell binding to CD20(+) lymphoma cells in vitro.	bromohydrin pyrophosphate	128-133	keratin 20	Homo sapiens	175-179
19278954-6	2009	Furthermore, BrHPP enhanced RTX-mediated depletion of CD20(+) cells in vitro from peripheral blood mononuclear cells of healthy subjects and enhanced ADCC by gammadelta T cells from patients with chronic lymphocytic leukemia.	bromohydrin pyrophosphate	13-18	keratin 20	Homo sapiens	54-58
19384869-5	2009	Stimulation of BM CD20(+) B cells by CpG-containing oligodeoxynucleotide-enhanced expression of activation markers (CD86 and CD54) triggered IL-6 and TNF-alpha secretion and cell proliferation.	Oligodeoxyribonucleotides	52-72	keratin 20	Homo sapiens	18-22
19604443-7	2009	However, only anti-CD20 infusion significantly (p=0.05) reduced concentration of fibrinogen (p=0.05), D-dimer (p&lt;0.001), as well as tPA levels (p&lt;0.01).	Tetradecanoylphorbol Acetate	135-138	keratin 20	Homo sapiens	19-23
19642457-2	2009	90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of beta irradiation.	ibritumomab tiuxetan	4-24	keratin 20	Homo sapiens	81-85
19588841-2	2009	Significant relationships between the concentrations of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) in the blood and the absolute densities of the total lymphocyte population, or of the T-cell subpopulation reactive with CD4 were observed, while there was no correlation between the blood PCB levels and the densities of total lymphocyte population, or CD4, CD8 or CD20 positive cells in peripheral blood.	2,3,4,7,8-pentachlorodibenzofuran	56-89	keratin 20	Homo sapiens	363-367
19588841-2	2009	Significant relationships between the concentrations of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) in the blood and the absolute densities of the total lymphocyte population, or of the T-cell subpopulation reactive with CD4 were observed, while there was no correlation between the blood PCB levels and the densities of total lymphocyte population, or CD4, CD8 or CD20 positive cells in peripheral blood.	2,3,4,7,8-pentachlorodibenzofuran	91-96	keratin 20	Homo sapiens	363-367
20616910-2	2009	Iodine 131 tositumomab ((131)I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to (131)I, a radioactive beta and gamma emitter.	Iodine-131	0-10	keratin 20	Homo sapiens	80-84
19351771-5	2009	Here, we describe the properties of TRU-015, a small modular immunopharmaceutical specific for CD20, encoded by a single-chain construct containing a single-chain Fv specific for CD20 linked to human IgG1 hinge, CH2, and CH3 domains but devoid of CH1 and CL domains.	tru	36-39	keratin 20	Homo sapiens	95-99
19351771-10	2009	CONCLUSION: These results indicate that TRU-015 may improve CD20-directed therapy by effectively depleting embedded malignant B cells and nonmalignant pathogenic B cells and do so with reduced complement activation.	tru	40-43	keratin 20	Homo sapiens	60-64
19517998-2	2009	In this paper, interactions of SPS isolated from Klebsiella strains K20 and K51 with cationic dyes pinacyanol chloride (PCYN) and acridine orange (AO) were studied by absorbance and fluorescence measurements.	quinaldine blue	99-118	keratin 20	Homo sapiens	68-71
19517998-2	2009	In this paper, interactions of SPS isolated from Klebsiella strains K20 and K51 with cationic dyes pinacyanol chloride (PCYN) and acridine orange (AO) were studied by absorbance and fluorescence measurements.	quinaldine blue	120-124	keratin 20	Homo sapiens	68-71
19517998-2	2009	In this paper, interactions of SPS isolated from Klebsiella strains K20 and K51 with cationic dyes pinacyanol chloride (PCYN) and acridine orange (AO) were studied by absorbance and fluorescence measurements.	Acridine Orange	130-145	keratin 20	Homo sapiens	68-71
19517998-2	2009	In this paper, interactions of SPS isolated from Klebsiella strains K20 and K51 with cationic dyes pinacyanol chloride (PCYN) and acridine orange (AO) were studied by absorbance and fluorescence measurements.	Acridine Orange	147-149	keratin 20	Homo sapiens	68-71
19521280-5	2009	Paraffin immunohistochemistry showed finely granular cytoplasmic ALK1 expression, positive CD138, IgA, p63 (VS38), focal positive epithelial membrane antigen and CD4, and lambda light chain restriction whereas negative CD20 and CD30 staining.	Paraffin	0-8	keratin 20	Homo sapiens	219-223
19300416-6	2009	CK20 expression was positive in RT-PCR of 51 cases (85%) of TCCB, but control group was positive in 2 cases (specificity 94.3%) with a cutoff value of crossover point (CT) = 30.	tccb	60-64	keratin 20	Homo sapiens	0-4
19300416-9	2009	CK20 mRNA values in TCCB group (mean 27712.57 copies/microl) were significantly higher than in non-cancer disease urological group (mean 74.45 copies/microl) and control group (mean 8.47 copies/microl) (p &lt; 0.001, p &lt; 0.001, respectively).	tccb	20-24	keratin 20	Homo sapiens	0-4
19460565-0	2009	Orthotopic liver transplantation after successful treatment with anti-CD20 monoclonal antibody (rituximab) for severe steroid-resistant autoimmune hemolytic anemia: a case report.	Steroids	118-125	keratin 20	Homo sapiens	70-74
19167677-4	2009	We found ATG to induce apoptosis in T-lymphocytes (CD4(+), CD8+), B-lymphocytes (CD20+), natural killer (NK)-cells (CD56(+)), and monocytes (CD14(+)).	atg	9-12	keratin 20	Homo sapiens	81-85
19188603-7	2009	ChIP analysis confirmed that CDX1 binds to the predicted CDX elements in this region of the KRT20 promoter in vivo.	Cefadroxil	29-32	keratin 20	Homo sapiens	92-97
19056850-7	2009	On the other hand, the methylation levels of lysine 20 (K20) on histone H4 showed a significant correlation with HP1gamma expression in both these preadipocyte cells and normal tissue samples.	Lysine	45-51	keratin 20	Homo sapiens	56-59
19153665-5	2009	Here, we show that a CD20-related signaling pathway able to induce an increase in [Ca(2+)](i) is differently activated after brain derived neurotrophic factor (BDNF) stimulation of normal and dystrophic blood-derived CD133(+) stem cells, supporting the assumption of a "CD20-related calcium impairment" affecting dystrophic cells.	Calcium	283-290	keratin 20	Homo sapiens	21-25
19153665-3	2009	The CD20 antigen plays a role in the modulation of intracellular calcium homeostasis through signaling pathways activation.	Calcium	65-72	keratin 20	Homo sapiens	4-8
18816698-0	2009	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children"s Oncology Group.	Ifosfamide	25-35	keratin 20	Homo sapiens	123-127
18816698-0	2009	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children"s Oncology Group.	Carboplatin	37-48	keratin 20	Homo sapiens	123-127
18816698-0	2009	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children"s Oncology Group.	Etoposide	54-63	keratin 20	Homo sapiens	123-127
18816698-1	2009	BACKGROUND: To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed and refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL).	Etoposide	191-200	keratin 20	Homo sapiens	85-89
18816698-1	2009	BACKGROUND: To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide (ICE) in patients with relapsed and refractory B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia (B-ALL).	Water	202-205	keratin 20	Homo sapiens	85-89
19514423-3	2009	Concentrations of IFN-alpha, IFN-gamma, TNF-alpha, IL-1beta, IL-4, IL-6 in blood serum in spontaneous and NDV and PGA stimulated PBMC production, content of CD3, CD4, CD8, CD16, CD25, HLADR, CD20, CD38 subpopulations of peripheral blood lymphocytes were examined.	Prostaglandins A	114-117	keratin 20	Homo sapiens	191-195
19154157-0	2009	Synthesis and evaluation of multivalent branched HPMA copolymer-Fab" conjugates targeted to the B-cell antigen CD20.	hpma copolymer	49-63	keratin 20	Homo sapiens	111-115
19154157-3	2009	In an attempt to overcome this limitation, high molecular weight, branched N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesized and conjugated with Fab" fragments of the anti-CD20 antibody, 1F5.	branched n-(2-hydroxypropyl)methacrylamide	66-108	keratin 20	Homo sapiens	191-195
19154157-3	2009	In an attempt to overcome this limitation, high molecular weight, branched N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesized and conjugated with Fab" fragments of the anti-CD20 antibody, 1F5.	hpma) copolymers	110-126	keratin 20	Homo sapiens	191-195
19819920-2	2009	A number of trials have shown significantly higher response rates and longer progression-free survival times in patients treated with the CD20-targeted radioimmunoconjugate yttrium-90-ibritumomab tiuxetan compared with the standard of care.	ibritumomab tiuxetan	173-204	keratin 20	Homo sapiens	138-142
19590992-1	2009	A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation.	VAD I protocol	153-156	keratin 20	Homo sapiens	209-213
19590992-1	2009	A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation.	Melphalan	171-180	keratin 20	Homo sapiens	209-213
18773247-0	2009	Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	42-62	keratin 20	Homo sapiens	80-84
18773247-8	2009	CONCLUSIONS: (90)Y-ibritumomab-tiuxetan localizes to the surface membrane of CD20+ lymphoma cells in affected lymph nodes.	y-ibritumomab-tiuxetan	17-39	keratin 20	Homo sapiens	77-81
19053310-0	2008	Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2.	Sulfhydryl Compounds	15-20	keratin 20	Homo sapiens	105-109
18772452-0	2008	Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	32-36
18772452-2	2008	The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide.	Lenalidomide	98-110	keratin 20	Homo sapiens	9-13
18772452-4	2008	In contrast to previous reports using CD20-positive lymphoma cell lines, lenalidomide down-regulated CD20 surface antigen expression in CLL patient cells via enhanced internalization, without influencing transcription.	Lenalidomide	73-85	keratin 20	Homo sapiens	101-105
18772452-5	2008	The CD20 surface antigen internalization enhanced delivery of an oligonucleotide incorporated into anti-CD20 immunoliposomes.	Oligonucleotides	65-80	keratin 20	Homo sapiens	4-8
18772452-5	2008	The CD20 surface antigen internalization enhanced delivery of an oligonucleotide incorporated into anti-CD20 immunoliposomes.	Oligonucleotides	65-80	keratin 20	Homo sapiens	104-108
18772452-6	2008	In addition, CD20 surface antigen down-modulation by lenalidomide in CLL was accompanied by diminished rituximab-mediated apoptosis and ADCC.	Lenalidomide	53-65	keratin 20	Homo sapiens	13-17
18772452-8	2008	In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies.	Lenalidomide	31-43	keratin 20	Homo sapiens	127-131
19053310-0	2008	Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2.	Cysteine	67-75	keratin 20	Homo sapiens	105-109
19014836-0	2008	Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.	tru	50-53	keratin 20	Homo sapiens	61-65
19061730-3	2008	This radioimmunotherapeutic agent consists of ibritumomab, a murine anti-CD20 monoclonal antibody, conjugated to the metal chelator tiuxetan for retention of the beta emitter (90)Y.	ibritumomab tiuxetan	46-57	keratin 20	Homo sapiens	73-77
18927323-2	2008	90Y-ibritumomab is an antibody targeting CD20 receptors on the surface of lymphocytes.	ibritumomab tiuxetan	0-15	keratin 20	Homo sapiens	41-45
18780832-9	2008	In vitro, CD20 up-regulation significantly enhanced rituximab cytotoxicity and could be elicited on prednisolone incubation.	Prednisolone	100-112	keratin 20	Homo sapiens	10-14
18552383-10	2008	CONCLUSIONS: Inoculation of native or human CD20-transfected murine 38C13 cells in the vitreous or the brain of immunocompetent mice provides useful novel models for evaluating the biology and treatment of PIOL and PCNSL.	pcnsl	215-220	keratin 20	Homo sapiens	44-48
21748080-5	2008	The trephine biopsy has the characteristic features of a honey comb appearance and flow cytometry is typically CD103, CD25, FMC7, CD11c, gamma or kappa light chain positive with the classic B lymphocyte markers CD19, CD20, CD79a.	trephine	4-12	keratin 20	Homo sapiens	217-221
18498245-9	2008	TD lymphoblasts showed increased expression of CD38, which hydrolyses NAD(+) into ADP-ribose, a trigger of Ca(2+) release from the endoplasmic reticulum that, in turn, facilitated CD20-induced apoptosis.	NAD	70-76	keratin 20	Homo sapiens	180-184
18498245-9	2008	TD lymphoblasts showed increased expression of CD38, which hydrolyses NAD(+) into ADP-ribose, a trigger of Ca(2+) release from the endoplasmic reticulum that, in turn, facilitated CD20-induced apoptosis.	Adenosine Diphosphate Ribose	82-92	keratin 20	Homo sapiens	180-184
18474602-3	2008	CD20 is a B cell-restricted tetraspanning protein organized in the plasma membrane as multimeric molecular complexes involved in BCR-activated calcium entry.	Calcium	143-150	keratin 20	Homo sapiens	0-4
18547992-7	2008	Both CD20(+) B cells and CD38(+) cells correlated with poor response of the rejection to steroids.	Steroids	89-97	keratin 20	Homo sapiens	5-9
18183493-1	2008	Rituximab, a chimeric anti-CD20 monoclonal antibody, is one of the most successful biomedicines and has been used to treat at least 370,000 patients with indolent, aggressive non-Hodgkin"s lymphoma and other malignant diseases.	biomedicines	83-95	keratin 20	Homo sapiens	27-31
18628480-0	2008	lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.	Lenalidomide	0-12	keratin 20	Homo sapiens	126-130
18474602-8	2008	These data provide new evidence of the involvement of CD20 in signaling downstream of the BCR and, together with the previously described involvement of CD20 in calcium influx, the first evidence of physical coupling of the BCR to a calcium entry pathway.	Calcium	161-168	keratin 20	Homo sapiens	153-157
18474602-8	2008	These data provide new evidence of the involvement of CD20 in signaling downstream of the BCR and, together with the previously described involvement of CD20 in calcium influx, the first evidence of physical coupling of the BCR to a calcium entry pathway.	Calcium	233-240	keratin 20	Homo sapiens	54-58
18474602-8	2008	These data provide new evidence of the involvement of CD20 in signaling downstream of the BCR and, together with the previously described involvement of CD20 in calcium influx, the first evidence of physical coupling of the BCR to a calcium entry pathway.	Calcium	233-240	keratin 20	Homo sapiens	153-157
18537979-6	2008	The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly.	Cyclophosphamide	78-94	keratin 20	Homo sapiens	36-40
18537979-6	2008	The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly.	Doxorubicin	96-107	keratin 20	Homo sapiens	36-40
18537979-6	2008	The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly.	Vincristine	109-120	keratin 20	Homo sapiens	36-40
18537979-6	2008	The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly.	Prednisone	122-132	keratin 20	Homo sapiens	36-40
18580460-3	2008	The presence of immature CD20 and mature CD138 plasma cells associate with more aggressive and steroid-recalcitrant graft rejection and portend poor graft outcomes.	Steroids	95-102	keratin 20	Homo sapiens	25-29
18426802-0	2008	Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.	Calcium	23-30	keratin 20	Homo sapiens	39-43
18426802-3	2008	In the current study, anti-CD20 mAb-induced calcium signaling was investigated.	Calcium	44-51	keratin 20	Homo sapiens	27-31
18426802-6	2008	Inhibitor analysis revealed that the signaling cascade employed by CD20 was strikingly similar to that utilized by the BCR, with inhibitors of Syk, Src, and PI3K, but not EGTA, p38, or ERK1/2, completely ablating calcium flux.	Calcium	213-220	keratin 20	Homo sapiens	67-71
18426802-9	2008	Collectively, these data indicate that CD20 induces cytosolic calcium flux through its ability to associate with and "hijack" the signaling potential of the BCR.	Calcium	62-69	keratin 20	Homo sapiens	39-43
18600519-5	2008	Using CD antibody microarrays to determine surface expression profiles for Raji cells treated with FdA, we found up-regulation of the following CD antigens: CD20, CD54, CD80, CD86, and CD95.	fda	99-102	keratin 20	Homo sapiens	157-161
18353542-4	2008	Stimuli that trigger a release of ceramide to mediate apoptosis include CD95, TNF-receptor, DR5, gamma-irradiation, cytotoxic drugs, UV-light, bacteria, viruses, some forms of developmental death, anti-CD20 and disruption of the cell"s contact with its matrix, to name a few.	Ceramides	34-42	keratin 20	Homo sapiens	202-206
18462369-8	2008	Immunohistochemically, only staining of Merkel cells with CK20 and negativity of aggregations with androgen receptors were diagnostically convincing for DTE.	Dithioerythritol	153-156	keratin 20	Homo sapiens	58-62
18600519-5	2008	Using CD antibody microarrays to determine surface expression profiles for Raji cells treated with FdA, we found up-regulation of the following CD antigens: CD20, CD54, CD80, CD86, and CD95.	Cadmium	6-8	keratin 20	Homo sapiens	157-161
18366248-9	2008	Atomic force microscopy and limited proteolysis indicated that statins, through cholesterol depletion, induce conformational changes in CD20 that result in impaired binding of anti-CD20 mAb.	Cholesterol	80-91	keratin 20	Homo sapiens	136-140
18520611-8	2008	Lidocaine had a very fast transfer rate constant (Ka part + K20) from the epidural space to the serum compartment.	Lidocaine	0-9	keratin 20	Homo sapiens	60-63
18520611-10	2008	The mean rate constant of elimination from the serum compartment (K20) was increased by 9.7% by dopamine.	Dopamine	96-104	keratin 20	Homo sapiens	66-69
18346788-5	2008	The crystal structure of C2H7 in complex with the CD20 epitope peptide was determined at 2.6A resolution.	c2h7	25-29	keratin 20	Homo sapiens	50-54
18414711-9	2008	The sensitivity of the CK7/CK20 pattern reached 100% in the subgroup of CIM patients with a history of acid reflux.	cim	72-75	keratin 20	Homo sapiens	27-31
18366248-9	2008	Atomic force microscopy and limited proteolysis indicated that statins, through cholesterol depletion, induce conformational changes in CD20 that result in impaired binding of anti-CD20 mAb.	Cholesterol	80-91	keratin 20	Homo sapiens	181-185
18366248-10	2008	An in vivo reduction of cholesterol induced by short-term treatment of five patients with hypercholesterolemia with atorvastatin resulted in reduced anti-CD20 binding to freshly isolated B cells.	Cholesterol	24-35	keratin 20	Homo sapiens	154-158
18366248-10	2008	An in vivo reduction of cholesterol induced by short-term treatment of five patients with hypercholesterolemia with atorvastatin resulted in reduced anti-CD20 binding to freshly isolated B cells.	Atorvastatin	116-128	keratin 20	Homo sapiens	154-158
18328441-3	2008	METHODS: A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes.	Mercaptopurine	85-101	keratin 20	Homo sapiens	173-177
18187315-1	2008	Electrochemical label free DNA hybridization discrimination of the brain tumor sequence CK20 has been made at the gold-thiol and thiol diluent binary and ternary mixed monolayer interfaces in presence of the [Fe(CN)6](3-) and double stranded DNA (dsDNA) specific cationic intercalators, proflavine (PF) and methylene blue (MB), respectively.	Sulfhydryl Compounds	119-124	keratin 20	Homo sapiens	88-92
18187315-1	2008	Electrochemical label free DNA hybridization discrimination of the brain tumor sequence CK20 has been made at the gold-thiol and thiol diluent binary and ternary mixed monolayer interfaces in presence of the [Fe(CN)6](3-) and double stranded DNA (dsDNA) specific cationic intercalators, proflavine (PF) and methylene blue (MB), respectively.	Sulfhydryl Compounds	129-134	keratin 20	Homo sapiens	88-92
18187315-1	2008	Electrochemical label free DNA hybridization discrimination of the brain tumor sequence CK20 has been made at the gold-thiol and thiol diluent binary and ternary mixed monolayer interfaces in presence of the [Fe(CN)6](3-) and double stranded DNA (dsDNA) specific cationic intercalators, proflavine (PF) and methylene blue (MB), respectively.	fe(cn)6	209-216	keratin 20	Homo sapiens	88-92
18187315-1	2008	Electrochemical label free DNA hybridization discrimination of the brain tumor sequence CK20 has been made at the gold-thiol and thiol diluent binary and ternary mixed monolayer interfaces in presence of the [Fe(CN)6](3-) and double stranded DNA (dsDNA) specific cationic intercalators, proflavine (PF) and methylene blue (MB), respectively.	Proflavine	287-297	keratin 20	Homo sapiens	88-92
18187315-1	2008	Electrochemical label free DNA hybridization discrimination of the brain tumor sequence CK20 has been made at the gold-thiol and thiol diluent binary and ternary mixed monolayer interfaces in presence of the [Fe(CN)6](3-) and double stranded DNA (dsDNA) specific cationic intercalators, proflavine (PF) and methylene blue (MB), respectively.	Proflavine	299-301	keratin 20	Homo sapiens	88-92
18187315-1	2008	Electrochemical label free DNA hybridization discrimination of the brain tumor sequence CK20 has been made at the gold-thiol and thiol diluent binary and ternary mixed monolayer interfaces in presence of the [Fe(CN)6](3-) and double stranded DNA (dsDNA) specific cationic intercalators, proflavine (PF) and methylene blue (MB), respectively.	Methylene Blue	307-321	keratin 20	Homo sapiens	88-92
18302712-5	2008	We generated a chimeric anti-CD20 monoclonal antibody (mAb), EMAB-6, which has a low fucose content.	Fucose	85-91	keratin 20	Homo sapiens	29-33
18302712-9	2008	Comparative studies between CLL and lymphoma cells coated with EMAB-6 or rituximab indicated that the difference of efficacy was more pronounced at low doses and when target cells expressed fewer CD20 molecules.	emab-6	63-69	keratin 20	Homo sapiens	196-200
17973121-1	2008	We present the cases of two children with steroid-resistant nephrotic syndrome (SRNS) who were treated with rituximab (anti-CD20 monoclonal antibody).	Steroids	42-49	keratin 20	Homo sapiens	124-128
18060882-2	2008	Here, we examined the regulation of CD20 expression after treatment with 0.5-2.0 Gy X-irradiation and hydrogen peroxide (H(2)O(2)), in the presence or absence of known antioxidants, in the Burkitt lymphoma cell lines Daudi and Raji.	Hydrogen Peroxide	102-119	keratin 20	Homo sapiens	36-40
18060882-4	2008	The kinetics of reactive oxygen species generation and changes in mitochondrial membrane potential after irradiation were also correlated with changes in CD20 expression.	Reactive Oxygen Species	16-39	keratin 20	Homo sapiens	154-158
18060882-6	2008	Buthionine sulfoximine, which depletes glutathione, also increased surface CD20, whereas antioxidants, such as PEG-catalase, PEG-SOD, vitamin C, and amifostine, decreased CD20 expression induced by radiation or H(2)O(2).	Buthionine Sulfoximine	0-22	keratin 20	Homo sapiens	75-79
18060882-6	2008	Buthionine sulfoximine, which depletes glutathione, also increased surface CD20, whereas antioxidants, such as PEG-catalase, PEG-SOD, vitamin C, and amifostine, decreased CD20 expression induced by radiation or H(2)O(2).	Buthionine Sulfoximine	0-22	keratin 20	Homo sapiens	171-175
18060882-6	2008	Buthionine sulfoximine, which depletes glutathione, also increased surface CD20, whereas antioxidants, such as PEG-catalase, PEG-SOD, vitamin C, and amifostine, decreased CD20 expression induced by radiation or H(2)O(2).	Amifostine	149-159	keratin 20	Homo sapiens	171-175
20641470-0	2004	Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody (USPIO-anti-CD20 MAb) is a molecular imaging agent developed for magnetic resonance imaging (MRI) of CD20 antigen-positive B cell lymphomas (1).	ferric oxide	29-39	keratin 20	Homo sapiens	45-49
20641470-0	2004	Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody (USPIO-anti-CD20 MAb) is a molecular imaging agent developed for magnetic resonance imaging (MRI) of CD20 antigen-positive B cell lymphomas (1).	ferric oxide	29-39	keratin 20	Homo sapiens	115-119
20641470-0	2004	Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody (USPIO-anti-CD20 MAb) is a molecular imaging agent developed for magnetic resonance imaging (MRI) of CD20 antigen-positive B cell lymphomas (1).	ferric oxide	99-109	keratin 20	Homo sapiens	115-119
20641470-0	2004	Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody (USPIO-anti-CD20 MAb) is a molecular imaging agent developed for magnetic resonance imaging (MRI) of CD20 antigen-positive B cell lymphomas (1).	ferric oxide	29-39	keratin 20	Homo sapiens	115-119
20641470-0	2004	Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody (USPIO-anti-CD20 MAb) is a molecular imaging agent developed for magnetic resonance imaging (MRI) of CD20 antigen-positive B cell lymphomas (1).	ferric oxide	99-109	keratin 20	Homo sapiens	45-49
20641470-0	2004	Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody Ultrasmall superparamagnetic iron oxide-anti-CD20 monoclonal antibody (USPIO-anti-CD20 MAb) is a molecular imaging agent developed for magnetic resonance imaging (MRI) of CD20 antigen-positive B cell lymphomas (1).	ferric oxide	99-109	keratin 20	Homo sapiens	115-119
17722077-7	2008	Anti-CD20 radioimmunoconjugates (RICs) (90)Yttrium-ibritumomab tiuxetan and (131)Iodine-tositumomab have been used in mantle cell lymphoma even when patients are relatively resistant to Rituximab-based therapy.	yttrium-ibritumomab tiuxetan	43-71	keratin 20	Homo sapiens	5-9
18197719-3	2008	Biologically inert SWNTs with polyethyleneglycol functionalization are conjugated to antibodies such as Rituxan to selectively recognize CD20 cell surface receptor on B-cells with little nonspecific binding to negative T-cells and Herceptin to recognize HER2/neu positive breast cancer cells.	Polyethylene Glycols	30-48	keratin 20	Homo sapiens	137-141
18194857-2	2008	90Y-ibritumomab tiuxetan is the only therapy approved for use after rituximab failure and is currently indicated in the EU for the treatment of adults with rituximab-relapsed or refractory CD20-positive follicular B-cell NHL.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	189-193
18190441-7	2008	CK20-positive Merkel cells were identified in 100% (15/15) of DTE and 3% (1/31) of mBCC (chi-square p &lt; 0.0001).	Dithioerythritol	62-65	keratin 20	Homo sapiens	0-4
18190441-8	2008	The expected pattern of AR-, CK20+ immunophenotype was present in 87% (13/15) of DTE cases.	Dithioerythritol	81-84	keratin 20	Homo sapiens	29-33
18190441-11	2008	CONCLUSIONS: Immunohistochemical stains for AR and CK20 are useful to differentiate DTE from mBCC.	Dithioerythritol	84-87	keratin 20	Homo sapiens	51-55
18190441-12	2008	The AR-, CK20+ immunophenotype is sensitive (87%) and specific for DTE (100%).	Dithioerythritol	67-70	keratin 20	Homo sapiens	9-13
17967882-1	2008	Methylation of histone H4 at lysine 20 (K20) has been implicated in transcriptional activation, gene silencing, heterochromatin formation, mitosis, and DNA repair.	Lysine	29-35	keratin 20	Homo sapiens	40-43
17971487-0	2008	Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.	DHAP protocol	44-48	keratin 20	Homo sapiens	102-106
18268399-11	2008	CONCLUSION: Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL.	ibritumomab tiuxetan	31-51	keratin 20	Homo sapiens	103-107
18268399-11	2008	CONCLUSION: Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL.	Chromium	82-84	keratin 20	Homo sapiens	103-107
18268399-12	2008	Thus, we will expand treatment of relapsed CD20-positive HL with 90Y ibritumomab tiuxetan at our institution.	ibritumomab tiuxetan	69-89	keratin 20	Homo sapiens	43-47
17967882-6	2008	Despite suggestions that it is required for normal mitosis and cell cycle progression, K20 methylation proceeds normally during colchicine treatment.	Colchicine	128-138	keratin 20	Homo sapiens	87-90
17967882-7	2008	Moreover, delays in PR-Set7 synthesis and K20 methylation which accompany altered cell cycle progression during sodium butyrate treatment appear to be secondary to histone hyperacetylation or other effects of butyrate since depletion of PR-Set7 did not affect cell cycle progression.	Butyric Acid	112-127	keratin 20	Homo sapiens	42-45
17967882-7	2008	Moreover, delays in PR-Set7 synthesis and K20 methylation which accompany altered cell cycle progression during sodium butyrate treatment appear to be secondary to histone hyperacetylation or other effects of butyrate since depletion of PR-Set7 did not affect cell cycle progression.	Butyrates	119-127	keratin 20	Homo sapiens	42-45
18006839-0	2007	Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.	fludarabine	95-106	keratin 20	Homo sapiens	27-31
17972021-6	2007	Cells exposed to hypoxia generate reactive oxygen species which activate PKC zeta which in turn phosphorylates the Na,K-ATPase at the Ser18 residue in the N-terminus of the alpha1-subunit leading the ubiquitination of any of the four lysines (K16, K17, K19, K20) adjacent to the Ser18 residue.	Reactive Oxygen Species	34-57	keratin 20	Homo sapiens	258-261
17899207-1	2008	The anti-CD20 antibody rituximab has been used successfully as a rescue therapy in some patients with therapy-refractory steroid-dependent nephrotic syndrome (SDNS), including both primary SDNS with minimal changes on biopsy and recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation.	Steroids	121-128	keratin 20	Homo sapiens	9-13
20641770-0	2004	Single-walled carbon nanotubes-(111)In-1,4,7,10-tetraazacyclododecane-N,N",N"",N"""-tetraacetic acid-rituximab The single-walled carbon nanotube-(111)In-labeled1,4,7,10-tetraazacyclododecane-N,N",N"",N"""-tetraacetic acid -rituximab (CNT-([(111)In]DOTA)(rituximab) is a nanoconstruct with multiple copies of the (111)In-labeled DOTA chelate and anti-CD20 monoclonal antibody (MAb) independently attached covalently to the CNT-sidewall and can be used for imaging lymphoid malignancies (1).	Carbon	14-20	keratin 20	Homo sapiens	350-354
20641770-0	2004	Single-walled carbon nanotubes-(111)In-1,4,7,10-tetraazacyclododecane-N,N",N"",N"""-tetraacetic acid-rituximab The single-walled carbon nanotube-(111)In-labeled1,4,7,10-tetraazacyclododecane-N,N",N"",N"""-tetraacetic acid -rituximab (CNT-([(111)In]DOTA)(rituximab) is a nanoconstruct with multiple copies of the (111)In-labeled DOTA chelate and anti-CD20 monoclonal antibody (MAb) independently attached covalently to the CNT-sidewall and can be used for imaging lymphoid malignancies (1).	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	39-100	keratin 20	Homo sapiens	350-354
20641770-9	2004	Later, ibritumomab (intact murine anti-CD20 MAb), was labeled with (111)In or (90)Y for NHL imaging and therapy (9, 10).	ibritumomab tiuxetan	7-18	keratin 20	Homo sapiens	39-43
18040144-3	2007	(90)Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttium-90 to the malignant B-cells.	y-ibritumomab tiuxetan	4-26	keratin 20	Homo sapiens	54-58
17886241-3	2007	Zevalin is a commercially available variation of the murine anti-CD20 antibody ibritumomab coupled to Yttrium 90 via the tiuxetan chelator.	ibritumomab tiuxetan	79-90	keratin 20	Homo sapiens	65-69
18040144-3	2007	(90)Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttium-90 to the malignant B-cells.	yttium-90	93-102	keratin 20	Homo sapiens	54-58
17661091-0	2007	Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.	Cyclophosphamide	104-120	keratin 20	Homo sapiens	88-92
17293073-3	2007	The aim of this study was to evaluate a possible role for positron emission tomography with [18F]-2-fluoro-2-desoxy-glucose (FDG) in the initial staging and in therapy monitoring of pediatric patients suffering from biopsy-proven CD20-positive PTLD after solid organ transplantation.	2-fluoro-2-desoxy-glucose	98-123	keratin 20	Homo sapiens	230-234
17850593-0	2007	Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.	Methotrexate	100-112	keratin 20	Homo sapiens	17-21
17875803-2	2007	A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell-non-Hodgkin"s lymphoma.	90y-it	67-73	keratin 20	Homo sapiens	20-24
17875803-2	2007	A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell-non-Hodgkin"s lymphoma.	90y-it	67-73	keratin 20	Homo sapiens	152-156
21487551-5	2007	In this report, we document a case of alcoholic hepatitis and methadone withdrawal masquerading unsuspected, hepatosplenic gamma/delta T-cell lymphoma with unusual CD20 positivity.	Methadone	62-71	keratin 20	Homo sapiens	164-168
17875803-0	2007	A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin"s lymphoma: a Children"s Oncology Group study.	90yttrium-ibritumomab-tiuxetan	19-49	keratin 20	Homo sapiens	103-107
17875803-2	2007	A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell-non-Hodgkin"s lymphoma.	90yttrium-ibritumomab-tiuxetan	35-65	keratin 20	Homo sapiens	20-24
17875803-2	2007	A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell-non-Hodgkin"s lymphoma.	90yttrium-ibritumomab-tiuxetan	35-65	keratin 20	Homo sapiens	152-156
17293073-3	2007	The aim of this study was to evaluate a possible role for positron emission tomography with [18F]-2-fluoro-2-desoxy-glucose (FDG) in the initial staging and in therapy monitoring of pediatric patients suffering from biopsy-proven CD20-positive PTLD after solid organ transplantation.	fluorescein-digalactoside	125-128	keratin 20	Homo sapiens	230-234
17715023-3	2007	RESULTS: The positivity rate of CK20 expression was 89.7% in HCC, and 100% in CA, SA and HP.	sa	82-84	keratin 20	Homo sapiens	32-36
17532766-12	2007	In conclusion, our experience clearly demonstrates that anti-CD20 monoclonal antibody rituximab is an effective and safe alternative treatment option for idiopathic AIHA, in particular, for steroid-refractory disease.	Steroids	190-197	keratin 20	Homo sapiens	61-65
17675267-8	2007	When we treated RRBL1 cells with trichostatin A, an epigenetic drug that modulates histone-acetylation status, we detected dramatically increased CD20 mRNA and protein expression, suggesting that epigenetic mechanisms may explain the CD20- phenotype in RRBL1 cells.	trichostatin A	33-47	keratin 20	Homo sapiens	146-150
17675267-8	2007	When we treated RRBL1 cells with trichostatin A, an epigenetic drug that modulates histone-acetylation status, we detected dramatically increased CD20 mRNA and protein expression, suggesting that epigenetic mechanisms may explain the CD20- phenotype in RRBL1 cells.	trichostatin A	33-47	keratin 20	Homo sapiens	234-238
17336267-0	2007	Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells.	Lipid Bilayers	117-130	keratin 20	Homo sapiens	101-105
17547519-1	2007	Iodine 131 (I131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope I131.	Iodine-131	0-10	keratin 20	Homo sapiens	57-61
17461736-6	2007	Anti-CD20+ monoclonal antibody therapy (rituximab) aiming at depleting B cells and suppressing antibody production has been used as rescue therapy in some episodes of steroid- and antilymphocyte-resistant humoral rejection.	Steroids	167-174	keratin 20	Homo sapiens	5-9
17336267-7	2007	Thus, the binding of Gb(3)/CD77 by its cognate ligand transmits information within the lipid bilayer of model lymphoma cells to impact the behaviour of selective proteins, most notably CD20, via a mechanism influenced by the level of cholesterol within the membrane.	globotriaosylceramide	21-26	keratin 20	Homo sapiens	185-189
17336267-7	2007	Thus, the binding of Gb(3)/CD77 by its cognate ligand transmits information within the lipid bilayer of model lymphoma cells to impact the behaviour of selective proteins, most notably CD20, via a mechanism influenced by the level of cholesterol within the membrane.	Lipid Bilayers	87-100	keratin 20	Homo sapiens	185-189
17336267-7	2007	Thus, the binding of Gb(3)/CD77 by its cognate ligand transmits information within the lipid bilayer of model lymphoma cells to impact the behaviour of selective proteins, most notably CD20, via a mechanism influenced by the level of cholesterol within the membrane.	Cholesterol	234-245	keratin 20	Homo sapiens	185-189
19707321-3	2007	I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin"s lymphoma (NHL).	Iodine-131	0-5	keratin 20	Homo sapiens	48-52
19707321-3	2007	I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin"s lymphoma (NHL).	Iodine-131	24-34	keratin 20	Homo sapiens	48-52
17487733-2	2007	It is routinely used in combination with the monoclonal anti-CD20 antibody rituximab (R-DHAP), particularly for peripheral blood stem cell (PBSC) mobilization.	r-dhap	86-92	keratin 20	Homo sapiens	61-65
17336267-3	2007	Engagement of Gb(3)/CD77 with SLT-B reduced the amount of CD20 and CXCR4 available, but levels of BCR, MHC Class II, CD21, CD27 and CD54 remained unchanged.	globotriaosylceramide	14-19	keratin 20	Homo sapiens	58-62
17336267-4	2007	Cholesterol depletion promoted a decrease in the number of sites accessed by CD20, CXCR4 and Gb(3)/CD77 antibodies.	Cholesterol	0-11	keratin 20	Homo sapiens	77-81
17548299-2	2007	Besides, one lysine within histone H4(K20) has been shown to be methylated by specific histone lysine methyltransferase.	Lysine	13-19	keratin 20	Homo sapiens	38-41
17218490-1	2007	BACKGROUND: As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease.	Vincristine	180-191	keratin 20	Homo sapiens	124-128
17218490-1	2007	BACKGROUND: As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease.	Prednisone	196-206	keratin 20	Homo sapiens	124-128
17323056-1	2007	BACKGROUND: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	61-81	keratin 20	Homo sapiens	177-181
17312330-0	2007	High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults &gt; or = 60 years old with relapsed or refractory B-cell lymphoma.	Iodine-131	11-15	keratin 20	Homo sapiens	34-38
17483756-8	2007	Because of the positive CD20- labeling, ZEM chemotherapy (idarubicine, cyclophosphamide, prednisolone) was given, resulting in disappearance of the nodules after four months and preliminary epidermal healing of the ulcer.	ZEM	40-43	keratin 20	Homo sapiens	24-28
17287964-4	2007	Encouraging results were also reported from monoclonal anti-CD20 antibodies, which are conjugated to radionuclides and exploit the high radiosensitivity of lymphomas.	Radioisotopes	101-114	keratin 20	Homo sapiens	60-64
17287964-5	2007	An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab.	ibritumomab tiuxetan	46-66	keratin 20	Homo sapiens	32-36
17287964-5	2007	An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab.	Yttrium-90	88-97	keratin 20	Homo sapiens	32-36
17396483-1	2007	Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen.	Iodine-131	12-22	keratin 20	Homo sapiens	119-123
17362749-4	2007	Immunohistochemical techniques using monoclonal anti-CD20 antibody was used on paraffin sections from 38 renal allograft biopsy specimens.	Paraffin	79-87	keratin 20	Homo sapiens	53-57
17396483-1	2007	Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen.	tositumomab I-131	36-42	keratin 20	Homo sapiens	119-123
17396483-1	2007	Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen.	ibritumomab tiuxetan	48-68	keratin 20	Homo sapiens	119-123
17354532-3	2007	Among novel developments based on biologicals, the anti-CD20 monoclonal antibody rituximab (anti-B cells) appears encouraging in open studies, in association or not with cyclophosphamide, and is generally well tolerated.	Cyclophosphamide	170-186	keratin 20	Homo sapiens	56-60
17264461-2	2007	Treatment with rituximab, a monoclonal antibody against CD20, was associated with remission of symptoms and a steroid sparing effect that persisted for more than 9 months.	Steroids	110-117	keratin 20	Homo sapiens	56-60
17823525-3	2007	An anti-CD20 monoclonal antibody (rituximab) was proposed because of resistance to high-dose steroids and other immunosuppressive agents.	Steroids	93-101	keratin 20	Homo sapiens	8-12
17198877-6	2007	RESULTS: Comprehensive transcriptional response is associated with curcumin treatment in HF4.9 cells, including differential expression of genes encoding apoptotic signaling proteins, tumor and metastasis suppressors, transcription and splicing factors, proteins involved in regulation of cell adhesion, migration (e.g., CXCR4), lymphoid development, or B-cell activation (e.g. CD20), and others.	Curcumin	67-75	keratin 20	Homo sapiens	378-382
17198877-11	2007	Other curcumin-regulated genes identified herein, e.g., CD20, are also seemingly pertinent to the pathophysiology of follicular lymphoma.	Curcumin	6-14	keratin 20	Homo sapiens	56-60
17204712-0	2007	Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin"s lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.	Iodine-131	34-38	keratin 20	Homo sapiens	52-56
16967494-0	2006	Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.	Fluorescein	14-25	keratin 20	Homo sapiens	71-75
17579276-9	2007	The predominant fatty acids of strain K-20 were C18:1Delta11 (50.8%) and C16:1 (17.2%).	Fatty Acids	16-27	keratin 20	Homo sapiens	38-42
17198274-1	2006	BACKGROUND: The presence of CD20+ lymphocyte renal allograft infiltrates has been associated with steroid-resistant rejection and poor graft survival.	Steroids	98-105	keratin 20	Homo sapiens	28-32
17169808-2	2006	The aim of this study was to evaluate the cytotoxicity of SDX-101 combined with agents proven to be effective as first-line treatment of B-CLL: the purine nucleoside analogs, fludarabine (FA) and cladribine (2-CdA), and the monoclonal antibodies, anti-CD52 (alemtuzumab; ALT) and anti-CD20 (rituximab; RIT).	Etodolac	58-65	keratin 20	Homo sapiens	285-289
16967494-11	2006	Using the CD4 T-cell as a biologic calibrator for FITC conjugate, the mean ABC value for CD20-FITC on normal B-cells was 199,300.	Fluorescein-5-isothiocyanate	50-54	keratin 20	Homo sapiens	89-93
16705086-9	2006	We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183).	Disulfides	166-175	keratin 20	Homo sapiens	60-64
16856917-3	2006	We present two patients with PCMZL and multiple skin lesions successfully treated with intralesional administration of the anti-CD20 monoclonal antibody rituximab.	pcmzl	29-34	keratin 20	Homo sapiens	128-132
16940276-1	2006	PURPOSE: To evaluate efficacy and safety of iodine-131 (131I) -rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin"s lymphoma (NHL).	Iodine-131	44-54	keratin 20	Homo sapiens	87-91
16940276-1	2006	PURPOSE: To evaluate efficacy and safety of iodine-131 (131I) -rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin"s lymphoma (NHL).	Iodine-131	56-60	keratin 20	Homo sapiens	87-91
18040802-12	2006	This study demonstrates the usefulness of voluntary oral self-dosing procedures for maintaining morphine dependence in nonhuman primates and demonstrates that the morphine withdrawal syndrome includes large alterations in blood parameters of immune system function, including nearly 50% reduction in numbers of CD4+, CD8+ and CD20+ cells.	Morphine	163-171	keratin 20	Homo sapiens	326-330
16823816-2	2006	In recent years the anti-CD20 monoclonal antibody rituximab has been used for the therapy of steroid-refractory AIHA and autoimmune thrombocytopenia, either idiopathic or in association with CLL.	Steroids	93-100	keratin 20	Homo sapiens	25-29
16951396-2	2006	This is an extremely rare, disseminated, and aggressive extranodal CD20(+) non-Hodgkin"s lymphoma (NHL) with poor outcome following anthracycline-based chemotherapy.	Anthracyclines	132-145	keratin 20	Homo sapiens	67-71
16826593-1	2006	Radioimmunotherapy (RIT) with Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) combines the tumor targeting attributes of a monoclonal antibody against the CD20 antigen and the pure beta-radiation of 90Y.	ibritumomab tiuxetan	47-67	keratin 20	Homo sapiens	155-159
16753870-2	2006	Rituximab, a chimeric monoclonal antibody against the CD20 molecule, has been used with success in patients with neuropathy and monoclonal IgM with anti-MAG or anti-GM1 ganglioside activity.	G(M1) Ganglioside	165-180	keratin 20	Homo sapiens	54-58
16849586-10	2006	PPARgamma involvement was further confirmed via ligand-dependent activation (P &lt; 0.01) as well as by induction of cytokeratin 20 (P &lt; 0.001) after resveratrol treatment.	Resveratrol	153-164	keratin 20	Homo sapiens	117-131
17087138-2	2006	90Y-ibritumomab tiuxetan is a monoclonal antibody directed against the CD20 antigen to which a radioactive isotope of yttrium is attached, used for treating follicular lymphomas (FL).	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	71-75
16430461-0	2006	Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.	fludarabine	24-35	keratin 20	Homo sapiens	80-84
16722594-11	2006	Hydroxychloroquine and non-steroidal anti-inflammatory drugs are used for milder disease; corticosteroids and immunosuppressive therapies are generally reserved for major organ involvement; anti-CD20 monoclonal antibody is now used in patients with severe disease who has not responded to conventional treatments.	Hydroxychloroquine	0-18	keratin 20	Homo sapiens	195-199
16360234-5	2006	Carcinogenesis via BilIN was characterized by MUC2-/CK7+/CK20-with increasing MUC1 expression.	Bile Pigments	19-24	keratin 20	Homo sapiens	57-61
16360234-6	2006	IPN-B was characterized by the intestinal phenotype (MUC2+/CK20+), and carcinogenesis leading to tubular adenocarcinoma was associated with increasing MUC1 expression and that to colloid carcinoma with MUC1-negativity.	ipn-b	0-5	keratin 20	Homo sapiens	59-63
16321828-2	2006	Especially the commercially available anti-CD20 antibody 90Y-ibritumomab tiuxetan is currently under investigation in various trials including dose escalation and autologous hematopoietic progenitor cell support.	ibritumomab tiuxetan	57-81	keratin 20	Homo sapiens	43-47
16503532-2	2006	METHODS: Anti-CD20 monoclonal antibody rituximab was labeled with (131)I by means of IODO-GEN method, and its effects on apoptosis of Raji cells were determined by Annexin-V/PI double-labeled cytometry.	1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril	85-93	keratin 20	Homo sapiens	14-18
16979436-1	2006	Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin"s lymphoma.	Iodine-131	0-10	keratin 20	Homo sapiens	162-166
16979436-1	2006	Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin"s lymphoma.	Iodine-131	12-17	keratin 20	Homo sapiens	162-166
16979436-1	2006	Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin"s lymphoma.	tositumomab I-131	32-38	keratin 20	Homo sapiens	162-166
16979437-3	2006	In clinical trials, (90)Y ibritumomab tiuxetan has produced rates of response as high as 83% in patients with relapsed or refractory CD20+ NHL.	ibritumomab tiuxetan	26-46	keratin 20	Homo sapiens	133-137
16979439-3	2006	Y-90 ibritumomab tiuxetan (Zevalin) and I-131 tositumomab (Bexxar) both recognize the CD-20 surface antigen found on normal and malignant B cells.	ibritumomab tiuxetan	5-25	keratin 20	Homo sapiens	86-91
16405612-2	2006	We report the case of a patient with PNP associated with a CD20+ non-Hodgkin follicular lymphoma who was treated with Rituximab plus corticosteroids and short courses of cyclosporin.	Cyclosporine	170-181	keratin 20	Homo sapiens	59-63
16455513-5	2006	Recently, the association of anti-CD20 and 131Iode was shown to be efficient in follicular lymphomas.	131iode	43-50	keratin 20	Homo sapiens	34-38
16977965-12	2006	LMC showed: CD 20 (+), bcl-2 (-), CD 10 (+/-), and bcl-6 (+) in the follicle, and bcl-2 (+), CD10 (-/+) and bcl-6 (-) in the interfollicular area.	LMC	0-3	keratin 20	Homo sapiens	12-17
16540013-3	2006	90Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttrium-90 to the malignant B-cells.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	52-56
16540013-3	2006	90Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver beta-emitting yttrium-90 to the malignant B-cells.	Yttrium-90	91-101	keratin 20	Homo sapiens	52-56
16540013-6	2006	A similar anti-CD20 radiotherapeutic compound, 131I-tositumomab, was subsequently approved in the USA.	tositumomab I-131	47-63	keratin 20	Homo sapiens	15-19
16111589-1	2005	PURPOSE: To evaluate two potential approaches to predicting site-specific patterns of recurrence after yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) for CD20+ B-cell Non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	114-134	keratin 20	Homo sapiens	164-168
16103877-0	2005	Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.	ammonium ferrous sulfate	62-65	keratin 20	Homo sapiens	25-29
15937686-6	2005	Rituximab, a monoclonal chimeric anti-CD20 antibody (IDEC-C2B8), was labelled with 131I using the Iodogen method.	Iodine-131	83-87	keratin 20	Homo sapiens	38-42
16091197-4	2005	Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well.	Iodine-131	86-91	keratin 20	Homo sapiens	61-65
16091197-4	2005	Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well.	Yttrium-90	108-112	keratin 20	Homo sapiens	61-65
16091197-4	2005	Other studies in indolent NHL suggest that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease and have potential utility as part of initial treatment as well.	ibritumomab tiuxetan	113-133	keratin 20	Homo sapiens	61-65
16275160-5	2005	Examination of fatty acid composition of total cell lipids using Ag+-HPLC, GC-FID and GC-MS analysis revealed a significant isomer-specific formation of conjugated metabolites of CLA such as CD16:2, CD20:2 and CD22:2 in human coronary artery smooth muscle cells treated with various CLA isomers.	Linoleic Acids, Conjugated	179-182	keratin 20	Homo sapiens	199-203
16285718-7	2005	Rituximab binding is abolished by reduction and alkylation of CD20, with data consistent with the proposed antibody epitope being within the disulfide-bonded loop formed between cysteine residues 167 and 183.	Disulfides	141-150	keratin 20	Homo sapiens	62-66
16285718-7	2005	Rituximab binding is abolished by reduction and alkylation of CD20, with data consistent with the proposed antibody epitope being within the disulfide-bonded loop formed between cysteine residues 167 and 183.	Cysteine	178-186	keratin 20	Homo sapiens	62-66
16285718-8	2005	Disulfide-bond-dependent antibody binding is partially recovered following reoxidation of reduced CD20.	Disulfides	0-9	keratin 20	Homo sapiens	98-102
16285718-9	2005	Antibody binding is unaffected by mutations of cysteines proposed to be in the intracellular domain of CD20.	Cysteine	47-56	keratin 20	Homo sapiens	103-107
16203814-1	2005	PURPOSE: Targeted radioimmunotherapy with yttrium-90 (90Y)-labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non-Hodgkin"s lymphoma.	Yttrium-90	42-52	keratin 20	Homo sapiens	200-204
16203814-1	2005	PURPOSE: Targeted radioimmunotherapy with yttrium-90 (90Y)-labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	67-87	keratin 20	Homo sapiens	200-204
16162271-3	2005	Like most but not all CD20 mAbs, rituximab induces a sharp change in the solubility of the CD20 protein in the non-ionic detergent Triton-X-100, reflecting a dramatic increase in the innate affinity of CD20 for membrane raft signalling domains.	Octoxynol	131-143	keratin 20	Homo sapiens	91-95
16162271-3	2005	Like most but not all CD20 mAbs, rituximab induces a sharp change in the solubility of the CD20 protein in the non-ionic detergent Triton-X-100, reflecting a dramatic increase in the innate affinity of CD20 for membrane raft signalling domains.	Octoxynol	131-143	keratin 20	Homo sapiens	91-95
16162271-6	2005	Cholesterol depletion prevented the association of hypercrosslinked CD20 with detergent-insoluble rafts, and attenuated both calcium mobilization and apoptosis induced with rituximab.	Cholesterol	0-11	keratin 20	Homo sapiens	68-72
16095505-5	2005	The CD20-positive group was significantly more likely to have steroid-resistant rejection and reduced graft survival compared to CD20-negative controls.	Steroids	62-69	keratin 20	Homo sapiens	4-8
16128896-13	2005	The anti-CD20 monoclonal antibody rituximab was given to two patients in conventional doses and a CR was seen in one patient.	Chromium	98-100	keratin 20	Homo sapiens	9-13
16115941-6	2005	RESULTS: Comparison of Rituximab with a previously described dimer and the newly generated polymer shows that the polymer induced apoptosis more effectively in CD20+ cells as shown by the terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay (Rituximab, 3%; dimer, 3%; polymer, 58%).	deoxyuridine triphosphate	239-243	keratin 20	Homo sapiens	160-164
16115941-9	2005	CONCLUSIONS: These data suggest that hyper-cross-linking-induced apoptosis can be simulated by the use of a dextran polymer of Rituximab, which, when used in vivo, can directly kill CD20+ lymphoma cells and improve the clinical efficacy of this important therapeutic for human B-cell lymphomas.	Dextrans	108-115	keratin 20	Homo sapiens	182-186
16164191-4	2005	Radioimmunotherapy using 131I- and 90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin"s lymphoma (NHL), including patients who are refractory to anti-CD20 monoclonal antibody (rituximab) therapy in the United States.	Iodine-131	25-29	keratin 20	Homo sapiens	131-135
16164191-4	2005	Radioimmunotherapy using 131I- and 90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin"s lymphoma (NHL), including patients who are refractory to anti-CD20 monoclonal antibody (rituximab) therapy in the United States.	Iodine-131	25-29	keratin 20	Homo sapiens	131-135
16029344-15	2005	CONCLUSIONS: Intravenous therapy with eight cycles of the anti-CD20 antibody rituximab is a non-toxic and effective treatment for a subset of patients with PCBCL (relapsed, aggressive entity, old patients, multiple lesions) with a long DR.	pcbcl	156-161	keratin 20	Homo sapiens	63-67
15900362-8	2005	All the cases of LP demonstrated the characteristic phenotype of this variant (CD45RB+, CD20+, CD15-, CD30-).	leucylproline	17-19	keratin 20	Homo sapiens	88-92
15944291-8	2005	The effect of bryostatin-1 on CD20 expression in non-Hodgkin"s lymphoma cells was mediated through the MAPK kinase/ERK signal transduction pathway and involved protein kinase C, but was independent of p38 MAPK and was insensitive to dexamethasone.	Dexamethasone	233-246	keratin 20	Homo sapiens	30-34
15815716-0	2005	Improved therapy of non-Hodgkin"s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.	Radioisotopes	60-73	keratin 20	Homo sapiens	102-106
15802280-4	2005	(90)Y-Ibritumomab tiuxetan (Zevalin); Schering AG, Berlin, Germany), the first RIT approved for use in relapsed/refractory indolent NHL, comprises the murine anti-CD20 monoclonal antibody ibritumomab, covalently linked to the high-energy beta-emitter, yttrium-90, by the chelator, tiuxetan.	ibritumomab tiuxetan	6-17	keratin 20	Homo sapiens	163-167
15834625-6	2005	The short-term effect of PE and IVIgand the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies.	Steroids	94-102	keratin 20	Homo sapiens	179-183
15730389-0	2005	Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.	Calcium	91-98	keratin 20	Homo sapiens	14-18
15788684-6	2005	The quantitative analysis revealed that fucose depletion could reduce the antigen amount on target cells required for constant degrees of ADCC induction by 10-fold for CC chemokine receptor 4 and 3-fold for CD20.	Fucose	40-46	keratin 20	Homo sapiens	207-211
15730389-0	2005	Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.	Calcium	91-98	keratin 20	Homo sapiens	54-58
15730389-4	2005	CD20 is a B-lymphocyte specific integral membrane protein, proposed to function as a store-operated calcium channel, which is activated upon receptor-stimulated calcium depletion of intracellular stores.	Calcium	100-107	keratin 20	Homo sapiens	0-4
15730389-7	2005	However, binding of Rituxan significantly increases the affinity of CD20 for lipid rafts resulting in its redistribution to a fraction resistant to Triton X-100 solubilization.	Octoxynol	148-160	keratin 20	Homo sapiens	68-72
15730389-8	2005	Furthermore, we demonstrate that disturbing the raft integrity by cholesterol extraction results in dissociation of CD20 from a Triton X-100 resistant fraction followed by complete inhibition of Rituxan-induced calcium entry and apoptosis.	Cholesterol	66-77	keratin 20	Homo sapiens	116-120
15730389-8	2005	Furthermore, we demonstrate that disturbing the raft integrity by cholesterol extraction results in dissociation of CD20 from a Triton X-100 resistant fraction followed by complete inhibition of Rituxan-induced calcium entry and apoptosis.	Octoxynol	128-140	keratin 20	Homo sapiens	116-120
15746068-9	2005	Cyclic guanosine 3",5"-monophosphate culture conditions using serum-free AIM-V medium containing human AB serum, recombinant human interleukin 2 (Proleukin) and CD3/CD28 Dynabeads were developed resulting in a 35-fold expansion of CD20 peptide-specific CTLs.	Cyclic GMP	0-36	keratin 20	Homo sapiens	231-235
15777935-0	2005	Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.	Glycosylphosphatidylinositols	124-127	keratin 20	Homo sapiens	38-42
15777935-0	2005	Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.	Glycosylphosphatidylinositols	124-127	keratin 20	Homo sapiens	158-162
15649140-1	2005	CD20 is a B-lymphocyte-specific integral membrane protein, implicated in the regulation of transmembrane calcium conductance, cell-cycle progression and B-lymphocyte proliferation.	Calcium	105-112	keratin 20	Homo sapiens	0-4
15713903-4	2005	Upon addition of alliin, allicin was formed in situ, killing the CD20+ tumor B cells via apoptosis.	allicin	25-32	keratin 20	Homo sapiens	65-69
15654538-6	2005	Another attractive approach is to link anti-CD20 antibodies to radioisotopes, thereby exploiting the radiosensitivity of malignant lymphomas: encouraging results were already presented for the yttrium-90-((90)Y-)labeled anti-CD20 antibody ibritumomab tiuxetan as well as for the iodine-131-((131)I-)labeled anti-CD20 antibody tositumomab.	Iodine	279-285	keratin 20	Homo sapiens	44-48
15654538-6	2005	Another attractive approach is to link anti-CD20 antibodies to radioisotopes, thereby exploiting the radiosensitivity of malignant lymphomas: encouraging results were already presented for the yttrium-90-((90)Y-)labeled anti-CD20 antibody ibritumomab tiuxetan as well as for the iodine-131-((131)I-)labeled anti-CD20 antibody tositumomab.	Iodine	279-285	keratin 20	Homo sapiens	225-229
15654538-6	2005	Another attractive approach is to link anti-CD20 antibodies to radioisotopes, thereby exploiting the radiosensitivity of malignant lymphomas: encouraging results were already presented for the yttrium-90-((90)Y-)labeled anti-CD20 antibody ibritumomab tiuxetan as well as for the iodine-131-((131)I-)labeled anti-CD20 antibody tositumomab.	Iodine	279-285	keratin 20	Homo sapiens	225-229
15621801-8	2005	On multivariate analysis for overall survival in patients with CD20-positive PTLD, low IPI (P = 0.004) and rituximab therapy (P = 0.03) were significant.	diprotin A	87-90	keratin 20	Homo sapiens	63-67
15621801-9	2005	Low IPI and rituximab therapy led to an improved overall survival in patients with CD20-positive PTLD.	diprotin A	4-7	keratin 20	Homo sapiens	83-87
15786024-6	2005	90Y-ibritumomab tiuxetan comprises the murine IgG1 anti-CD20 antibody ibritumomab, covalently linked to the beta-emitter 90 Y by a chelator tiuxetan.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	56-60
15786024-6	2005	90Y-ibritumomab tiuxetan comprises the murine IgG1 anti-CD20 antibody ibritumomab, covalently linked to the beta-emitter 90 Y by a chelator tiuxetan.	tiuxetan	16-24	keratin 20	Homo sapiens	56-60
15786026-3	2005	Two anti-CD20 RIT agents have now been approved for the treatment of refractory NHL: 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) is approved in both the United States and Europe, and 131I-tositumomab (Bexxar; Corixa Corp, Seattle, WA) is approved only in the United States.	ibritumomab tiuxetan	85-109	keratin 20	Homo sapiens	9-13
15649140-7	2005	This review outlines recent biochemical studies characterizing the role of CD20 in calcium signalling in B-lymphocytes and evaluates an engagement of lipid rafts in the regulation of CD20-mediated calcium conductivity.	Calcium	83-90	keratin 20	Homo sapiens	75-79
15649140-7	2005	This review outlines recent biochemical studies characterizing the role of CD20 in calcium signalling in B-lymphocytes and evaluates an engagement of lipid rafts in the regulation of CD20-mediated calcium conductivity.	Calcium	197-204	keratin 20	Homo sapiens	183-187
15585616-0	2004	Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.	auristatin	58-68	keratin 20	Homo sapiens	53-57
16304400-7	2005	Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well.	Iodine-131	95-100	keratin 20	Homo sapiens	70-74
16304400-7	2005	Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well.	Yttrium-90	117-121	keratin 20	Homo sapiens	70-74
16304400-7	2005	Other studies in NHL have clearly demonstrated that radiolabeled anti-CD20 antibodies (such as I-131 tositumomab and Y-90 ibritumomab tiuxetan) may be useful in relapsed and refractory disease, and have potential utility as part of initial treatment as well.	ibritumomab tiuxetan	122-142	keratin 20	Homo sapiens	70-74
15585616-2	2004	Its efficacy has been increased when used in combination with chemotherapy, yet anti-CD20 monoclonal antibodies (mAbs) directly conjugated with drugs such as doxorubicin (Dox) have failed to deliver drug or to demonstrate antitumor activity.	Doxorubicin	158-169	keratin 20	Homo sapiens	85-89
15585616-2	2004	Its efficacy has been increased when used in combination with chemotherapy, yet anti-CD20 monoclonal antibodies (mAbs) directly conjugated with drugs such as doxorubicin (Dox) have failed to deliver drug or to demonstrate antitumor activity.	Doxorubicin	171-174	keratin 20	Homo sapiens	85-89
15585616-3	2004	We have produced anti-CD20 antibody-drug conjugates that possess potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).	monomethyl auristatin E	124-147	keratin 20	Homo sapiens	22-26
15585616-3	2004	We have produced anti-CD20 antibody-drug conjugates that possess potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).	Dipeptides	193-202	keratin 20	Homo sapiens	22-26
15585616-3	2004	We have produced anti-CD20 antibody-drug conjugates that possess potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).	valine-citrulline	204-221	keratin 20	Homo sapiens	22-26
15585616-3	2004	We have produced anti-CD20 antibody-drug conjugates that possess potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).	Polyvinyl Chloride	223-225	keratin 20	Homo sapiens	22-26
15585616-5	2004	Unlike rituximab, which showed diffuse surface localization, rituximab-vcMMAE capped and was internalized within 4 hours after binding to CD20(+) B cells.	rituximab-vcmmae	61-77	keratin 20	Homo sapiens	138-142
15585616-7	2004	Anti-CD20 antibody-drug conjugates prepared with Dox were internalized and localized as with rituximab-vcMMAE, yet these were not effective for drug delivery (IC(50) &gt; 50 microg/mL).	Doxorubicin	49-52	keratin 20	Homo sapiens	5-9
15627024-7	2004	New therapeutic agents such as temozolomide, topotecan, or intrathecal rituximab (anti-CD20 monoclonal antibody) have demonstrated a modest but true activity as single-agent therapy in relapsed PCNSL and are of interest, in terms of their good safety profile, for inclusion in new polychemotherapy regimen as primary treatment.	pcnsl	194-199	keratin 20	Homo sapiens	87-91
15844660-4	2004	The radioimmunoconjugate 90Y-ibritumomab tiuxetan is directed against the B-cell antigen, CD20.	ibritumomab tiuxetan	25-49	keratin 20	Homo sapiens	90-94
15621757-0	2004	Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies.	Bendamustine Hydrochloride	0-12	keratin 20	Homo sapiens	134-138
15621757-0	2004	Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies.	Mitoxantrone	13-25	keratin 20	Homo sapiens	134-138
15621757-0	2004	Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies.	((2r,3s,5r)-3-Hydroxy-5-(3-Methoxynaphthalen-2-Yl)methyl-Tetrahydrogen-Triphosphate	37-40	keratin 20	Homo sapiens	134-138
15621757-2	2004	We have developed a new chemoimmunotherapy for patients with relapsed or refractory CD20-positive indolent lymphomas and CLL by combining the chemotherapeutic agents Bendamustine (B) and Mitoxantrone (M) with the monoclonal antibody Rituximab.	Bendamustine Hydrochloride	166-178	keratin 20	Homo sapiens	84-88
15621757-2	2004	We have developed a new chemoimmunotherapy for patients with relapsed or refractory CD20-positive indolent lymphomas and CLL by combining the chemotherapeutic agents Bendamustine (B) and Mitoxantrone (M) with the monoclonal antibody Rituximab.	Mitoxantrone	187-199	keratin 20	Homo sapiens	84-88
15621757-14	2004	BMR is a well tolerated very effective outpatient treatment for relapsed and refractory CD20-positive indolent lymphomas and CLL.	((2r,3s,5r)-3-Hydroxy-5-(3-Methoxynaphthalen-2-Yl)methyl-Tetrahydrogen-Triphosphate	0-3	keratin 20	Homo sapiens	88-92
15517123-6	2004	Furthermore, clinical trials have demonstrated promising activity of monoclonal antibodies conjugated to radioisotopes such as the (131)iodine anti-CD20 antibody tositumomab or the (90)yttrium anti-CD20 antibody ibritumomab tiuxetan.	Iodine	136-142	keratin 20	Homo sapiens	148-152
15640794-2	2004	Iodine [(131)I] tositumomab, administered in combination with unlabelled tositumomab, is a novel radioimmunotherapeutic regimen that targets the CD20 antigen present on normal and malignant B-cells.	Iodine	0-6	keratin 20	Homo sapiens	145-149
15529247-2	2004	Recently two randomized trials of the German Low Grade Lymphoma Study Group (GLSG) demonstrated the superiority of a combined immunochemotherapy with the anti-CD20 antibody rituximab in first-line therapy (R-CHOP) as well as in relapsed disease (R-FCM).	-fcm	247-251	keratin 20	Homo sapiens	159-163
15251978-2	2004	Because cGVHD has clinical, histologic, and laboratory findings of autoimmune diseases and anti-B-cell therapy has shown efficacy in autoimmune diseases, we hypothesized that monoclonal anti-CD20 antibody therapy might improve patients with cGVHD.	cgvhd	8-13	keratin 20	Homo sapiens	191-195
15195108-0	2004	Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray.	Oligonucleotides	90-105	keratin 20	Homo sapiens	22-26
15498146-1	2004	Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation.	Yttrium-90	39-49	keratin 20	Homo sapiens	190-194
15498146-1	2004	Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation.	ibritumomab tiuxetan	58-78	keratin 20	Homo sapiens	190-194
15016644-0	2004	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.	ibritumomab tiuxetan	24-44	keratin 20	Homo sapiens	68-72
15453924-1	2004	We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab standard therapy in 143 rituximab-naive patients with relapsed or refractory low-grade, follicular, or transformed CD20+ non-Hodgkin"s lymphoma (NHL).	Yttrium-90	84-94	keratin 20	Homo sapiens	245-249
15274103-7	2004	When compared to the control group, there was a larger number of CD8+, CD4+, CD20+, granzyme B+, and perforin+ lymphocytes in the CBO group.	cbo	130-133	keratin 20	Homo sapiens	77-81
15170171-4	2004	Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, Vincristine and Cyclophosphamide results in a profound depletion of B cells in peripheral blood.	Vincristine	132-143	keratin 20	Homo sapiens	35-39
15170171-4	2004	Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, Vincristine and Cyclophosphamide results in a profound depletion of B cells in peripheral blood.	Cyclophosphamide	148-164	keratin 20	Homo sapiens	35-39
15342663-10	2004	In addition, a phase I study of a radiolabeled anti-CD20 antibody (ibritumomab tiuxetan) was completed in 2003, and a phase II study for indolent B-NHL will be initiated.	ibritumomab tiuxetan	67-87	keratin 20	Homo sapiens	52-56
15199219-6	2004	A mean of 96, 72 and 64% of the CD14-, CD16- and CD20-positive cells from peripheral blood of rheumatoid arthritis (RA) patients showed an uptake of albumin after incubation with AFLc-HSA in vitro.	aflc-hsa	179-187	keratin 20	Homo sapiens	49-53
15289357-9	2004	PT-100 also demonstrated ability to augment antitumor activity of rituximab and trastuzumab in xenograft models of human CD20(+) B-cell lymphoma and HER-2(+) colon carcinoma where antibody-dependent cytotoxicity can be mediated by innate effector cells responsive to the cytokines and chemokines up-regulated by PT-100.	talabostat	0-6	keratin 20	Homo sapiens	121-125
15293570-1	2004	Imatinib mesylate and rituximab are molecularly targeted drugs against the BCR-ABL fusion protein and the CD20 antigen, respectively.	Imatinib Mesylate	0-17	keratin 20	Homo sapiens	106-110
15293570-3	2004	We have investigated the case of a patient with Philadelphia chromosome-positive and CD20+ acute lymphocytic leukemia who acquired resistance to imatinib and rituximab.	Imatinib Mesylate	145-153	keratin 20	Homo sapiens	85-89
15103391-0	2004	The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.	saporin-s6	24-34	keratin 20	Homo sapiens	76-80
15016644-1	2004	We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20(+), B-cell, non-Hodgkin lymphoma (NHL).	ibritumomab tiuxetan	50-70	keratin 20	Homo sapiens	156-160
14976189-1	2004	CD20 is a B cell-specific membrane protein that functions in store-operated calcium entry and serves as a useful target for antibody-mediated therapeutic depletion of B cells.	Calcium	76-83	keratin 20	Homo sapiens	0-4
15158763-1	2004	In a previous paper, we showed that naturally occurring conjugated linoleic acid (CLA) from butter fat is metabolized in vivo to higher metabolites such as conjugated diene (CD) 18:3, CD 20:3 and CD 20:4, all the while retaining the conjugated diene structure.	Linoleic Acid	67-80	keratin 20	Homo sapiens	184-189
15158763-1	2004	In a previous paper, we showed that naturally occurring conjugated linoleic acid (CLA) from butter fat is metabolized in vivo to higher metabolites such as conjugated diene (CD) 18:3, CD 20:3 and CD 20:4, all the while retaining the conjugated diene structure.	Linoleic Acid	67-80	keratin 20	Homo sapiens	196-201
15158763-1	2004	In a previous paper, we showed that naturally occurring conjugated linoleic acid (CLA) from butter fat is metabolized in vivo to higher metabolites such as conjugated diene (CD) 18:3, CD 20:3 and CD 20:4, all the while retaining the conjugated diene structure.	Linoleic Acids, Conjugated	82-85	keratin 20	Homo sapiens	184-189
15158763-1	2004	In a previous paper, we showed that naturally occurring conjugated linoleic acid (CLA) from butter fat is metabolized in vivo to higher metabolites such as conjugated diene (CD) 18:3, CD 20:3 and CD 20:4, all the while retaining the conjugated diene structure.	Linoleic Acids, Conjugated	82-85	keratin 20	Homo sapiens	196-201
15158763-1	2004	In a previous paper, we showed that naturally occurring conjugated linoleic acid (CLA) from butter fat is metabolized in vivo to higher metabolites such as conjugated diene (CD) 18:3, CD 20:3 and CD 20:4, all the while retaining the conjugated diene structure.	diene	244-249	keratin 20	Homo sapiens	196-201
14976189-7	2004	The mechanism underlying antibody-induced association of CD20 with Triton-resistant rafts was investigated and found not to require cellular ATP, kinase activity, actin polymerization, or antibody cross-linking but was dependent on the epitope recognized.	Adenosine Triphosphate	141-144	keratin 20	Homo sapiens	57-61
15111325-5	2004	The effect of TZ was significantly augmented when the autocrine-stimulated epidermal growth factor receptor pathway was inhibited and this resulted in induction of CK20 expression.	Troglitazone	14-16	keratin 20	Homo sapiens	164-168
15192961-8	2004	Immunohistochemical staining using paraffin-embedded tissue revealed intraluminal tumor cells expressing leukocyte common antigen and CD20 but not CD3.	Paraffin	35-43	keratin 20	Homo sapiens	134-138
14729658-0	2004	186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma.	186rhenium	0-10	keratin 20	Homo sapiens	24-28
15023434-1	2004	Anti-CD20 antibodies radiolabeled with I-131 tositumomab (Bexxar) or Y-90-Ibritumomab tiuxetan (Zevalin), are similarly efficacious in treating chemotherapy-refractory non-Hodgkin"s lymphoma.	tositumomab I-131	58-64	keratin 20	Homo sapiens	5-9
15023434-1	2004	Anti-CD20 antibodies radiolabeled with I-131 tositumomab (Bexxar) or Y-90-Ibritumomab tiuxetan (Zevalin), are similarly efficacious in treating chemotherapy-refractory non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	69-94	keratin 20	Homo sapiens	5-9
15160923-2	2004	Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin"s lymphomas.	Iodine-131	25-35	keratin 20	Homo sapiens	56-60
15160923-2	2004	Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin"s lymphomas.	Iodine-131	25-35	keratin 20	Homo sapiens	200-204
14748653-3	2004	The iodine-131 tositumomab regimen was approved by the US Food and Drug Administration in June 2003 for the treatment of patients with CD20-positive, follicular non-Hodgkin"s lymphoma, both with and without transformation, whose disease is refractory to rituximab (Rituxan) and has relapsed following chemotherapy.	Iodine	4-10	keratin 20	Homo sapiens	135-139
15045033-1	2004	This article will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin"s lymphomas.	ibritumomab tiuxetan	53-73	keratin 20	Homo sapiens	122-126
15045033-1	2004	This article will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20, for patients with relapsed B-cell non-Hodgkin"s lymphomas.	Yttrium-90	77-87	keratin 20	Homo sapiens	122-126
15045033-2	2004	Ibritumomab is the murine parent anti-CD20 antibody that was engineered to make the human chimeric antibody rituximab.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	38-42
15032688-5	2004	For example, the cells derived from Fanconi anemia (FA) patients are intolerant of oxidative stress and the therapeutic effect of anti-CD20 monoclonal antibody rituximab on B cell lymphoproliferative disorders is due to the generation of ROS.	Reactive Oxygen Species	238-241	keratin 20	Homo sapiens	135-139
14697987-0	2003	B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen.	fludarabine	143-154	keratin 20	Homo sapiens	57-61
14697987-8	2003	Notably, lymph node enlargement and CD20+ blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P =.036).	fludarabine	121-132	keratin 20	Homo sapiens	36-40
14697987-8	2003	Notably, lymph node enlargement and CD20+ blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P =.036).	fludarabine	121-124	keratin 20	Homo sapiens	36-40
14697987-8	2003	Notably, lymph node enlargement and CD20+ blood excess occurred significantly more frequently among patients receiving a Fludarabine (Flu) and anti-thymocyte globulin (ATG) conditioning regimen than those whose treatment lacked Flu independent of whether they received ATG (0.80 vs 0.44; P =.036).	fludarabine	134-137	keratin 20	Homo sapiens	36-40
14617792-0	2003	Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin"s lymphoma B cell lines to paclitaxel-induced apoptosis.	Paclitaxel	173-183	keratin 20	Homo sapiens	16-20
14617792-3	2003	This study examined the apoptotic signaling mediated by rituximab on rituximab- and paclitaxel-resistant CD20(+) NHL B cell lines (Ramos, Raji, Daudi, and 2F7).	Paclitaxel	84-94	keratin 20	Homo sapiens	105-109
12845484-6	2003	B-CLL cells from five patients were cultured for 24 h in RPMI/10% FCS while exposed to 213Bi conjugated to CD20 antibody or after external 60Co gamma irradiation.	213bi	87-92	keratin 20	Homo sapiens	107-111
12845484-10	2003	Full dose range experiments demonstrated 213Bi-conjugated CD20 antibody to be more effective than equivalent doses of external gamma irradiation, but showed that similar plateau values were reached at 10 Gy.	213bi	41-46	keratin 20	Homo sapiens	58-62
12902896-4	2003	We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.	Cyclophosphamide	63-79	keratin 20	Homo sapiens	157-162
14500384-0	2003	CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.	Octoxynol	93-105	keratin 20	Homo sapiens	0-4
14500384-6	2003	Using crmA-transfected cells and caspase inhibitors, we showed that phosphatidylserine translocation and mitochondrial permeability transition evoked during CD20-induced apoptosis appeared caspase independent.	crma	6-10	keratin 20	Homo sapiens	157-161
12938216-7	2003	Paradoxically, one functional consequence of CD20 down-regulation was enhanced calcium signaling upon CD20 cross-linking.	Calcium	79-86	keratin 20	Homo sapiens	45-49
12938216-7	2003	Paradoxically, one functional consequence of CD20 down-regulation was enhanced calcium signaling upon CD20 cross-linking.	Calcium	79-86	keratin 20	Homo sapiens	102-106
12938216-8	2003	These observations support the notion that CD20 engages downstream signaling pathways that alter calcium homeostasis rather than functioning as a calcium channel itself, such signal transduction is enhanced upon CD20 internalization, and CD40 is a regulator of CD20-mediated signaling.	Calcium	97-104	keratin 20	Homo sapiens	43-47
12938216-8	2003	These observations support the notion that CD20 engages downstream signaling pathways that alter calcium homeostasis rather than functioning as a calcium channel itself, such signal transduction is enhanced upon CD20 internalization, and CD40 is a regulator of CD20-mediated signaling.	Calcium	97-104	keratin 20	Homo sapiens	212-216
12938216-8	2003	These observations support the notion that CD20 engages downstream signaling pathways that alter calcium homeostasis rather than functioning as a calcium channel itself, such signal transduction is enhanced upon CD20 internalization, and CD40 is a regulator of CD20-mediated signaling.	Calcium	97-104	keratin 20	Homo sapiens	212-216
12902896-4	2003	We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.	Vincristine	81-92	keratin 20	Homo sapiens	157-162
12902896-4	2003	We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.	Prednisone	98-108	keratin 20	Homo sapiens	157-162
12931119-1	2003	We reviewed the clinical outcome of 8 patients with steroid-refractory chronic graft-versus-host disease (GVHD) who received an anti-CD20 chimeric monoclonal antibody (rituximab).	Steroids	52-59	keratin 20	Homo sapiens	133-137
14503945-0	2003	131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.	Iodine-131	0-4	keratin 20	Homo sapiens	10-14
12819245-1	2003	Currently available monoclonal antibodies against the B cell surface antigen CD20 have been employed to explore whether specific inhibition of B cells may help improve the outcome of idiopathic membranous nephropathy (IMN) and may avoid the side effects of steroids and immunosuppressants.	Steroids	257-265	keratin 20	Homo sapiens	77-81
14529425-6	2003	Radioimmunotherapy with the rituximab and ibritumomab tiuxetan (Zevalin) regimen was recently approved for the treatment of relapsed or refractory low-grade, follicular or CD20+ transformed NHL, including rituximab refractory follicular NHL.	ibritumomab tiuxetan	42-62	keratin 20	Homo sapiens	172-176
12939722-5	2003	A similar anti-CD20 radiotherapeutic compound, iodine 131 ((131)I)-tositumomab ((131)I-T), is also under consideration for approval.	Iodine	47-53	keratin 20	Homo sapiens	15-19
12837157-0	2003	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin"s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.	ibritumomab tiuxetan	7-27	keratin 20	Homo sapiens	33-37
12835728-0	2003	A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.	Cholesterol	2-13	keratin 20	Homo sapiens	24-28
12835728-8	2003	Of significant interest, the CD20 epitope recognized by FMC7 was unusual in that it was exceptionally sensitive to membrane cholesterol.	Cholesterol	124-135	keratin 20	Homo sapiens	29-33
12835728-10	2003	FMC7 mAb binding thus appears to be a sensitive indicator of the level of plasma membrane cholesterol and reveals a conformational state of CD20 that is regulated by cholesterol.	Cholesterol	166-177	keratin 20	Homo sapiens	140-144
12837157-3	2003	Upon relapse 3 years later, the patient was treated again with radioimmunotherapy consisting of 90Y-ibritumomab tiuxetan anti-CD20 monoclonal antibody, with a good response and acceptable bone marrow suppression.	ibritumomab tiuxetan	96-120	keratin 20	Homo sapiens	126-130
12837157-0	2003	Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin"s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.	Yttrium-90	119-129	keratin 20	Homo sapiens	33-37
12837157-1	2003	Ibritumomab tiuxetan is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy-refractory CD20+ B-cell non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	0-20	keratin 20	Homo sapiens	130-134
12737946-2	2003	CLL B lymphocytes transform (mature) to a plasmacytic phenotype with loss of CD19 and CD20 and the appearance of cytoplasmic immunoglobulin when treated in vitro with phorbol esters.	Phorbol Esters	167-181	keratin 20	Homo sapiens	86-90
16224429-7	2003	This study indicates that immune-based therapies such as rituximab and ibritumomab-tiuxetan (anti-CD20) and epratuzumab (anti-CD22) are feasible in pediatric cases of mature B-cell NHLs.	ibritumomab tiuxetan	71-91	keratin 20	Homo sapiens	98-102
12468339-9	2002	More than 50% of the patients with PMs that were positive for CK20 had an invasive evolution.	Promethium	35-38	keratin 20	Homo sapiens	62-66
12663713-1	2003	PURPOSE: Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of tumor response in patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL).	Yttrium-90	39-49	keratin 20	Homo sapiens	71-75
12663713-1	2003	PURPOSE: Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a high rate of tumor response in patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL).	ibritumomab tiuxetan	92-112	keratin 20	Homo sapiens	71-75
12543813-2	2003	This accumulation of the CD20 tetraspan protein in rafts does not change the existing lipid and phosphoprotein composition but makes sphingolipids and the Src regulator Cbp/PAG (Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain) transmembrane phosphoprotein more resistant to n-octyl-beta-pyranoside, a detergent that dissociates sphingolipid clusters.	Sphingolipids	133-146	keratin 20	Homo sapiens	25-29
12543813-2	2003	This accumulation of the CD20 tetraspan protein in rafts does not change the existing lipid and phosphoprotein composition but makes sphingolipids and the Src regulator Cbp/PAG (Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain) transmembrane phosphoprotein more resistant to n-octyl-beta-pyranoside, a detergent that dissociates sphingolipid clusters.	Glycosphingolipids	229-246	keratin 20	Homo sapiens	25-29
12543813-2	2003	This accumulation of the CD20 tetraspan protein in rafts does not change the existing lipid and phosphoprotein composition but makes sphingolipids and the Src regulator Cbp/PAG (Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain) transmembrane phosphoprotein more resistant to n-octyl-beta-pyranoside, a detergent that dissociates sphingolipid clusters.	n-octyl-beta-pyranoside	316-339	keratin 20	Homo sapiens	25-29
12543813-2	2003	This accumulation of the CD20 tetraspan protein in rafts does not change the existing lipid and phosphoprotein composition but makes sphingolipids and the Src regulator Cbp/PAG (Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomain) transmembrane phosphoprotein more resistant to n-octyl-beta-pyranoside, a detergent that dissociates sphingolipid clusters.	Sphingolipids	133-145	keratin 20	Homo sapiens	25-29
12543813-6	2003	Lastly, redistribution of CD20 in rafts renders the glycosylphosphatidyl inositol (GPI)-linked CD55 C"-defense protein hypersensitive to glycosylphosphatidyl inositol-specific phospholipases.	Glycosylphosphatidylinositols	52-81	keratin 20	Homo sapiens	26-30
12543813-6	2003	Lastly, redistribution of CD20 in rafts renders the glycosylphosphatidyl inositol (GPI)-linked CD55 C"-defense protein hypersensitive to glycosylphosphatidyl inositol-specific phospholipases.	Glycosylphosphatidylinositols	83-86	keratin 20	Homo sapiens	26-30
12543813-6	2003	Lastly, redistribution of CD20 in rafts renders the glycosylphosphatidyl inositol (GPI)-linked CD55 C"-defense protein hypersensitive to glycosylphosphatidyl inositol-specific phospholipases.	Glycosylphosphatidylinositols	137-166	keratin 20	Homo sapiens	26-30
12499256-3	2002	Similar in vitro binding and cytotoxicity were observed for anti-CD19-targeted and anti-CD20-targeted liposomal formulations of doxorubicin (DXR).	Doxorubicin	128-139	keratin 20	Homo sapiens	88-92
12520740-5	2002	Change of CD20 expression on the myeloma cells were measured by flow cytometer after and before myeloma cells were treated with thalidomide.	Thalidomide	128-139	keratin 20	Homo sapiens	10-14
12520740-7	2002	CONCLUSION: Thalidomide could enhance the inhibition of Mabthera on colony formation of MM patients" myeloma cells, which is related to that thalidomide enhances CD20 antigen expression of myeloma cells.	Thalidomide	12-23	keratin 20	Homo sapiens	162-166
12520740-7	2002	CONCLUSION: Thalidomide could enhance the inhibition of Mabthera on colony formation of MM patients" myeloma cells, which is related to that thalidomide enhances CD20 antigen expression of myeloma cells.	Thalidomide	141-152	keratin 20	Homo sapiens	162-166
12622905-10	2002	The paraffin-embedded tissues of all cases showed immunoreactivity for B-cell markers CD20, CD45RA.	Paraffin	4-12	keratin 20	Homo sapiens	86-90
12385432-7	2002	A Barrett"s type CK7/ CK20 staining pattern was seen in 100% of Barrett"s, 78% of CIM, and 0% of GIM patients.	cim	82-85	keratin 20	Homo sapiens	22-26
15969005-5	2003	The data of mutant clone DNA sequence showed that the amino acid of light chain gene of the parent anti-CD20 antibody (H47) was successful mutated as Ser (GAG)-Asn (CAG).	Serine	150-153	keratin 20	Homo sapiens	104-108
15969005-5	2003	The data of mutant clone DNA sequence showed that the amino acid of light chain gene of the parent anti-CD20 antibody (H47) was successful mutated as Ser (GAG)-Asn (CAG).	Glycosaminoglycans	155-158	keratin 20	Homo sapiens	104-108
15969005-5	2003	The data of mutant clone DNA sequence showed that the amino acid of light chain gene of the parent anti-CD20 antibody (H47) was successful mutated as Ser (GAG)-Asn (CAG).	Asparagine	160-163	keratin 20	Homo sapiens	104-108
15969005-5	2003	The data of mutant clone DNA sequence showed that the amino acid of light chain gene of the parent anti-CD20 antibody (H47) was successful mutated as Ser (GAG)-Asn (CAG).	GUANOSINE 5'-TRIPHOSPHATE P3-[1-(2-NITROPHENYL)ETHYL ESTER]	165-168	keratin 20	Homo sapiens	104-108
12621016-1	2003	UNLABELLED: Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT).	ibritumomab tiuxetan	12-32	keratin 20	Homo sapiens	44-48
12621016-1	2003	UNLABELLED: Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT).	ibritumomab tiuxetan	88-99	keratin 20	Homo sapiens	44-48
12621016-1	2003	UNLABELLED: Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT).	tiuxetan	24-32	keratin 20	Homo sapiens	44-48
12663145-5	2003	CD20, CD5, and sIgM molecules were capable of transferring into TX-100-insoluble state in the absence of additional cross-linking.	polyethylene glycol monooctylphenyl ether	64-70	keratin 20	Homo sapiens	0-4
12520708-4	2003	GCCs and MCs were discriminated by CD20 and CD38 density.	gccs	0-4	keratin 20	Homo sapiens	35-39
12520708-4	2003	GCCs and MCs were discriminated by CD20 and CD38 density.	mcs	9-12	keratin 20	Homo sapiens	35-39
12899647-1	2003	Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes.	Iodine-131	0-10	keratin 20	Homo sapiens	149-153
12899647-1	2003	Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes.	Iodine	37-43	keratin 20	Homo sapiens	149-153
12899647-1	2003	Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes.	Iodine-131	101-111	keratin 20	Homo sapiens	149-153
12899647-51	2003	The patent covers iodine-131 tositumomab and other anti-CD20 antibodies used to aid in selective tumour targeting.	Iodine	18-24	keratin 20	Homo sapiens	56-60
14598889-12	2003	In group I, 5 of 9 animals had positive signals of human CK-20 in their bone marrow as a sign of DTC.	dtc	97-100	keratin 20	Homo sapiens	57-62
12901152-3	2003	During the past decade, two products targeted to the CD20 antigen on B cells, iodine-131 tositumomab and yttrium-90 (90Y) ibritumomab tiuxetan, have been tested extensively in registration trials for potential licensing approval by the US Food and Drug Administration (FDA).	yttrium-90 (90y) ibritumomab tiuxetan	105-142	keratin 20	Homo sapiens	53-57
15154741-2	2003	90Y-ibritumomab tiuxetan consists of the anti-CD20 monoclonal antibody (MAb) ibritumomab covalently linked to tiuxetan for chelation of 90Y for therapy.	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	46-50
15154741-2	2003	90Y-ibritumomab tiuxetan consists of the anti-CD20 monoclonal antibody (MAb) ibritumomab covalently linked to tiuxetan for chelation of 90Y for therapy.	tiuxetan	16-24	keratin 20	Homo sapiens	46-50
15154742-2	2003	90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin"s lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y.	ibritumomab tiuxetan	4-24	keratin 20	Homo sapiens	165-169
15154742-2	2003	90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin"s lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y.	ibritumomab tiuxetan	4-15	keratin 20	Homo sapiens	165-169
15154742-2	2003	90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin"s lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y.	tiuxetan	16-24	keratin 20	Homo sapiens	165-169
12384807-9	2002	We observed this beta-glucan effect irrespective of antigen (GD2, GD3, CD20, epidermal growth factor-receptor, HER-2), human tumor type (neuroblastoma, melanoma, lymphoma, epidermoid carcinoma and breast carcinoma) or tumor sites (s.c. versus systemic).	beta-Glucans	17-28	keratin 20	Homo sapiens	71-75
12271407-2	2002	The purpose of this study was to evaluate the distribution and pharmacokinetics of iodine-131 labelled rituximab in humans for radioimmunotherapy of relapsed CD20-positive NHL.	Iodine-131	83-93	keratin 20	Homo sapiens	158-162
12074764-7	2002	Ibritumomab is the murine anti-CD20 antibody that was engineered to develop the human chimeric antibody rituximab.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	31-35
12468399-6	2002	The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab.	ibritumomab tiuxetan	35-55	keratin 20	Homo sapiens	25-29
12218775-6	2002	This study uses four-color flow cytometry to show that HLA-A*0201-tHLA-stained CD8(-) cells can be divided into two subsets: 87% represent B-lymphocytes (CD19(+), CD45RA(+), HLA-DR(+), and CD20(+)), and 13% represent T-helper cells (CD3(+), CD4(+), CD45RA(+), and CD27(+)).	thla	66-70	keratin 20	Homo sapiens	189-193
12357380-0	2002	Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.	Methotrexate	118-130	keratin 20	Homo sapiens	141-145
12447847-5	2002	The anti-CD20 monoclonal antibody rituximab also is effective in treating CLL and is being evaluated in combination with chemotherapeutic agents (cyclophosphamide) and fludarabine.	Cyclophosphamide	146-162	keratin 20	Homo sapiens	9-13
12218101-1	2002	The B cell Ag receptor (BCR) and CD20, a putative calcium channel, inducibly associate with cholesterol-dependent membrane microdomains known as lipid rafts.	Cholesterol	92-103	keratin 20	Homo sapiens	33-37
12095495-9	2002	Within the pill cycle of Cileste we observed an increase in CD20+ and CD20+ CD5+ cells from days 1-8.	cileste	25-32	keratin 20	Homo sapiens	60-64
12121615-6	2002	While H4-arginine 3 (H4-R3) methylation is mediated by PRMT1, the enzyme(s) responsible for H4-lysine 20 (H4-K20) methylation is not known.	h4-lysine	92-101	keratin 20	Homo sapiens	109-112
12270062-1	2002	In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab.	fludarabine	100-111	keratin 20	Homo sapiens	255-259
12095495-9	2002	Within the pill cycle of Cileste we observed an increase in CD20+ and CD20+ CD5+ cells from days 1-8.	cileste	25-32	keratin 20	Homo sapiens	70-74
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	Alanine	12-19	keratin 20	Homo sapiens	178-182
12141952-8	2002	The triple combination of fludarabine/cyclophosphamide/mitoxantrone and fludarabine combinations with anti-CD20 (rituximab) or anti-CD52 (Campath-1H) antibody, might be even be more promising, since a relevant number of complete molecular remissions are achieved with these drugs.	Cyclophosphamide	38-54	keratin 20	Homo sapiens	107-111
12031367-10	2002	The lymphocytic infiltrate in SU is similar to that seen in IC but with fewer CD20+ cells.	su	30-32	keratin 20	Homo sapiens	78-82
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	Alanine	12-19	keratin 20	Homo sapiens	203-207
11923690-5	2002	We present the case of a 50-year-old woman with hemodynamically significant humoral rejection resistant to steroids, cyclophos-phamide, and plasmapheresis who responded to the addition of anti-CD20 monoclonal antibody therapy (rituximab).	Steroids	107-115	keratin 20	Homo sapiens	193-197
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	Alanine	12-19	keratin 20	Homo sapiens	203-207
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	Proline	24-31	keratin 20	Homo sapiens	178-182
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	Proline	24-31	keratin 20	Homo sapiens	203-207
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	Proline	24-31	keratin 20	Homo sapiens	203-207
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	4-ACETAMIDO-2,4-DIDEXOY-D-GLYCERO-BETA-D-GALACTO-OCTOPYRANOSYLPHOSPHONIC ACID (AN AXIAL PHOSPHONATE)	58-61	keratin 20	Homo sapiens	178-182
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	4-ACETAMIDO-2,4-DIDEXOY-D-GLYCERO-BETA-D-GALACTO-OCTOPYRANOSYLPHOSPHONIC ACID (AN AXIAL PHOSPHONATE)	58-61	keratin 20	Homo sapiens	203-207
11964291-4	2002	Mutation of alanine and proline at positions 170 and 172 (AxP) (single-letter amino acid codes; x indicates the identical amino acid at the same position in the murine and human CD20 sequences) in human CD20 abrogated the binding of all CD20 mAbs tested.	4-ACETAMIDO-2,4-DIDEXOY-D-GLYCERO-BETA-D-GALACTO-OCTOPYRANOSYLPHOSPHONIC ACID (AN AXIAL PHOSPHONATE)	58-61	keratin 20	Homo sapiens	203-207
11930095-5	2002	Anti-CD20 therapy was associated with withdrawal of tacrolimus or ciclosporine therapy in all patients.	Tacrolimus	52-62	keratin 20	Homo sapiens	5-9
11930095-5	2002	Anti-CD20 therapy was associated with withdrawal of tacrolimus or ciclosporine therapy in all patients.	Cyclosporine	66-78	keratin 20	Homo sapiens	5-9
11877757-10	2002	In iodine-131 ((131)I)--anti-CD20 studies, (131)I was demonstrated to have variable excretion, and estimated total-body radiation dose from tracer study proved a predictive surrogate for marrow toxicity.	Iodine	3-9	keratin 20	Homo sapiens	29-33
11960274-3	2002	After treatment with three different combination chemotherapy regimens, at relapse he received radioimmunotherapy with iodine (131)I tositumomab (anti-CD20), with very good response.	Iodine	119-125	keratin 20	Homo sapiens	151-155
11895917-1	2002	PURPOSE: Rituximab (chimeric anti-CD20) can reverse the cisplatin-resistant phenotype of AIDS-related non-Hodgkin"s lymphoma cell lines and results in cisplatin-mediated apoptosis.	Cisplatin	56-65	keratin 20	Homo sapiens	34-38
11895917-1	2002	PURPOSE: Rituximab (chimeric anti-CD20) can reverse the cisplatin-resistant phenotype of AIDS-related non-Hodgkin"s lymphoma cell lines and results in cisplatin-mediated apoptosis.	Cisplatin	151-160	keratin 20	Homo sapiens	34-38
11830481-9	2002	Introduction of the p38 inhibitor SB203580 into the system completely blocked signaling downstream of p38, as evidenced by the absence of MAPKAP K2 activity, and significantly reduced the degree of anti-CD20-induced apoptosis.	SB 203580	34-42	keratin 20	Homo sapiens	203-207
11877757-11	2002	Yttrium-90 ((90)Y)--anti-CD20, which has little (90)Y excretion from the body, demonstrated the injected dose per body weight to be more predictive of marrow toxicity than indium-111 ((111)In) tracer dosimetry methods in heavily pretreated patients, and showed maximal safety with standard mCi/kg therapy dosing.	Yttrium-90	0-10	keratin 20	Homo sapiens	25-29
11877765-1	2002	BACKGROUND: Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates indium-111 ((111)In) for imaging and dosimetry and yttrium-90 ((90)Y) for radioimmunotherapy (RIT).	ibritumomab tiuxetan	72-83	keratin 20	Homo sapiens	46-50
11877765-1	2002	BACKGROUND: Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates indium-111 ((111)In) for imaging and dosimetry and yttrium-90 ((90)Y) for radioimmunotherapy (RIT).	tiuxetan	119-127	keratin 20	Homo sapiens	46-50
11877767-0	2002	High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support.	Iodine	88-94	keratin 20	Homo sapiens	121-125
11877767-5	2002	The aim of this pilot study was to investigate whether high-dose, myeloablative RIT with the iodine-131 ((131)I)-labeled chimeric anti-CD20 antibody C2B8 (rituximab, obtained as Mabthera from Roche Pharma, Reinach, Switzerland) is therapeutically effective in MCL patients.	Iodine	93-99	keratin 20	Homo sapiens	135-139
12054068-1	2002	Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular/low-grade and transformed non-Hodgkin"s lymphoma.	tositumomab I-131	0-6	keratin 20	Homo sapiens	49-53
12211077-9	2002	Significant increases in the proportion of CD20(+) (P &lt; 0.01) and CD8(+) cells (P &lt; 0.01) among mitotic and interphasic lymphocytes from both zineb- and azzurro-treated cultures were observed only when a concentration of 25.0 microg/ml was employed.	Zineb	148-153	keratin 20	Homo sapiens	43-47
12211077-9	2002	Significant increases in the proportion of CD20(+) (P &lt; 0.01) and CD8(+) cells (P &lt; 0.01) among mitotic and interphasic lymphocytes from both zineb- and azzurro-treated cultures were observed only when a concentration of 25.0 microg/ml was employed.	azzurro	159-166	keratin 20	Homo sapiens	43-47
12211077-11	2002	The MAC methodology revealed that among the different lymphocyte subpopulations analyzed (CD20, CD3, CD4, and CD8), the induction of micronuclei by zineb and its commercial formulation azzurro was restricted to CD20(+) B-cells and T-suppressor/cytotoxic CD8(+) lymphocytes.	Zineb	148-153	keratin 20	Homo sapiens	90-94
12211077-11	2002	The MAC methodology revealed that among the different lymphocyte subpopulations analyzed (CD20, CD3, CD4, and CD8), the induction of micronuclei by zineb and its commercial formulation azzurro was restricted to CD20(+) B-cells and T-suppressor/cytotoxic CD8(+) lymphocytes.	Zineb	148-153	keratin 20	Homo sapiens	211-215
12211077-11	2002	The MAC methodology revealed that among the different lymphocyte subpopulations analyzed (CD20, CD3, CD4, and CD8), the induction of micronuclei by zineb and its commercial formulation azzurro was restricted to CD20(+) B-cells and T-suppressor/cytotoxic CD8(+) lymphocytes.	azzurro	185-192	keratin 20	Homo sapiens	90-94
12211077-11	2002	The MAC methodology revealed that among the different lymphocyte subpopulations analyzed (CD20, CD3, CD4, and CD8), the induction of micronuclei by zineb and its commercial formulation azzurro was restricted to CD20(+) B-cells and T-suppressor/cytotoxic CD8(+) lymphocytes.	azzurro	185-192	keratin 20	Homo sapiens	211-215
11850494-1	2002	90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for the treatment of relapsed or refractory low-grade, follicular, or CD20+ transformed non-Hodgkin"s lymphoma (NHL).	ibritumomab tiuxetan	0-24	keratin 20	Homo sapiens	153-157
12440819-7	2002	The number of CD8 positive and CD20 positive cells infiltrating tumor nests and tumor stroma were significantly increased in TMC and AMC as opposed to the PDC-NOS group.	tmc	125-128	keratin 20	Homo sapiens	31-35
12440819-7	2002	The number of CD8 positive and CD20 positive cells infiltrating tumor nests and tumor stroma were significantly increased in TMC and AMC as opposed to the PDC-NOS group.	7-amino-4-methylcoumarin	133-136	keratin 20	Homo sapiens	31-35
12054068-1	2002	Bexxar (131I tositumomab) is a radiolabeled anti-CD20 monoclonal antibody for the treatment of relapsed and refractory follicular/low-grade and transformed non-Hodgkin"s lymphoma.	Iodine-131	8-12	keratin 20	Homo sapiens	49-53
11675350-10	2001	In conclusion, the results of the present study suggest that CD20, CD59, and complement have a role in the in vitro cytotoxic effect of rituximab, which is mediated by a caspase-independent process that involves ROS generation.	Reactive Oxygen Species	212-215	keratin 20	Homo sapiens	61-65
11762415-0	2001	Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin"s lymphoma.	Yttrium-90	9-18	keratin 20	Homo sapiens	32-36
11762415-0	2001	Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin"s lymphoma.	ibritumomab tiuxetan	38-58	keratin 20	Homo sapiens	32-36
11762415-1	2001	Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that chelates Yttrium or Indium and is directed against the CD 20 molecules of B lymphocytes.	ibritumomab tiuxetan	9-29	keratin 20	Homo sapiens	177-182
11762415-1	2001	Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that chelates Yttrium or Indium and is directed against the CD 20 molecules of B lymphocytes.	tiuxetan	21-29	keratin 20	Homo sapiens	177-182
11762415-1	2001	Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that chelates Yttrium or Indium and is directed against the CD 20 molecules of B lymphocytes.	2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid	109-115	keratin 20	Homo sapiens	177-182
11587375-1	2001	Clinical trials of an yttrium-90 (90Y)-conjugated monoclonal antibody to CD20 in patients with relapsed B cell non-Hodgkin lymphoma (NHL) are reviewed.	Yttrium-90	22-32	keratin 20	Homo sapiens	73-77
11668468-14	2001	When a CK7 positive/CK20 negative adenocarcinoma also demonstrated either TTF-1 positive or PE-10 positive staining, it was likely that the adenocarcinoma was of pulmonary origin (P &lt; 0.035; Fisher exact test).	INDOLINE, 1-(2-(2-PYRIDYL)ETHYL)-	92-97	keratin 20	Homo sapiens	20-24
11587375-2	2001	Ibritumomab is the murine parent anti-CD20 antibody engineered to make the human chimeric antibody rituximab.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	38-42
11308027-7	2001	The CMP-N-acetylneuraminic acid content of both K88 and K20 cells and the sialylation of cell surface glycoconjugates of K20 cells could be significantly increased by supplementing the medium with N-acetylmannosamine.	CMP-N-acetylneuraminic acid	4-31	keratin 20	Homo sapiens	56-59
11284065-4	2001	For this reason, the new synthetic chimeric, monoclonal anti-CD20 antibody Rituximab is an alternative treatment for patients with pCBCL.	pcbcl	131-136	keratin 20	Homo sapiens	61-65
11308027-7	2001	The CMP-N-acetylneuraminic acid content of both K88 and K20 cells and the sialylation of cell surface glycoconjugates of K20 cells could be significantly increased by supplementing the medium with N-acetylmannosamine.	CMP-N-acetylneuraminic acid	4-31	keratin 20	Homo sapiens	121-124
11308027-7	2001	The CMP-N-acetylneuraminic acid content of both K88 and K20 cells and the sialylation of cell surface glycoconjugates of K20 cells could be significantly increased by supplementing the medium with N-acetylmannosamine.	N-acetylmannosamine	197-216	keratin 20	Homo sapiens	56-59
11308027-7	2001	The CMP-N-acetylneuraminic acid content of both K88 and K20 cells and the sialylation of cell surface glycoconjugates of K20 cells could be significantly increased by supplementing the medium with N-acetylmannosamine.	N-acetylmannosamine	197-216	keratin 20	Homo sapiens	121-124
11308027-8	2001	This N-acetylmannosamine-induced increase was drastically reduced by co-supplementation with N-acetylglucosamine only in K20 cells.	N-acetylmannosamine	5-24	keratin 20	Homo sapiens	121-124
11308027-8	2001	This N-acetylmannosamine-induced increase was drastically reduced by co-supplementation with N-acetylglucosamine only in K20 cells.	Acetylglucosamine	93-112	keratin 20	Homo sapiens	121-124
11722986-10	2001	Iodine-131, Yttrium-90, and Copper-67 labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and other cell surface antigens have been tested and demonstrate higher overall response rates (50-80%) and complete response rates (20-40%) than unlabeled antibodies.	Iodine-131	0-10	keratin 20	Homo sapiens	78-83
11258413-1	2001	The purpose of this study was to investigate whether marrow radiation absorbed dose estimates predict haematotoxicity following radioimmunotherapy with an yttrium-90 labelled anti-CD20 monoclonal antibody in non-Hodgkin"s B-cell lymphoma (NHL).	Yttrium-90	155-165	keratin 20	Homo sapiens	180-184
11341356-5	2001	The Papanicolaou-stained archived urine slides were destained and then restained immunocytochemically with monoclonal antibody against CK20.	papanicolaou	4-16	keratin 20	Homo sapiens	135-139
11722986-10	2001	Iodine-131, Yttrium-90, and Copper-67 labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and other cell surface antigens have been tested and demonstrate higher overall response rates (50-80%) and complete response rates (20-40%) than unlabeled antibodies.	Copper	28-34	keratin 20	Homo sapiens	78-83
11225995-2	2000	The function of CD20 is unknown, although it is thought to be involved in B-cell activation, regulation of B-cell growth, and transmembrane calcium flux.	Calcium	140-147	keratin 20	Homo sapiens	16-20
12426170-2	2001	METHODS: Immunohistochemical method was used to detect the expression of CD20, CD45RO and cyclin D1 in 31 formalin- fixed and paraffin-embedded tissue samples of human small cell lymphomas.	Formaldehyde	106-114	keratin 20	Homo sapiens	73-77
12426170-2	2001	METHODS: Immunohistochemical method was used to detect the expression of CD20, CD45RO and cyclin D1 in 31 formalin- fixed and paraffin-embedded tissue samples of human small cell lymphomas.	Paraffin	126-134	keratin 20	Homo sapiens	73-77
11641934-2	2001	Clinical results show that NBHT enhances response to conventional therapy of moderate bronchial asthma as confirmed by a significant relief of the clinical symptoms, by a significant rise of volumic and flow parameters of external respiration function, a fall in the number of CD 20+ B cells, low level of serum IgE, increased number of phagocyting neutrophils and cells carrying erythroblast antigen in peripheral blood.	nbht	27-31	keratin 20	Homo sapiens	277-282
11226003-3	2000	Ibritumomab is the murine parent anti-CD20 antibody that is linked through a MX-DTPA chelator to yttrium 90 (90Y) to form the radioimmunoconjugate 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA).	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	38-42
11226003-3	2000	Ibritumomab is the murine parent anti-CD20 antibody that is linked through a MX-DTPA chelator to yttrium 90 (90Y) to form the radioimmunoconjugate 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA).	2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid	77-84	keratin 20	Homo sapiens	38-42
11226003-3	2000	Ibritumomab is the murine parent anti-CD20 antibody that is linked through a MX-DTPA chelator to yttrium 90 (90Y) to form the radioimmunoconjugate 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA).	ibritumomab tiuxetan	147-171	keratin 20	Homo sapiens	38-42
11106083-4	2000	In addition, the identification of this case supports the suggestion that the use of CD20 antibodies alone in paraffin sections may lead to an incorrect determination of cell lineage in some cases.	Paraffin	110-118	keratin 20	Homo sapiens	85-89
11067958-2	2000	In (51)Cr release assays with whole blood as effector source, RAJI cells were effectively killed by a mouse/human chimeric IgG1 construct of CD20 Ab 1F5, whereas ARH-77 proved resistant to killing by this Ab.	Chromium	7-9	keratin 20	Homo sapiens	141-145
11049969-0	2000	A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.	tositumomab I-131	22-44	keratin 20	Homo sapiens	51-55
11049969-2	2000	We conducted a phase I/II trial to estimate the maximum tolerated dose (MTD) of iodine 131 ((131)I)-tositumomab (anti-CD20 antibody) that could be combined with etoposide and cyclophosphamide followed by ASCT in patients with relapsed B-cell lymphomas.	Iodine	80-86	keratin 20	Homo sapiens	118-122
11125287-9	2000	Concerning therapy, 131-iodine labeled anti-CD20 antibodies gave spectacular results in non-Hodgkin"s B lymphomas.	Iodine	24-30	keratin 20	Homo sapiens	44-48
11012903-3	2000	CLA can be metabolized to conjugated linolenic acid (CD18:3) and to conjugated eicosatrienoic acid (CD20:3) and these metabolites may be implicated in CLA activity.	Linoleic Acids, Conjugated	0-3	keratin 20	Homo sapiens	100-104
11012903-3	2000	CLA can be metabolized to conjugated linolenic acid (CD18:3) and to conjugated eicosatrienoic acid (CD20:3) and these metabolites may be implicated in CLA activity.	Eicosatrienoic acid	79-98	keratin 20	Homo sapiens	100-104
11012903-3	2000	CLA can be metabolized to conjugated linolenic acid (CD18:3) and to conjugated eicosatrienoic acid (CD20:3) and these metabolites may be implicated in CLA activity.	Linoleic Acids, Conjugated	151-154	keratin 20	Homo sapiens	100-104
11012903-11	2000	The increased levels of CLA in plasma and adipose tissue of end-stage CRF patients may be due either to a reduced metabolization of CLA to CD18:3 and CD20:3, or to an altered site distribution with reduced incorporation in cellular membranes and accumulation in the plasma and adipose tissue.	Linoleic Acids, Conjugated	24-27	keratin 20	Homo sapiens	150-154
10970137-0	2000	Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine.	Cladribine	126-136	keratin 20	Homo sapiens	73-77
11002234-9	2000	The administration of the second weekly docetaxel dose resulted in a further decrease of CD56(+) (P = 0.012) and CD20(+) (P = 0.007) cells.	Docetaxel	40-49	keratin 20	Homo sapiens	113-117
10741703-9	2000	Phenotypic analysis by flow cytometric analysis on pre- and post-bryostatin 1-treated peripheral blood lymphocytes revealed up-regulation in the coexpression of CD11c/ CD22 on CD20+ B cells in two of four CLL patients studied, which is consistent with in vitro findings of differentiation of CLL cells to a hairy cell phenotype.	bryostatin 1	65-77	keratin 20	Homo sapiens	176-180
10753604-0	2000	Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.	Tyrosine	79-87	keratin 20	Homo sapiens	10-14
10753604-0	2000	Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.	Calcium	105-112	keratin 20	Homo sapiens	10-14
10753604-6	2000	Treatment of Ramos with EGTA and BAPTA to block changes in cytoplasmic Ca(2+) likewise prevented CD20-induced apoptosis.	Egtazic Acid	24-28	keratin 20	Homo sapiens	97-101
10753604-6	2000	Treatment of Ramos with EGTA and BAPTA to block changes in cytoplasmic Ca(2+) likewise prevented CD20-induced apoptosis.	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid	33-38	keratin 20	Homo sapiens	97-101
10711261-0	1999	L26 (CD20) staining of Bouin fixed bone marrow biopsies.	bouin	23-28	keratin 20	Homo sapiens	5-9
10644703-4	2000	Consistent with these results, direct activation of G(s) by cholera toxin or by an anti-Galpha(s) antibody exhibiting beta-adrenergic receptor-mimetic properties (K-20) resulted in an isoproterenol-like inhibition of NADPH-dependent H(2)O(2) generation.	Isoproterenol	184-197	keratin 20	Homo sapiens	118-167
10644703-4	2000	Consistent with these results, direct activation of G(s) by cholera toxin or by an anti-Galpha(s) antibody exhibiting beta-adrenergic receptor-mimetic properties (K-20) resulted in an isoproterenol-like inhibition of NADPH-dependent H(2)O(2) generation.	NADP	217-222	keratin 20	Homo sapiens	118-167
10644703-5	2000	In addition, a peptide corresponding to the target sequence of K-20 blocked the action of the catecholamine, apparently by competition between the peptide and G(s) for activated beta-adrenergic receptors, indicating that the G protein betagamma-subunits mediating the inhibitory effects of the catecholamine were in fact derived from G(s).	Catecholamines	94-107	keratin 20	Homo sapiens	63-67
10644703-5	2000	In addition, a peptide corresponding to the target sequence of K-20 blocked the action of the catecholamine, apparently by competition between the peptide and G(s) for activated beta-adrenergic receptors, indicating that the G protein betagamma-subunits mediating the inhibitory effects of the catecholamine were in fact derived from G(s).	Catecholamines	294-307	keratin 20	Homo sapiens	63-67
11701541-11	2000	In Section II, Dr. Kaminski reviews the different therapeutic monoclonal antibody options such as rituximab, Bexxar (Iodine-labeled anti-CD20) and Ytrium-labeled anti-CD20 antibody.	Iodine	117-123	keratin 20	Homo sapiens	137-141
11701541-11	2000	In Section II, Dr. Kaminski reviews the different therapeutic monoclonal antibody options such as rituximab, Bexxar (Iodine-labeled anti-CD20) and Ytrium-labeled anti-CD20 antibody.	ytrium	147-153	keratin 20	Homo sapiens	167-171
10707790-8	2000	CONCLUSIONS: These efforts resulted in the identification of dexamethasone (Dex) as a potent inducer of Muc-1 core protein on MM plasma cells, and interferon-gamma (IFN-gamma) as a potent inducer of CD20 on MM plasma cells and B-cells.	Dexamethasone	76-79	keratin 20	Homo sapiens	199-203
10585592-0	2000	Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas.	Iodine-131	28-38	keratin 20	Homo sapiens	44-48
10585592-1	2000	Preliminary clinical trials suggest that iodine-131 ((131)I)-labeled anti-CD20 monoclonal antibodies (MAbs) are effective single agents for the treatment of relapsed non-Hodgkin"s B-cell lymphomas.	Iodine-131	41-51	keratin 20	Homo sapiens	74-78
10585592-10	2000	Thus, combination regimens containing (131)I-labeled anti-CD20 antibodies and nucleoside analogs or topoisomerase inhibitors appear particularly attractive for future clinical trials.	Iodine-131	38-44	keratin 20	Homo sapiens	58-62
11247389-6	2000	With characteristic intertrabecular nodular interstitial infiltrates of CD20+ small lymphocytes and corresponding clinical data (splenomegaly, lymphocytosis in peripheral blood and sporadic elevation of IgM levels) it was very suggestive of SMZL diagnosis.	smzl	241-245	keratin 20	Homo sapiens	72-76
10478178-6	1999	131I labeled anti-CD-20 monoclonal antibodies and 131I-MIBG are used for the therapy of lymphoma and pheochromocytoma, respectively.	Iodine-131	0-4	keratin 20	Homo sapiens	18-23
10497188-3	1999	A peptide corresponding to the target sequence of K-20 not only neutralized the receptor-mimetic effects of the antibody but inhibited the whole spectrum of isoproterenol action as well, including its antagonistic effects on adenylyl cyclase and NADPH-dependent H(2)O(2) generation.	Isoproterenol	157-170	keratin 20	Homo sapiens	50-54
10497188-3	1999	A peptide corresponding to the target sequence of K-20 not only neutralized the receptor-mimetic effects of the antibody but inhibited the whole spectrum of isoproterenol action as well, including its antagonistic effects on adenylyl cyclase and NADPH-dependent H(2)O(2) generation.	NADP	246-251	keratin 20	Homo sapiens	50-54
10497188-3	1999	A peptide corresponding to the target sequence of K-20 not only neutralized the receptor-mimetic effects of the antibody but inhibited the whole spectrum of isoproterenol action as well, including its antagonistic effects on adenylyl cyclase and NADPH-dependent H(2)O(2) generation.	hippuric acid	264-267	keratin 20	Homo sapiens	50-54
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	1,2-dichloroethylene	38-42	keratin 20	Homo sapiens	19-22
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	Adenosine Monophosphate	49-52	keratin 20	Homo sapiens	19-22
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	Vinyl Chloride	71-85	keratin 20	Homo sapiens	19-22
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	Adenosine Monophosphate	92-95	keratin 20	Homo sapiens	19-22
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	ethylene	130-136	keratin 20	Homo sapiens	19-22
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	Adenosine Monophosphate	92-95	keratin 20	Homo sapiens	19-22
10525741-1	1999	One mixed culture (K20) could degrade cDCE (400 &amp;mgr;mol l(-1)) or vinyl chloride (100 &amp;mgr;mol l(-1)) in the presence of ethene (&lt;/= 80 &amp;mgr;mol l(-1) and &lt;/= 210 &amp;mgr;mol l(-1), respectively).	Adenosine Monophosphate	92-95	keratin 20	Homo sapiens	19-22
10525741-4	1999	The mixed culture K20 was highly tolerant against cDCE (up to 6 mmol l(-1) in the liquid phase).	1,2-dichloroethylene	50-54	keratin 20	Homo sapiens	18-21
10525741-6	1999	Transformation yields (T(y), defined as unit mass of chloroethene degraded per unit mass of ethene consumed) of the mixed culture K20 were relatively high (0.51 and 0.61 for cDCE and vinyl chloride, respectively).	Vinyl Chloride	53-65	keratin 20	Homo sapiens	130-133
10525741-6	1999	Transformation yields (T(y), defined as unit mass of chloroethene degraded per unit mass of ethene consumed) of the mixed culture K20 were relatively high (0.51 and 0.61 for cDCE and vinyl chloride, respectively).	1,2-dichloroethylene	174-178	keratin 20	Homo sapiens	130-133
10525741-6	1999	Transformation yields (T(y), defined as unit mass of chloroethene degraded per unit mass of ethene consumed) of the mixed culture K20 were relatively high (0.51 and 0.61 for cDCE and vinyl chloride, respectively).	Vinyl Chloride	183-197	keratin 20	Homo sapiens	130-133
10541376-7	1999	The Ibritumomab antibody targets the CD20 antigen.	ibritumomab tiuxetan	4-15	keratin 20	Homo sapiens	37-41
10561019-4	1999	Anti-CD20 antibodies radiolabeled with iodine 131 and yttrium 90 given at nonmyeloablative doses yield remissions in 75% to 80% of cases, including 35% to 40% complete remissions.	Iodine	39-45	keratin 20	Homo sapiens	5-9
10561019-4	1999	Anti-CD20 antibodies radiolabeled with iodine 131 and yttrium 90 given at nonmyeloablative doses yield remissions in 75% to 80% of cases, including 35% to 40% complete remissions.	Yttrium-90	54-64	keratin 20	Homo sapiens	5-9
10416603-2	1999	In this study, we combined this Adv (Adv-E1AdB) with a fiber mutation, F/K20, which has a stretch of 20 lysine residues added at the COOH-terminus of the fiber and shows high transduction efficiency to gliomas.	Lysine	104-110	keratin 20	Homo sapiens	73-76
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	Cyclophosphamide	39-55	keratin 20	Homo sapiens	172-176
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	Doxorubicin	57-68	keratin 20	Homo sapiens	172-176
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	Vincristine	70-81	keratin 20	Homo sapiens	172-176
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	Prednisolone	83-95	keratin 20	Homo sapiens	172-176
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	purine	100-106	keratin 20	Homo sapiens	172-176
10444162-2	1999	Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.	fludarabine	127-138	keratin 20	Homo sapiens	172-176
10335483-0	1999	Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines.	Vincristine	97-108	keratin 20	Homo sapiens	89-93
10410141-8	1999	Furthermore, radionuclides are also employed in the therapy of cancer, such 131I-labeled anti-CD20 antibody for the B-cell lymphoma and 89Sr for the palliation of bone pain caused by prostate and breast cancer metastases.	Iodine-131	76-80	keratin 20	Homo sapiens	94-98
9751613-3	1998	In vitro, L6-CD but not 1F5-CD selectively metabolized 5-FCyt to 5-FU on H2981 human lung adenocarcinoma cells because of the presence and absence of cell surface L6 and CD20 antigens, respectively.	l6-cd	10-15	keratin 20	Homo sapiens	170-174
10529513-1	1999	Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission.	fludarabine	179-190	keratin 20	Homo sapiens	47-51
10529513-1	1999	Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission.	Pentostatin	192-203	keratin 20	Homo sapiens	47-51
9887430-3	1998	RESULTS: Phenotype features were similar in patients with pSS and sSS, except that CD20+ lymphocyte expression was significantly higher in the sSS group (p = 0.023).	sss	143-146	keratin 20	Homo sapiens	83-87
9779701-0	1998	Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.	Iodine-131	60-70	keratin 20	Homo sapiens	84-88
9779701-2	1998	This is our first opportunity to report long-term follow-up data and late toxicities in 29 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous stem-cell rescue.	Iodine	136-142	keratin 20	Homo sapiens	152-156
9639515-3	1998	We constructed a fusion protein of the single-chain Fv anti-CD20 mouse monoclonal antibody (MoAb) 1H4 and human beta-glucuronidase for the activation of the nontoxic prodrug N-[4-doxorubicin-N-carbonyl(-oxymethyl) phenyl] O-beta-glucuronyl carbamate to doxorubicin at the tumor site.	1H4	98-101	keratin 20	Homo sapiens	60-64
9698365-3	1998	Mutation of K64 and R68 caused the largest decrease in affinity for a heparin Sepharose matrix, with smaller effects seen with mutations of K20, R60, and K67.	Heparin	70-77	keratin 20	Homo sapiens	140-143
9639515-3	1998	We constructed a fusion protein of the single-chain Fv anti-CD20 mouse monoclonal antibody (MoAb) 1H4 and human beta-glucuronidase for the activation of the nontoxic prodrug N-[4-doxorubicin-N-carbonyl(-oxymethyl) phenyl] O-beta-glucuronyl carbamate to doxorubicin at the tumor site.	Doxorubicin	179-190	keratin 20	Homo sapiens	60-64
9417086-4	1998	All of the detergent-insoluble CD20 was found in the low density fractions of sucrose density gradients, indicating that CD20 redistributes to glycolipid-rich membrane domains, analogous to caveolae in some cell types.	Sucrose	78-85	keratin 20	Homo sapiens	31-35
9672771-5	1998	Chimeric anti-CD20 antibodies and 131I-labeled anti-CD20 antibodies appear particularly promising, producing response rates of 50% to 95%.	Iodine-131	34-38	keratin 20	Homo sapiens	52-56
9672771-6	1998	Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made.	3-cresol	21-24	keratin 20	Homo sapiens	88-92
9672771-6	1998	Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made.	Chromium	21-23	keratin 20	Homo sapiens	88-92
9672771-6	1998	Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made.	Chromium	116-118	keratin 20	Homo sapiens	88-92
9473230-4	1998	The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20-mediated apoptosis may be related to changes in Ca2+ concentration.	Egtazic Acid	109-113	keratin 20	Homo sapiens	148-152
9473230-4	1998	The apoptotic effects of these MoAbs can be inhibited by chelation of extracellular or intracellular Ca2+ by EGTA or Bapta AM, indicating that anti-CD20-mediated apoptosis may be related to changes in Ca2+ concentration.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	117-125	keratin 20	Homo sapiens	148-152
9417086-4	1998	All of the detergent-insoluble CD20 was found in the low density fractions of sucrose density gradients, indicating that CD20 redistributes to glycolipid-rich membrane domains, analogous to caveolae in some cell types.	Sucrose	78-85	keratin 20	Homo sapiens	121-125
9426516-11	1998	Cases of LPHD showed coexpression of CD20 and topo II alpha in 84.4% of the L &amp; H cells, a significant increase over the level of tumor cell coexpression seen in NSHD and MCHD (P &lt; .001).	Adenosine Monophosphate	79-82	keratin 20	Homo sapiens	37-41
9406707-1	1997	BACKGROUND: In treatment of non-Hodgkin"s lymphoma patients with predose-plus-I-131-labeled anti-B1 (anti-CD20) monoclonal antibody, an intratherapy single photon emission computed tomography (SPECT) image is an important part of research estimates of tumor dosimetry.	Iodine-131	78-83	keratin 20	Homo sapiens	106-110
9354667-6	1997	The composite PU.1 and Pip site likely accounts for both lineage and stage-specific expression of CD20 whereas the CD20 E box binding proteins enhance overall promoter activity and may link the promoter to a distant enhancer.	piperidine	23-26	keratin 20	Homo sapiens	98-102
9440626-4	1997	Fluorescein isothiocyanate- or phycoerythrin-conjugated monoclonal antibodies with specificity for CD3, CD4, CD8, and CD20 (lymphocyte subpopulations), for CD69 (activated lymphocytes), and for CD16/56 (natural killer cells) were used.	Fluorescein-5-isothiocyanate	0-26	keratin 20	Homo sapiens	118-122
8920755-2	1996	More recently, a dose-dependent decrease of specific subpopulations of mitogen-activated human peripheral blood lymphocytes (PBL), including helper-inducer/memory cells (CD4+CD29+) and B cells (CD20+), was reported after in vitro treatment with dioxin concentrations as low as 10(-12)-10(-14) M TCDD [1].	Polychlorinated Dibenzodioxins	295-299	keratin 20	Homo sapiens	194-198
9367598-2	1997	The pH-dependent dissolution behavior of HFO suggested that k20[ identical withFecys-] &gt;&gt; k21[ identical withFecys0].	ferric oxide	41-44	keratin 20	Homo sapiens	60-63
18470734-3	1997	It is only immunohistology (CD20, CD43, CD68) of the paraffin blocks from the resection specimen that can lead to the final diagnosis of intermediate grade malignant lymphoma.	Paraffin	53-61	keratin 20	Homo sapiens	28-32
9248862-5	1997	On the other hand, CD20+ cell percentage was found higher in lead+cadmium exposed group than controls.	Cadmium	66-73	keratin 20	Homo sapiens	19-23
8920755-2	1996	More recently, a dose-dependent decrease of specific subpopulations of mitogen-activated human peripheral blood lymphocytes (PBL), including helper-inducer/memory cells (CD4+CD29+) and B cells (CD20+), was reported after in vitro treatment with dioxin concentrations as low as 10(-12)-10(-14) M TCDD [1].	Dioxins	245-251	keratin 20	Homo sapiens	194-198
9816191-0	1996	Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.	Yttrium-90	0-10	keratin 20	Homo sapiens	24-28
8899501-7	1996	CD20-cy+ B cells were seen mainly in the portal areas, and were significantly less common in AHB than in AHA and AHC.	Cysteine	5-7	keratin 20	Homo sapiens	0-4
8549666-5	1996	Of the cell-surface differentiation markers CD10, CD20, CD21, and CD23, the expression of CD20 was suppressed by DMSO treatment, and partial restoration of the expression was observed 24 to 48 h after release from DMSO.	Dimethyl Sulfoxide	113-117	keratin 20	Homo sapiens	50-54
8549666-5	1996	Of the cell-surface differentiation markers CD10, CD20, CD21, and CD23, the expression of CD20 was suppressed by DMSO treatment, and partial restoration of the expression was observed 24 to 48 h after release from DMSO.	Dimethyl Sulfoxide	113-117	keratin 20	Homo sapiens	90-94
8549666-5	1996	Of the cell-surface differentiation markers CD10, CD20, CD21, and CD23, the expression of CD20 was suppressed by DMSO treatment, and partial restoration of the expression was observed 24 to 48 h after release from DMSO.	Dimethyl Sulfoxide	214-218	keratin 20	Homo sapiens	90-94
7623531-1	1995	25 patients with relapsed B-cell lymphomas were evaluated with trace labelled doses (2.5 mg/kg, 185-370 MBq [5-10 mCi]) of 131I-labelled anti-CD20 (B1) antibody in a phase II trial.	Iodine-131	123-127	keratin 20	Homo sapiens	142-146
8599867-8	1996	Phenotypic analysis of the peripheral mononuclear cells in 34 consecutive CLL patients revealed a marked reduction in CD5/CD20 and CD4 cell numbers after three courses of fludarabine with less effect on CD8 and CD56 cells.	fludarabine	171-182	keratin 20	Homo sapiens	122-126
8821949-3	1996	Within a defined population between 1947 and 1994, we found 12 cases of primary sinonasal T-cell lymphoma, all with a CD20-, CD3+ immunophenotype in paraffin sections.	Paraffin	149-157	keratin 20	Homo sapiens	118-122
7503365-11	1995	In the single case of LPn, they were of B-cell lineage (CD45+, CD20+, CD45RO-, CD15-, CD30-).	CHEMBL1269671	22-25	keratin 20	Homo sapiens	63-67
7623531-6	1995	131I-anti-CD20 (B1) antibody therapy produces complete responses of long duration in most patients with relapsed B-cell lymphomas when given at maximally tolerated doses with autologous stem cell rescue.	Iodine-131	0-4	keratin 20	Homo sapiens	10-14
7538976-7	1995	Breast cancer patients who showed a greater than median decrease in CD20-HLA-DR+ lymphocytes following cyclophosphamide treatment had a survival advantage over patients who had less than the median decrease in the percent CD20-HLA-DR+ lymphocytes.	Cyclophosphamide	103-119	keratin 20	Homo sapiens	68-72
7538976-5	1995	In the surviving breast cancer patients there was a significant decrease in the percentage of non-B lymphocyte HLA-DR+ (CD20-HLA-DR+) cells following cyclophosphamide treatment.	Cyclophosphamide	150-166	keratin 20	Homo sapiens	120-124
7538976-7	1995	Breast cancer patients who showed a greater than median decrease in CD20-HLA-DR+ lymphocytes following cyclophosphamide treatment had a survival advantage over patients who had less than the median decrease in the percent CD20-HLA-DR+ lymphocytes.	Cyclophosphamide	103-119	keratin 20	Homo sapiens	222-226
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Cyclosporine	143-157	keratin 20	Homo sapiens	56-60
8991823-8	1995	Immunohistochemically, lymphocytes in the lamina propria were prevalently CD20 + (B cells) and CD4 + (Th cells), some were CD45RO + (memory) and finally few CD8 + (Tc/s cells).	Sulfur	8-9	keratin 20	Homo sapiens	74-78
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Cyclosporine	143-157	keratin 20	Homo sapiens	262-266
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Calcium	244-251	keratin 20	Homo sapiens	56-60
7599111-4	1994	After PMA treatment, NALM-26 was induced to express CD20, CD25 and CD28, and to increase its expression of both CD5 and CD13.	nalm-26	21-28	keratin 20	Homo sapiens	52-56
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Calcium	244-251	keratin 20	Homo sapiens	262-266
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Calcium	283-290	keratin 20	Homo sapiens	56-60
7743602-4	1994	The synergistic interaction of CD40 signals with PMA or CD20 show differential requirements for CD40 crosslinking and different sensitivity to cyclosporine A, suggesting that CD40 receptor may use different effector mechanisms for synergy with calcium-dependent CD20 signals or with calcium-independent signals from PMA.	Calcium	283-290	keratin 20	Homo sapiens	262-266
8085940-4	1994	(1991) found that a dose-dependent decrease of peripheral blood lymphocyte (PBL) subpopulations in humans and non-human primates, including helper-inducer/memory cells (CD4+CD29+) and B cells (CD20+) occurred in pokeweed mitogen (PWM) stimulated cultures at concentrations as low as 10(-12)-10(-14) M TCDD.	Polychlorinated Dibenzodioxins	301-305	keratin 20	Homo sapiens	193-197
7962309-4	1994	Similarly, using FITC-labeled recombinant hGH, receptor expression on CD20+ cells was significantly higher than that on CD2+ cells.	Fluorescein-5-isothiocyanate	17-21	keratin 20	Homo sapiens	70-74
7687326-0	1993	Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.	Iodine-131	44-48	keratin 20	Homo sapiens	63-67
7687326-2	1993	As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed.	Iodine-131	87-91	keratin 20	Homo sapiens	121-125
7687326-2	1993	As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed.	Iodine-131	87-91	keratin 20	Homo sapiens	166-170
7686949-5	1993	Addition of the Ca2+ ionophore, ionomycin, increased CD20 phosphorylation both in activated B cells and in cells from the hairy cell line; addition of EGTA to either cell type decreased basal levels of CD20 phosphorylation.	Ionomycin	32-41	keratin 20	Homo sapiens	53-57
7686949-5	1993	Addition of the Ca2+ ionophore, ionomycin, increased CD20 phosphorylation both in activated B cells and in cells from the hairy cell line; addition of EGTA to either cell type decreased basal levels of CD20 phosphorylation.	Ionomycin	32-41	keratin 20	Homo sapiens	202-206
7686949-5	1993	Addition of the Ca2+ ionophore, ionomycin, increased CD20 phosphorylation both in activated B cells and in cells from the hairy cell line; addition of EGTA to either cell type decreased basal levels of CD20 phosphorylation.	Egtazic Acid	151-155	keratin 20	Homo sapiens	202-206
7686949-6	1993	Ionomycin treatment of these cells resulted in increased kinase activity of cytosolic extracts toward syntide-2, a synthetic peptide substrate for calcium/calmodulin-dependent kinase II (CaM-KII), with kinetics similar to those of CD20 phosphorylation in the cell line.	Ionomycin	0-9	keratin 20	Homo sapiens	231-235
7686929-3	1993	To better characterize the negative signal delivered by soluble K20, we have investigated its effects on the phospholipid metabolism, both in Jurkat and CD4+ T cells.	Phospholipids	109-121	keratin 20	Homo sapiens	64-67
7686929-4	1993	In CD3-activated T cells, K20 inhibited the increase of diacylglycerol (DAG) and phosphatidic acid levels, but did not modify phosphatidylinositol 4,5-bisphosphate levels, cytosolic Ca2+ raise, and inositolphosphates formation, indicating that K20 did not inhibit phosphatidylinositol 4,5-bisphosphate hydrolysis by phospholipase C-gamma.	Diglycerides	56-70	keratin 20	Homo sapiens	26-29
7686929-4	1993	In CD3-activated T cells, K20 inhibited the increase of diacylglycerol (DAG) and phosphatidic acid levels, but did not modify phosphatidylinositol 4,5-bisphosphate levels, cytosolic Ca2+ raise, and inositolphosphates formation, indicating that K20 did not inhibit phosphatidylinositol 4,5-bisphosphate hydrolysis by phospholipase C-gamma.	Diglycerides	72-75	keratin 20	Homo sapiens	26-29
7686929-4	1993	In CD3-activated T cells, K20 inhibited the increase of diacylglycerol (DAG) and phosphatidic acid levels, but did not modify phosphatidylinositol 4,5-bisphosphate levels, cytosolic Ca2+ raise, and inositolphosphates formation, indicating that K20 did not inhibit phosphatidylinositol 4,5-bisphosphate hydrolysis by phospholipase C-gamma.	Phosphatidic Acids	81-98	keratin 20	Homo sapiens	26-29
7686949-8	1993	Phosphopeptide maps of CD20 from untreated hairy cells or ionomycin-treated HCLL-7876 cells were similar to maps of CD20 that had been phosphorylated in vitro by CaM-KII.	Ionomycin	58-67	keratin 20	Homo sapiens	23-27
7686929-4	1993	In CD3-activated T cells, K20 inhibited the increase of diacylglycerol (DAG) and phosphatidic acid levels, but did not modify phosphatidylinositol 4,5-bisphosphate levels, cytosolic Ca2+ raise, and inositolphosphates formation, indicating that K20 did not inhibit phosphatidylinositol 4,5-bisphosphate hydrolysis by phospholipase C-gamma.	Inositol Phosphates	198-216	keratin 20	Homo sapiens	26-29
1632463-8	1992	This is in spite of the fact that RS cells expressing B-cell-associated antigen CD20 were detectable in 7/8 cases of LP HD and 6/24 cases of NS and MC HD with monoclonal antibody L26.	leucylproline	117-119	keratin 20	Homo sapiens	80-84
7686929-4	1993	In CD3-activated T cells, K20 inhibited the increase of diacylglycerol (DAG) and phosphatidic acid levels, but did not modify phosphatidylinositol 4,5-bisphosphate levels, cytosolic Ca2+ raise, and inositolphosphates formation, indicating that K20 did not inhibit phosphatidylinositol 4,5-bisphosphate hydrolysis by phospholipase C-gamma.	Phosphatidylinositol 4,5-Diphosphate	264-301	keratin 20	Homo sapiens	26-29
7686929-5	1993	Moreover, in these conditions, K20 increased phosphatidylethanolamine levels, without variation of phosphatidylcholine, phosphatidylserine, and phosphatidylinositol, suggesting that K20 specifically increased the phosphatidylethanolamine biosynthesis from DAG.	phosphatidylethanolamine	45-69	keratin 20	Homo sapiens	31-34
7686929-5	1993	Moreover, in these conditions, K20 increased phosphatidylethanolamine levels, without variation of phosphatidylcholine, phosphatidylserine, and phosphatidylinositol, suggesting that K20 specifically increased the phosphatidylethanolamine biosynthesis from DAG.	phosphatidylethanolamine	213-237	keratin 20	Homo sapiens	31-34
7686929-5	1993	Moreover, in these conditions, K20 increased phosphatidylethanolamine levels, without variation of phosphatidylcholine, phosphatidylserine, and phosphatidylinositol, suggesting that K20 specifically increased the phosphatidylethanolamine biosynthesis from DAG.	phosphatidylethanolamine	213-237	keratin 20	Homo sapiens	182-185
7686929-5	1993	Moreover, in these conditions, K20 increased phosphatidylethanolamine levels, without variation of phosphatidylcholine, phosphatidylserine, and phosphatidylinositol, suggesting that K20 specifically increased the phosphatidylethanolamine biosynthesis from DAG.	Diglycerides	256-259	keratin 20	Homo sapiens	31-34
7686929-5	1993	Moreover, in these conditions, K20 increased phosphatidylethanolamine levels, without variation of phosphatidylcholine, phosphatidylserine, and phosphatidylinositol, suggesting that K20 specifically increased the phosphatidylethanolamine biosynthesis from DAG.	Diglycerides	256-259	keratin 20	Homo sapiens	182-185
7686929-6	1993	Thus, the effects of K20 on DAG and phosphatidic acid levels resulted from an accelerated catabolism rather than from a defect of synthesis.	Diglycerides	28-31	keratin 20	Homo sapiens	21-24
7686929-6	1993	Thus, the effects of K20 on DAG and phosphatidic acid levels resulted from an accelerated catabolism rather than from a defect of synthesis.	Phosphatidic Acids	36-53	keratin 20	Homo sapiens	21-24
7680653-10	1993	The BAT box and Oct-2 were also implicated in the induction of CD20 in the pre-B cell line, PB-697, via phorbol esters.	Lead	92-94	keratin 20	Homo sapiens	63-67
7680653-10	1993	The BAT box and Oct-2 were also implicated in the induction of CD20 in the pre-B cell line, PB-697, via phorbol esters.	Phorbol Esters	104-118	keratin 20	Homo sapiens	63-67
7680653-11	1993	The induction of CD20 mRNA was temporally associated with induction of Oct-2 mRNA and a BAT box-deleted CD20-CAT construct, in contrast to the wild type, was poorly induced by phorbol esters.	Phorbol Esters	176-190	keratin 20	Homo sapiens	104-108
7678037-3	1993	The cytoplasmic domains of CD20 contain multiple serine and threonine residues, of which at least two are followed by acidic sequences typical of substrate sites favored by casein kinase II.	Serine	49-55	keratin 20	Homo sapiens	27-31
7678037-3	1993	The cytoplasmic domains of CD20 contain multiple serine and threonine residues, of which at least two are followed by acidic sequences typical of substrate sites favored by casein kinase II.	Threonine	60-69	keratin 20	Homo sapiens	27-31
7678037-4	1993	Tryptic mapping of CD20 isolated from intact cells treated with insulin showed increased phosphorylation on peptides having similar migration to those phosphorylated by casein kinase II in vitro.	Peptides	108-116	keratin 20	Homo sapiens	19-23
1486031-6	1992	On the other hand, YOS-B expressed mature B-cell markers, CD19, CD20, CD21 and surface immunoglobulin, but not myeloid-associated antigens.	yos-b	19-24	keratin 20	Homo sapiens	64-68
7680616-5	1993	Staurosporine reversed both the phorbol ester- and the CD20-induced down-regulation.	Staurosporine	0-13	keratin 20	Homo sapiens	55-59
7680616-9	1993	The ability of anti-IgM to mobilize intracellular calcium was reduced in sIgM down-regulated cells, suggesting that B cells activation through the antigen receptor may be negatively regulated by CD20 and positively by IL-4.	Calcium	50-57	keratin 20	Homo sapiens	195-199
1284133-6	1992	After the 6 months of CsA therapy we observed a significant increase of CD3+, HLA-DR+, CD3+, CD16+ and/or CD56+, total B, and CD20+, CD5+ cells in the 11 patients with PsA compared to pretreatment values.	Cyclosporine	22-25	keratin 20	Homo sapiens	126-130
1382718-3	1992	Because we showed earlier that the CD20 molecule is consistently hyperphosphorylated in hairy cells and because previous studies showed that CD20 is involved in regulating intracytoplasmic free calcium concentrations ([Ca2+]i) in normal B lymphocytes, we measured [Ca2+]i in tumor cell samples from patients with HCL and studied the effect of IFN-alpha on this parameter.	Calcium	194-201	keratin 20	Homo sapiens	35-39
1382718-3	1992	Because we showed earlier that the CD20 molecule is consistently hyperphosphorylated in hairy cells and because previous studies showed that CD20 is involved in regulating intracytoplasmic free calcium concentrations ([Ca2+]i) in normal B lymphocytes, we measured [Ca2+]i in tumor cell samples from patients with HCL and studied the effect of IFN-alpha on this parameter.	Calcium	194-201	keratin 20	Homo sapiens	141-145
1374290-9	1992	CD20 phosphorylation also increased following the direct addition of exogenous phosphatidic acid to resting B cells.	Phosphatidic Acids	79-96	keratin 20	Homo sapiens	0-4
1378917-4	1992	However surface expression of CD20 was induced by phorbol ester (TPA) on both LiLa-1 and LK63 cell lines.	Phorbol Esters	50-63	keratin 20	Homo sapiens	30-34
1378917-4	1992	However surface expression of CD20 was induced by phorbol ester (TPA) on both LiLa-1 and LK63 cell lines.	Tetradecanoylphorbol Acetate	65-68	keratin 20	Homo sapiens	30-34
1378917-9	1992	Following exposure to TPA the 50-55 kD species was reduced over 48-72 h while the level of the p33-37 CD20 protein was increased.	Tetradecanoylphorbol Acetate	22-25	keratin 20	Homo sapiens	102-106
1375291-2	1992	By using multiparameter FACS analyses to quantitate surface density of CD20 and intracellular glutathione (GSH) levels simultaneously, we further show that the distribution of intracellular glutathione (GSH) levels in B cells of HIV-infected individuals is more heterogeneous than in uninfected controls.	Glutathione	190-201	keratin 20	Homo sapiens	71-75
1540096-8	1992	Finally, the monocyte counts and proportions of B cells (HLA-DR+ or CD20+ cells) responded to cortisol infusion and LPS in a pattern distinct from that of lipopolysaccharide alone.	Hydrocortisone	94-102	keratin 20	Homo sapiens	68-72
1370255-7	1992	Incubation of CD20+ B cells with phorbol myristate acetate (PMA) for 72 hr increased the frequency of CD5 expressing B cells by more than threefold.	Tetradecanoylphorbol Acetate	33-58	keratin 20	Homo sapiens	14-18
1370255-7	1992	Incubation of CD20+ B cells with phorbol myristate acetate (PMA) for 72 hr increased the frequency of CD5 expressing B cells by more than threefold.	Tetradecanoylphorbol Acetate	60-63	keratin 20	Homo sapiens	14-18
1371204-5	1992	A further MAb, IT-Ks20.8, recognized CK 20 in sections of formalin-fixed, paraffin-embedded tissue samples.	Formaldehyde	58-66	keratin 20	Homo sapiens	37-42
1371204-5	1992	A further MAb, IT-Ks20.8, recognized CK 20 in sections of formalin-fixed, paraffin-embedded tissue samples.	Paraffin	74-82	keratin 20	Homo sapiens	37-42
1375291-3	1992	Finally, we show that the intracellular GSH levels correlate with CD20 expression on a per-cell basis in all infected individuals.	Glutathione	40-43	keratin 20	Homo sapiens	66-70
1804309-2	1991	Using intact human peripheral blood B cells of young subjects labeled with orthophosphate, increased phosphorylation levels of serine/threonine and tyrosine substrates were demonstrated on indicator phosphoproteins corresponding to the CD20 isoforms and microtubule-associated protein 2 kinase after cross-linking sIg and costimulation with phorbol diesters.	Phosphates	75-89	keratin 20	Homo sapiens	236-240
1528302-5	1992	MAb IPO-10 defined the antigen which appears on B cell progenitors following HLA-DR and proceeding CD19, CD10, CD22, CD37; cy mu and CD20 and have been lost during terminal differentiation.	ipo-10	4-10	keratin 20	Homo sapiens	133-137
1719097-6	1991	Electrophoretic mobility shift assays with overlapping oligonucleotide probes spanning -280/-186 revealed that a 25-bp probe (-225/-201) bound a nuclear protein present in B cell lines expressing the CD20/B1 antigen but not in Jurkat (T cell), U937 (promonocytic), U251 (glioma), or HeLa cells.	Oligonucleotides	55-70	keratin 20	Homo sapiens	200-204
1719097-9	1991	This sequence element is also important in phorbol ester-induced CD20 expression in the pre-B cell line BP-697.	Phorbol Esters	43-56	keratin 20	Homo sapiens	65-69
1804309-2	1991	Using intact human peripheral blood B cells of young subjects labeled with orthophosphate, increased phosphorylation levels of serine/threonine and tyrosine substrates were demonstrated on indicator phosphoproteins corresponding to the CD20 isoforms and microtubule-associated protein 2 kinase after cross-linking sIg and costimulation with phorbol diesters.	Serine	127-133	keratin 20	Homo sapiens	236-240
1804309-2	1991	Using intact human peripheral blood B cells of young subjects labeled with orthophosphate, increased phosphorylation levels of serine/threonine and tyrosine substrates were demonstrated on indicator phosphoproteins corresponding to the CD20 isoforms and microtubule-associated protein 2 kinase after cross-linking sIg and costimulation with phorbol diesters.	Threonine	134-143	keratin 20	Homo sapiens	236-240
1804309-2	1991	Using intact human peripheral blood B cells of young subjects labeled with orthophosphate, increased phosphorylation levels of serine/threonine and tyrosine substrates were demonstrated on indicator phosphoproteins corresponding to the CD20 isoforms and microtubule-associated protein 2 kinase after cross-linking sIg and costimulation with phorbol diesters.	Tyrosine	148-156	keratin 20	Homo sapiens	236-240
1871958-1	1991	A monoclonal antibody, termed K-20, was generated against an anaplastic thymic carcinoma cell line, Ty-82.	Thr-Tyr	100-102	keratin 20	Homo sapiens	30-34
2010164-7	1991	In contrast, log CD20 (dose of agonist required to raise the heart rate by 20 beats/min) for isoproterenol, a beta-adrenoceptor agonist, was similar in cirrhotic patients and controls (2.81 +/- 0.38 vs. 2.94 +/- 0.45, p = 0.49).	Isoproterenol	93-106	keratin 20	Homo sapiens	17-21
1703181-4	1991	The induction of c-myc mRNA by anti-IgM or anti-CD20 is blocked by inhibitors of protein kinase C (PKC) such as staurosporine and by pretreatment of B cells with phorbol esters to reduce cellular PKC levels.	Staurosporine	112-125	keratin 20	Homo sapiens	48-52
1703181-4	1991	The induction of c-myc mRNA by anti-IgM or anti-CD20 is blocked by inhibitors of protein kinase C (PKC) such as staurosporine and by pretreatment of B cells with phorbol esters to reduce cellular PKC levels.	Phorbol Esters	162-176	keratin 20	Homo sapiens	48-52
2273464-7	1990	For the isomers of the cephalosporin prodrug ester Ro 19-5248 only k12 and k20 were operative in buffers; in human plasma all pathways were operative and there was no evidence of cephalosporoic acid formation.	Cephalosporins	23-36	keratin 20	Homo sapiens	75-78
1702899-4	1990	Isoprinosine significantly enhanced the lymphoproliferative response after stimulation with phytohaemagglutinin (PHA) and purified derivative of tuberculin (PPD), while isoprinosine had no effect on the following immune parameters: the expression of surface markers on blood mononuclear cells including CD2, CD3, CD4, CD8, CD14, CD19, CD20, CD25, leu-8, and HLA-DR.	Inosine Pranobex	0-12	keratin 20	Homo sapiens	335-339
2273464-7	1990	For the isomers of the cephalosporin prodrug ester Ro 19-5248 only k12 and k20 were operative in buffers; in human plasma all pathways were operative and there was no evidence of cephalosporoic acid formation.	Esters	45-50	keratin 20	Homo sapiens	75-78
2095748-6	1990	Findings in both groups of patients mimicked the results of parenteral epinephrine administration: a pan-B and -T lymphocytosis with marked increase in CD56 (fourfold to fivefold) and CD8 cells (threefold to fourfold) as well as moderate increases in CD20 and CD4 cells (twofold), resulting in a decrease in the CD4/CD8 ratio compared with control values.	Epinephrine	71-82	keratin 20	Homo sapiens	251-255
32858539-0	2021	Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome.	bcg	121-124	keratin 20	Homo sapiens	60-64
33807051-4	2021	The CD20-binding antibody rituximab (RTX) appears a promising steroid-sparing therapy, although long-term data are lacking.	Steroids	62-69	keratin 20	Homo sapiens	4-8
32858539-6	2021	Patients with CK20(+) CIS [28 (65%)] and patients with CK20(-) CIS [15 (35%)] had the same rates of Bacillus Calmete-Guerin (BCG) failure but patients with CK20(-) CIS had higher stage progression [3 CK20(+) (11%) vs. 6 CK20(-) (40%); P=0.02].	bacillus calmete-guerin	100-123	keratin 20	Homo sapiens	14-18
32858539-6	2021	Patients with CK20(+) CIS [28 (65%)] and patients with CK20(-) CIS [15 (35%)] had the same rates of Bacillus Calmete-Guerin (BCG) failure but patients with CK20(-) CIS had higher stage progression [3 CK20(+) (11%) vs. 6 CK20(-) (40%); P=0.02].	bacillus calmete-guerin	100-123	keratin 20	Homo sapiens	55-59
32858539-6	2021	Patients with CK20(+) CIS [28 (65%)] and patients with CK20(-) CIS [15 (35%)] had the same rates of Bacillus Calmete-Guerin (BCG) failure but patients with CK20(-) CIS had higher stage progression [3 CK20(+) (11%) vs. 6 CK20(-) (40%); P=0.02].	bacillus calmete-guerin	100-123	keratin 20	Homo sapiens	55-59
32858539-6	2021	Patients with CK20(+) CIS [28 (65%)] and patients with CK20(-) CIS [15 (35%)] had the same rates of Bacillus Calmete-Guerin (BCG) failure but patients with CK20(-) CIS had higher stage progression [3 CK20(+) (11%) vs. 6 CK20(-) (40%); P=0.02].	bacillus calmete-guerin	100-123	keratin 20	Homo sapiens	55-59
32858539-6	2021	Patients with CK20(+) CIS [28 (65%)] and patients with CK20(-) CIS [15 (35%)] had the same rates of Bacillus Calmete-Guerin (BCG) failure but patients with CK20(-) CIS had higher stage progression [3 CK20(+) (11%) vs. 6 CK20(-) (40%); P=0.02].	bacillus calmete-guerin	100-123	keratin 20	Homo sapiens	55-59
34930453-0	2021	Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript.	venetoclax	16-26	keratin 20	Homo sapiens	127-131
34820001-7	2022	Taken together, these findings warranted further investigation on NAV-006 as a next generation anti-CD20 antibody that could improve the efficacy of parent RTX in NHL patients with high levels of CA125.	nav-006	66-73	keratin 20	Homo sapiens	100-104
34942000-5	2022	Nevertheless, neutrophils do trogocytose rituximab-opsonized B lymphoma cells, yet this only reduces CD20 surface expression, and is thought to render tumor cells therapeutically resistant to further rituximab-dependent destruction.	trogocytose	29-40	keratin 20	Homo sapiens	101-105
34538717-6	2022	The bsAb also induces significant natural killer cell activation and antibody-dependent cytotoxicity of up to 25% as well as up to 65% phagocytosis by human macrophages in the presence of CD20+ tumor cells.	Antibodies, Bispecific	4-8	keratin 20	Homo sapiens	188-192
34926302-9	2021	In addition, selinexor enhanced ADCC against lymphoma cells coated with the anti-CD20 antibodies rituximab and obinutuzumab.	selinexor	13-22	keratin 20	Homo sapiens	81-85
34259093-2	2021	Pembrolizumab, a monoclonal CD20 antibody, was attached to the surfaces of DOX-loaded microbubbles.	Doxorubicin	75-78	keratin 20	Homo sapiens	28-32
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	70-73	keratin 20	Homo sapiens	183-187
34741188-9	2021	The proportion and magnitude of response was significantly lower in IMID treated with anti-CD20 drugs.	imid	68-72	keratin 20	Homo sapiens	91-95
34827631-4	2021	Results: A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (p < 0.001), in the CD8 (p = 0.009), and CD20 counts (p < 0.001).	resiniferatoxin	102-105	keratin 20	Homo sapiens	183-187
34196167-0	2021	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kdelta inhibitor idelalisib.	idelalisib	115-125	keratin 20	Homo sapiens	28-32
34227176-4	2021	Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope.	ibritumomab tiuxetan	0-11	keratin 20	Homo sapiens	80-84
34521023-9	2021	This RGA can be applied to evaluate the -ADCP bioactivity for anti-CD20 mAbs in lot release, stability testing as well as biosimilar comparability.	adcp	41-45	keratin 20	Homo sapiens	67-71
34227176-4	2021	Ibritumomab tiuxetan radioimmunotherapy (RIT) is a radioimmunoconjugate of anti-CD20 monoclonal antibody linked to chelator tiuxetan and radioisotope.	2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid	12-20	keratin 20	Homo sapiens	80-84
34698343-0	2022	A Method for the Elution of Anti-CD20 With an EDTA/Glycine Acid Solution for Accurate Immunophenotyping of B Lymphocytes Sensitized With Rituximab.	Edetic Acid	46-50	keratin 20	Homo sapiens	33-37
34570196-3	2021	The introduction of rituximab, an anti-CD20 antibody which can be used by TAMs to performed antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, has challenged this paradigm.	tams	74-78	keratin 20	Homo sapiens	39-43
34698343-0	2022	A Method for the Elution of Anti-CD20 With an EDTA/Glycine Acid Solution for Accurate Immunophenotyping of B Lymphocytes Sensitized With Rituximab.	glycine acid	51-63	keratin 20	Homo sapiens	33-37
34698343-5	2022	An EDTA/glycine acid (EGA) elution method was used to dissociate CD20-rituximab complexes; afterwards, CD20-positive immunoreactivity was assessed by flow cytometry.	Edetic Acid	3-7	keratin 20	Homo sapiens	65-69
34698343-5	2022	An EDTA/glycine acid (EGA) elution method was used to dissociate CD20-rituximab complexes; afterwards, CD20-positive immunoreactivity was assessed by flow cytometry.	glycine acid	8-20	keratin 20	Homo sapiens	65-69
34661744-1	2022	BACKGROUND: The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease.	Steroids	105-112	keratin 20	Homo sapiens	62-66
34681595-1	2021	We report a lymphoma patient with profound B-cell deficiency after chemotherapy combined with anti-CD20 antibody successfully treated with remdesivir and convalescent plasma for prolonged SARS-CoV-2 infection.	remdesivir	139-149	keratin 20	Homo sapiens	99-103
34210684-7	2021	Immunotherapy response, with increased expression of Granzyme B and Caspase 3 and decreased expression of CK20 and ATP activity, was exhibited in 4/19 (21.1%) Pembrolizumab treated and 2/19 (10.5%) Nivolumab treated iPTOs.	iptos	216-221	keratin 20	Homo sapiens	106-110
34483021-7	2021	Low CD19 and CD20 counts and a shorter interval from the last B cell depleting therapy infusion to the first vaccine dose were associated with a negative spike RBD antibody response (non-seroconverter) in patients on BCDT.	bcdt	217-221	keratin 20	Homo sapiens	13-17
34795154-3	2021	The alignment of amino acid sequences revealed that 5 Lys residues (K20, K26, K44, K139, and K166) of the 13 Lys residues within NS5A (genotype 2a, JFH1 strain) were conserved compared to those of HCV (genotype 1b, Con1 strain).	Lysine	54-57	keratin 20	Homo sapiens	68-71
34729253-4	2021	Insertion of poly(A) tracks into the sequences of interleukin-2 and membrane protein CD20 results in a programmable reduction of mRNA stability and attenuation of protein expression regardless of the presence of a signaling sequence.	Poly A	13-20	keratin 20	Homo sapiens	85-89
34544820-1	2021	BACKGROUND: The chimeric anti-CD20 monoclonal antibody rituximab is effective in steroid-dependent and calcineurin inhibitor-dependent forms of nephrotic syndrome, but many patients relapse at 1 year.	Steroids	81-88	keratin 20	Homo sapiens	30-34
34795154-3	2021	The alignment of amino acid sequences revealed that 5 Lys residues (K20, K26, K44, K139, and K166) of the 13 Lys residues within NS5A (genotype 2a, JFH1 strain) were conserved compared to those of HCV (genotype 1b, Con1 strain).	Lysine	109-112	keratin 20	Homo sapiens	68-71
34638227-4	2021	We demonstrate time- and dose-dependent induction of anti-CD20 CAR expression and function with metabolites of the clinically-approved drug tamoxifen, and the absence of background CAR activity in the non-induced state.	Tamoxifen	140-149	keratin 20	Homo sapiens	58-62
34571726-7	2021	Besides, co-administration of vincristine with monoclonal antibodies has also emerged, the typical example of which is the anti-CD20 antibody rituximab.	Vincristine	30-41	keratin 20	Homo sapiens	128-132
34461632-6	2021	Given bortezomib"s activity in relapsed ALL and its synergism with rituximab in B-cell lymphomas, the addition of bortezomib to rituximab and chemotherapy may provide an incremental benefit in CD20-positive-precursor B-cell ALL.	Bortezomib	114-124	keratin 20	Homo sapiens	193-197
34416738-9	2021	The obtained results showed that the optimum conditions to fabricate a uniform CS/GO coating on the scaffolds were 2wt% GO, CD=20 mA cm-2, and DC=0.5.	graphene oxide	82-84	keratin 20	Homo sapiens	124-129
34275396-11	2021	Early phase studies suggested the combinations of acalabrutinib with a CD20 antibody and venetoclax led to high rates of undetectable minimal residual disease in the bone marrow in CLL patients and might provide a fixed-duration therapeutic option for patients with CLL.	acalabrutinib	50-63	keratin 20	Homo sapiens	71-75
34552880-9	2021	In conclusion, prior Rituximab before autologous HSCT and cyclosporine administration after allogeneic HSCT negatively affected the antibody response to Sars-COV2 vaccine, possibly due to their immunosuppressive action on CD20 +B cells and T cells, respectively.	Cyclosporine	58-70	keratin 20	Homo sapiens	222-226
34361811-4	2021	Here, we intend to demonstrate that DFMT is a platform that will be effective on other receptors than previously validated CD20.	dfmt	36-40	keratin 20	Homo sapiens	123-127
35461090-2	2022	The treatment of PCNSL is ineffective partly due to the blood-brain barrier (BBB) restriction of delivery of many drugs including anti-CD20 (Rituximab; RTX) which is a standard treatment for systemic B-cell lymphomas.	resiniferatoxin	152-155	keratin 20	Homo sapiens	135-139
34075554-9	2021	DMTs-such as sphingosine-1-phosphate receptor modulators, which sequester lymphocytes from circulation; alemtuzumab; and anti-CD20 therapies, which rely on depleting populations of immune cells-have been shown to attenuate responses to conventional vaccines.	Dimethyl trisulfide	0-4	keratin 20	Homo sapiens	126-130
34132894-1	2022	BACKGROUND: Rituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained remission in children with steroid-dependent nephrotic syndrome.	Steroids	116-123	keratin 20	Homo sapiens	41-45
34073233-9	2021	Tumours with an elevated expression of markers associated with luminal differentiation (KRT20, ERBB2, ESR1) were associated with a higher chance of pCR (55% vs. 15.8%, p = 0.009).	Phenobarbital	63-70	keratin 20	Homo sapiens	88-93
34104541-6	2021	The density of CD8+ cells was decreased and the density of FoxP3+ cells and CD20+ cells was increased in PT post-NAC.	Platinum	105-107	keratin 20	Homo sapiens	76-80
34104541-6	2021	The density of CD8+ cells was decreased and the density of FoxP3+ cells and CD20+ cells was increased in PT post-NAC.	nac	113-116	keratin 20	Homo sapiens	76-80
35403851-8	2022	We analyzed 62 consecutive patients with refractory or relapsed CD20 + B cell lymphoma who received R-DHAP therapy in our hospital, including 29 and 33 cases in groups A and B, respectively.	r-dhap	100-106	keratin 20	Homo sapiens	64-68
34268530-6	2021	Acalabrutinib is approved as monotherapy in the R/R or TN setting, and in the TN setting can be combined with the anti-CD20 monoclonal antibody obinutuzumab.	acalabrutinib	0-13	keratin 20	Homo sapiens	119-123
34204102-1	2021	PURPOSE: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin"s lymphoma using the theranostic pair of 111In and 90Y anti-CD20 ibritumomab tiuxetan (Zevalin ) at myeloablative radiation-absorbed doses with autologous stem cell support.	ibritumomab tiuxetan	264-271	keratin 20	Homo sapiens	237-241
34073233-10	2021	Elevated ERBB2 expression was positively correlated with luminal expression features such as KRT20, and negatively with basal characteristics such as KRT5.	Phenobarbital	57-64	keratin 20	Homo sapiens	93-98
34073233-11	2021	Patients with MIBC showing a high expression of ERBB2, ESR1, or KRT20 have a significantly higher chance of pCR following NAC.	4-METHYL-2-PENTANOL	14-18	keratin 20	Homo sapiens	64-69
35426564-0	2022	Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.	remdesivir	0-10	keratin 20	Homo sapiens	66-70
35426564-2	2022	We aim to present our experience with remdesivir treatment in anti-CD20-treated patients with prolonged symptoms, a patient population for which no data from randomized controlled trials are available.	remdesivir	38-48	keratin 20	Homo sapiens	67-71
35426564-3	2022	METHODS: From the beginning of the pandemic until February 2021, we included all consecutive patients from our healthcare network on anti-CD20 treatment with prolonged COVID-19 symptoms, who received remdesivir.	remdesivir	200-210	keratin 20	Homo sapiens	138-142
35240381-1	2022	The conventional treatment options (including alkylating agents, steroids, calcinurine inhibitors) have been largely replaced by anti-CD20 antibodies to achieve remission of nephrotic proteinuria in primary membranous nephropathy (PMN) patients.	Steroids	65-73	keratin 20	Homo sapiens	134-138
35240381-1	2022	The conventional treatment options (including alkylating agents, steroids, calcinurine inhibitors) have been largely replaced by anti-CD20 antibodies to achieve remission of nephrotic proteinuria in primary membranous nephropathy (PMN) patients.	calcinurine	75-86	keratin 20	Homo sapiens	134-138
35571853-2	2022	Luciferase gene expression in HeLa cells mediated by PEG-CK18C, PEG-CK9CK9, and PEG-K9CK9C was reported to be 35-, 5.4-, and 1.3-fold higher than that mediated by cysteine-uninstalled PEGylated oligolysine PEG-K20, respectively.	Polyethylene Glycols	53-56	keratin 20	Homo sapiens	210-213
35579623-9	2022	The MTT test signified anti-CD20 scFvs could affect cell viability in Raji cells but had no impact on Jurkat cells and also, Raji cells viability was affected more significantly by anti-CD20 scFv-V3.	monooxyethylene trimethylolpropane tristearate	4-7	keratin 20	Homo sapiens	28-32
35603278-2	2022	Methods: The purpose of this exploratory study was to assess short-term PROs and serum kynurenine metabolites for associated neurotoxicity among patients treated in an anti-CD20, anti-CD19 (LV20.19) CAR T cell phase I clinical trial (NCT03019055).	Kynurenine	87-97	keratin 20	Homo sapiens	173-177
35563543-4	2022	We found that high CK20 and low CK5/6 expression were both observed in UTUC tumor origin and subsequent NMIBC after RNU.	rnu	116-119	keratin 20	Homo sapiens	19-23
35226739-4	2022	Furthermore, pre-treatment with TAK-981 enhanced macrophage phagocytosis or NK cell cytotoxicity against CD20-positive target cells in combination with the anti-CD20 antibody rituximab.	TAK-981	32-39	keratin 20	Homo sapiens	105-109
35226739-4	2022	Furthermore, pre-treatment with TAK-981 enhanced macrophage phagocytosis or NK cell cytotoxicity against CD20-positive target cells in combination with the anti-CD20 antibody rituximab.	TAK-981	32-39	keratin 20	Homo sapiens	161-165
35226739-5	2022	In vivo studies demonstrated enhanced antitumor activity of TAK-981 and rituximab in CD20-positive lymphoma xenograft models.	TAK-981	60-67	keratin 20	Homo sapiens	85-89
35410313-6	2022	Rituximab-induced CD20 internalization in JeKo-1 cells was completely blocked by concurrent treatment with BI-1206, a recombinant human monoclonal antibody targeting FcgammaRIIB.	bi-1206	107-114	keratin 20	Homo sapiens	18-22
35410313-7	2022	Combinational therapies with rituximab-ibrutinib, rituximab-venetoclax and rituximab-CHOP also induced CD20 internalization which was again effectively blocked by BI-1206.	ibrutinib	39-48	keratin 20	Homo sapiens	103-107
35410313-7	2022	Combinational therapies with rituximab-ibrutinib, rituximab-venetoclax and rituximab-CHOP also induced CD20 internalization which was again effectively blocked by BI-1206.	rituximab-venetoclax	50-70	keratin 20	Homo sapiens	103-107
35410313-7	2022	Combinational therapies with rituximab-ibrutinib, rituximab-venetoclax and rituximab-CHOP also induced CD20 internalization which was again effectively blocked by BI-1206.	bi-1206	163-170	keratin 20	Homo sapiens	103-107
35340036-8	2022	NAC-DP increased the proportion of peripheral CD19+ CD20+ CD38+ plasmablastsin AR and LAR patients, but not in HC.	nac-dp	0-6	keratin 20	Homo sapiens	52-56
35444638-8	2022	In vitro, coculture of LGMSC-Exos with peripheral blood mononuclear cells of patients with pSS markedly reduced the proportions of CD19+CD20-CD27+CD38+ plasma cells among peripheral blood mononuclear cells.	pss	91-94	keratin 20	Homo sapiens	136-140
35158284-7	2022	Utilizing a KRAS-GTP pull-down assay, it was demonstrated that K20 decreased the active form of KRAS (KRAS-GTP) in NCI-H358 cells.	Guanosine Triphosphate	17-20	keratin 20	Homo sapiens	63-66
35158284-9	2022	Further, K20 could inhibit the formation of H358 or H23 tumor colonies.	ZINC78587988	44-48	keratin 20	Homo sapiens	9-12
35105946-7	2022	After an inverse probability of treatment weighting approach, we observed in anti-CD20-exposed patients with B-cell lymphoid disease a decreased mortality of 63% (95% CI = 31-80) in the CCP-treated group compared to the CCP-untreated subgroup, confirmed in the other sensitivity analyses.	ccp	186-189	keratin 20	Homo sapiens	82-86
35340036-10	2022	In vitro DP stimulation increased proliferating CD19+ CD20+ CD38+ plasmablasts in LAR and AR patients, but not in HC.	Dipyridamole	9-11	keratin 20	Homo sapiens	54-58
35414868-7	2022	Antibody-polymer conjugates of CD20 and CD8a prepared by both coupling reactions were employed in conjunction with commercial metal-conjugated antibodies for multi-parameter single-cell immunoassays.	Polymers	9-16	keratin 20	Homo sapiens	31-35
35218445-9	2022	Treatment with prednisolone upregulated expression of CD20 and an apoptosis-inducing protein BIM, which might augment perforin/granzyme B-mediated cell death.	Prednisolone	15-27	keratin 20	Homo sapiens	54-58
35182224-0	2022	Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.	vedotin	35-42	keratin 20	Homo sapiens	5-9
35163524-8	2022	Incubation of cells with PgE1-OH and L-902688 preserved the expression of CD20 molecules, further confirming the anti-leukemic potential of EP4 receptor agonists in combination with anti-CD20 MAbs.	pge1-oh	25-32	keratin 20	Homo sapiens	74-78
35363211-7	2022	INTERVENTIONS AND OUTCOMES: She was treated with pulse methylprednisolone, whose platelet counts normalized after therapy with plasmapheresis and an anti-CD20 monoclonal antibody (rituximab).	Methylprednisolone	55-73	keratin 20	Homo sapiens	154-158
35163524-8	2022	Incubation of cells with PgE1-OH and L-902688 preserved the expression of CD20 molecules, further confirming the anti-leukemic potential of EP4 receptor agonists in combination with anti-CD20 MAbs.	L-902688	37-45	keratin 20	Homo sapiens	74-78
35145511-9	2021	CD20+, CD4+, CD68+, Foxp3+CD4+ cells were demonstrated to infiltrate higher in TM while CD20+ and CD68+ cells were also enriched in NS and TB regions respectively.	Terbium	139-141	keratin 20	Homo sapiens	88-92
35158894-2	2022	The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan.	ibritumomab tiuxetan	134-145	keratin 20	Homo sapiens	76-80
35158894-2	2022	The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan.	2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid	146-154	keratin 20	Homo sapiens	76-80
35158872-4	2022	DFS was predicted by high QA of CD3+, CD8+ and CD20+ cells in TC.	Technetium	62-64	keratin 20	Homo sapiens	47-51